


Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases

Cara L. Mack,¹ David Adams ,² David N. Assis,³ Nanda Kerkar,⁴ Michael P. Manns,⁵ Marlyn J. Mayo,⁶ John M. Vierling,⁷ Mouaz Alsawas,⁸ Mohammad H. Murad,⁹ and Albert J. Czaja¹⁰

WHAT'S NEW SINCE 2010 GUIDELINES?

- Histological features of NAFLD are present in 17%-30% of adult patients with AIH, and concurrent NAFLD may influence response to therapy.
- Diagnostic scoring systems should be used only to support clinical judgment in challenging cases of AIH and to define AIH cohorts for clinical studies.
- Immune checkpoint inhibitors have been associated with immune-mediated liver injury and are frequently steroid-responsive, but the liver injury lacks autoantibodies and typical histological features of AIH.
- Elastography may be used to assess the stages of hepatic fibrosis noninvasively.
- Testing for TPMT activity prior to AZA treatment is encouraged in all patients.
- Budesonide and AZA or predniso(lo)ne and AZA are recommended as first-line AIH treatments in children and adults who do not have cirrhosis, acute severe hepatitis, or ALF.
- AZA can be continued throughout pregnancy, whereas the use of MMF is contraindicated in pregnancy.
- Liver tissue examination prior to drug withdrawal in individuals with ≥ 2 years of biochemical remission is preferred but not mandatory in adults and required in children.
- MMF or TAC can be used as second-line treatment in children and adults with AIH who have failed to respond to first-line therapy.
- Patients with acute severe AIH should receive predniso(lo)ne followed by LT if no improvement within 2 weeks, whereas patients with AIH and ALF should be evaluated directly for LT.
- Glucocorticoids can be discontinued after LT and patients monitored for recurrence of AIH.

Abbreviations: AASLD, American Association for the Study of Liver Diseases; AIH, autoimmune hepatitis; ALF, acute liver failure; ALT, alanine aminotransferase; AMA, antimitochondrial antibodies; ANA, antinuclear antibodies; anti- α -actinin, antibody to alpha-actinin; anti-HBc, antibodies to hepatitis B core antigen; anti-LC1, antibodies to liver cytosol type 1; anti-LKM1, antibodies to LKM1; anti-PD-1, antibody to PD-1; anti-SLA, antibodies to SLA; ARFI, acoustic radiation force impulse imaging; ASC, autoimmune sclerosing cholangitis; AST, aspartate aminotransferase; AZA, azathioprine; Breg, B regulatory cell; CD, cluster of differentiation; CI, confidence interval; CsA, cyclosporine; CTL, cytotoxic T lymphocyte; CTLA-4, cytotoxic T lymphocyte antigen-4; GGT, gamma-glutamyltransferase; GRADE, Grading of Recommendations Assessment, Development, and Evaluation; HAV, hepatitis A virus; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HLA, human leukocyte antigen; IAHG, International Autoimmune Hepatitis Group; IBD, inflammatory bowel disease; IgG, immunoglobulin G; IL, interleukin; INR, international normalized ratio; iTreg, inducible T regulatory cell; LKM1, liver kidney microsomal type 1; LT, liver transplantation; MAIT, mucosal invariant T; MMF, mycophenolate mofetil; 6-MP, 6-mercaptopurine; MRE, magnetic resonance elastography; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; NK, natural killer; OR, odds ratio; pANCA, perinuclear antineutrophil cytoplasmic antibody; PBC, primary biliary cholangitis; PD-1, programmed death protein-1; PSC, primary sclerosing cholangitis; SLA, soluble liver antigen; SMA, smooth muscle

Purpose and Scope

The objectives of this document are to provide guidance in the diagnosis and management of autoimmune hepatitis (AIH) based on current evidence and expert opinion and to present guidelines to clinically relevant questions based on systematic reviews of the literature and the quality of evidence.⁽¹⁾ This practice guideline/guidance constitutes an update of the guidelines on AIH published in 2010 by the American Association for the Study of Liver Diseases (AASLD).⁽²⁾ It updates the epidemiology, diagnosis, management, and outcomes of AIH in adults and children.

The document is divided into “guideline recommendations” and “guidance statements.” Guideline recommendations were based on evidence derived from systematic reviews of the medical literature and supported, if appropriate, by meta-analyses. The systematic reviews and meta-analyses were conducted independently by the Mayo Clinic Evidence-Based Practice Center. Findings were analyzed and

interpreted by a multidisciplinary panel of experts, including both content and methodology experts, who rated the quality of evidence and determined the strength of each recommendation. The quality of clinical evidence was determined by its source (e.g., randomized controlled trial or observational study), and the strength of the recommendation was determined by assessing the quality of evidence, balance of benefits and harms, patient values and preferences, and use of resources and costs. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system was used to categorize each recommendation as strong or conditional (Table 1).^(3,4) Details of the methodology, systematic reviews, and meta-analyses are published separately. The guideline recommendations focus on pertinent management issues for which sufficient evidence was available to render a recommendation. They address glucocorticoid and azathioprine therapy as first-line management, second-line medications after failure of first-line therapy, and maintenance management after liver transplantation (LT;

antibodies; SR, systematic review; SSSE, steroid-specific side effect; TAC, tacrolimus; Tfb, T follicular helper; 6-TGN, 6-thioguanine nucleotide; T_h, T helper; TNF- α , tumor necrosis factor- α ; TPMT, thiopurine methyltransferase; UC, ulcerative colitis; UDCA, ursodeoxycholic acid; ULN, upper limit of normal; VCTE, vibration-controlled transient elastography.

Received November 25, 2019; accepted November 25, 2019.

Additional Supporting Information may be found at onlinelibrary.wiley.com/doi/10.1002/hep.31065/supinfo.

Funding for the development of this Practice Guideline and Guidance was provided by the American Association for the Study of Liver Diseases.

© 2020 by the American Association for the Study of Liver Diseases.

View this article online at [wileyonlinelibrary.com](https://onlinelibrary.wiley.com).

DOI 10.1002/hep.31065

Potential conflict of interest: Dr. Mack consults for Albireo. Dr. Kerkar advises High Tide and received royalties from Elsevier. Dr. Manns consults for, is on the speakers' bureau for, and received grants from Falk. He consults for and received grants from Novartis. Dr. Vierling advises and received grants from CymaBay, Enanta, Genkyotex, Intercept, Lilly, Novartis, and TaiwanJ. He advises Arena, BioIncept, Blade, and GlaxoSmithKline and received grants from Allergan and NGM.

ARTICLE INFORMATION:

From the ¹Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO; ²Centre for Liver Research, University of Birmingham, Birmingham, UK; ³Department of Internal Medicine, Yale School of Medicine, New Haven, CT; ⁴Golisano Children's Hospital at Strong, University of Rochester Medical Center, NY; ⁵Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany; ⁶Division of Digestive and Liver Diseases, University of Texas SW Medical Center, Dallas, TX; ⁷Medicine and Surgery, Baylor College of Medicine, Houston, TX; ⁸Mayo Clinic Minnesota, Rochester, MN; ⁹Mayo Knowledge and Encounter Research Unit, Mayo Clinic College of Medicine, Rochester, MN; ¹⁰Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN.

ADDRESS CORRESPONDENCE AND REPRINT REQUESTS TO:

Cara L. Mack, M.D.
Department of Pediatrics
University of Colorado School of Medicine
13123 E. 16th Ave., B290

Aurora, CO 80045
E-mail: cara.mack@childrenscolorado.org
Tel.: +1-720-271-0830

TABLE 1. GRADE Assessment of Clinical Studies

Study Design	Rating Quality	Strength Determinants	Strength and Implications of Recommendation
Randomized controlled trial	High	Quality of evidence	Strong
	Moderate	Balance of benefits and harms	<ul style="list-style-type: none"> • Most people would want course • Most people should take course • Can be adapted as policy in most cases
	Low	Patient values and preferences	
Observational	Very low	Resources and costs Feasibility Accessibility Equity	Conditional <ul style="list-style-type: none"> • Many people would select course • Requires decision aids and shared decision-making • Debatable policy choice

Quality downgrades: selection bias, inconsistency, imprecision, indirectness, publication bias. Quality upgrades: large effect, very large effect, dose–response gradient, confounders produce no effect.

TABLE 2. Definitions of AIH and Its Treatment Outcomes

Condition	Definition
AIH	Characteristic histologic abnormalities (lymphoplasmacytic interface hepatitis), elevated AST, ALT, and total IgG and the presence of one or more characteristic autoantibodies
Inactive cirrhosis	Absence of inflammatory infiltrates in both portal tracts and fibrous bands in cirrhosis
Acute severe AIH	Jaundice, INR > 1.5 < 2, no encephalopathy; no previously recognized liver disease ⁽³⁷⁰⁾
ALF	INR ≥ 2; hepatic encephalopathy within 26 weeks of onset of illness; no previously recognized liver disease ^(100,136)
Biochemical remission	Normalization of serum AST, ALT, and IgG* levels
Histological remission	Absence of inflammation in liver tissue after treatment
Treatment failure	Worsening laboratory or histological findings despite compliance with standard therapy
Incomplete response	Improvement of laboratory and histological findings that are insufficient to satisfy criteria for remission
Relapse	Exacerbation of disease activity after induction of remission and drug withdrawal (or nonadherence)
Treatment intolerance	Inability to continue maintenance therapy due to drug-related side effects

*Patients with cirrhosis in biochemical remission may have persistent elevation of IgG.

see Supporting Table S1 for patient/intervention/comparison/outcome questions related to systematic reviews).

“Guidance statements” were developed by consensus of an expert panel based on formal review and analysis of the published literature on the topic. The quality (level) of evidence and the strength of each guidance statement were not formally rated for the guidance statements. “Guidance statements” were used to address topics for which a sufficient number of randomized controlled trials were not available to justify a systematic review and meta-analysis. The “guidance statements” and “guideline recommendations” were also reviewed by members of the AIH Association, a 501(c)(3) nonprofit organization, in order to incorporate patient and public perspectives. “Guidance statements” and “guideline recommendations” are intended to provide health care practitioners with updated information and rigorously assessed, evidence-based recommendations. They are intended

to aid, not supersede, clinical judgment. For ease of reading this AIH guidance/guidelines document, a glossary of definitions is provided in Table 2.

AIH is an immune-mediated inflammatory liver disease of uncertain cause which affects all ages, both genders, and all ethnicities. Patients may be asymptomatic, be chronically ill, or present with acute liver failure (ALF); and the diagnosis must be considered in all patients with acute or chronic liver inflammation, including patients with graft dysfunction after LT. AIH does not have a signature diagnostic feature, and the diagnosis requires the presence of a constellation of typical features which can vary between patients with the same disease and can occur in other liver diseases. Progression to advanced hepatic fibrosis, cirrhosis, death from liver failure, or LT are possible outcomes. Treatment with immunosuppressive agents has been life-saving, but management regimens may be long-term, associated with serious side effects, and variably effective.

Background

EPIDEMIOLOGY

AIH occurs at all ages and within all ethnic groups, and its manifestations appear to vary by race and ethnicity. Alaskan Natives have a high frequency of icteric AIH at presentation, Hispanics more commonly present with cirrhosis, and African Americans have accelerated progression of disease and a higher rate of recurrence after LT compared to other races.^(5,6) Female predominance occurs in adults (71%-95% women)⁽⁷⁻¹²⁾ and children (60%-76% girls).⁽¹³⁻¹⁶⁾ Early epidemiological reports suggested that the onset of AIH had age peaks at 10-30 and 40-60 years, but the findings may have been influenced by referral bias.⁽¹⁷⁻¹⁹⁾ Older peak ages at onset (>60 years) have been reported in Denmark⁽¹¹⁾ and New Zealand.⁽¹⁰⁾

The estimated incidence of AIH varies worldwide depending on the region and the age at onset. Incidence rates in adults range from 0.67 (southern Israel) to 2 cases per 100,000 person-years (Canterbury region of New Zealand).^(10,17,20) Pediatric incidences are lower, ranging from 0.23 (Canada)⁽¹⁶⁾ to 0.4 per 100,000 person-years (United States).⁽¹⁵⁾ Over the past few decades there has been a near 50% increase in incidence in Spain, Denmark, Sweden, and the Netherlands.^(11,12,17,21-23) The prevalence of AIH in adults ranges from 4 (Singapore) to 42.9 (Alaska natives) per 100,000 persons.^(17,24,25) The prevalence in children ranges from 2.4 (non-native Canadian children)⁽²⁶⁾ and 3 per 100,000 persons (United States)⁽¹⁵⁾ to 9.9 per 100,000 persons (native Canadian children).^(17,26)

GENETIC PREDISPOSITIONS

In common with other autoimmune diseases, the primary genetic associations in AIH involve major histocompatibility complex loci. Human leukocyte antigen (HLA) associations cluster within the conserved 8.1 ancestral haplotype which defines the alleles carried by most Caucasians⁽²⁷⁾ and results from linkage disequilibrium within HLA class I, II, and III loci: *HLA-A1*, *Cw7*, *B8*, *TNFAB*a2b3*, *TNFN*s*, *C2*c*, *Bf*s*, *C4A*Q0*, *C4B*1*, *DRB1*03:01*, *DRB1*04:01*, *DRB1*13:01*, *DRB3*01:01*, *DQA1*05:01*, *DQB1*02:01*.⁽²⁸⁻³²⁾ *HLA-DRB1*03:01* haplotypes associated with AIH are the result of additional genetic recombinations.

AIH also has non-HLA genetic associations, but the odds ratios (ORs) for risk of AIH are far lower than those for HLA alleles. Susceptibility for AIH has been associated with genetic polymorphisms encoding cytotoxic T lymphocyte antigen-4 (CTLA-4),⁽³³⁾ tumor necrosis factor- α (TNF- α),^(34,35) Fas (cluster of differentiation 95 [CD95] or apoptosis antigen-1),^(36,37) vitamin D receptor,^(38,39) signal transducer and activator of transcription 4,⁽⁴⁰⁾ transforming growth factor-beta 1,⁽⁴¹⁾ macrophage migration inhibitory factor,⁽⁴²⁾ SH2B adapter protein 3,⁽⁴³⁾ caspase recruitment domain family member 10,⁽⁴³⁾ and the interleukin-23 (IL-23) receptor.⁽⁴⁴⁾ Dysfunctional products of genetic variants or deficient levels of gene product may disrupt homeostatic mechanisms that affect the proliferation and survival of autoreactive T and B cells, regulate cytokine production, and modulate inflammatory and immune responses.

AIH is a complex genetic disease that requires interplay among genetic, epigenetic, immunologic, and environmental factors. A rare exception is AIH associated with an autosomal recessive mutation in the autoimmune regulator gene on chromosome 21q22.3, which has been associated with autoimmune polyglandular syndrome type 1 (APS-1).⁽⁴⁵⁾ Environmental exposures play greater roles than genetics in shaping the immune repertoire, and specific environmental factors, such as viral infections or xenobiotic exposures, can act as environmental triggers for loss of self-tolerance to autoantigens in persons genetically susceptible to AIH.^(46,47)

PATHOGENESIS

Autoreactive CD4 and CD8 T cells break self-tolerance to hepatic autoantigens as the result of environmental triggers and inability of autoantigen-specific natural T regulatory cells (nTregs) and inducible T regulatory cells (iTregs) to prevent autoreactivity⁽⁴⁸⁻⁵⁰⁾ (Fig. 1). Concurrently, in the absence of effective B regulatory cell (Breg) inhibition, autoreactive B cells produce autoantibodies.⁽⁵¹⁾ Peptide autoantigens are presented by class II and class I HLA alleles to autoreactive T-cell receptors on CD4 T helper (Th) cells and CD8 cytotoxic T lymphocytes (CTLs), respectively. Binding of different autoantigens to B-cell receptors initiates secretion of specific autoantibodies.

The composition of the local cytokine milieu dictates CD4 Th cells to differentiate into Th1, Th2,




FIG. 1. Current concepts of the immunopathogenesis of AIH. Current knowledge supports a multistep working model of the immunopathogenesis of AIH, in which a break in self-tolerance to hepatocyte autoantigens initiates immunological responses causing progressive hepatic necroinflammation and fibrogenesis.⁽⁵⁰⁾ In the first step, thymic autoantigen-specific nTregs are incapable of preventing immune responses to hepatic autoantigens during hepatic or systemic immune responses to environmental triggers, such as viral infections or xenobiotics. In the second step, professional antigen-presenting cells (APCs) present autoantigenic peptides to autoreactive α/β T cell receptors (TCRs) on naive CD4⁺ Th cells, and CD8⁺ T cells and APCs activate MAIT cells by presenting bacterially processed vitamin B antigens to MAIT cell TCRs.⁽⁵⁴⁾ Costimulation is a crucial third step, which induces expression of T-cell genes required for proliferation, differentiation, and maturation of autoantigen-specific CD4⁺ Th subsets (e.g., Th1, Th2, Th3, Th9, Th17, iTregs, Tr1, Tfh cells) and both CD8⁺ CTLs and CD8⁺ Tregs. In the fourth step, secretion of specific cytokines by subsets of CD4⁺ Th cells produces a variety of immunological sequelae, including CD4⁺ Th2 cytokine stimulation of B-cell autoantibody production, CD4⁺ Tfh-cell activation of B cells into antibody-secreting plasma cells, Treg stimulation of Breg development through IL-35 mechanisms and cytokine-activated macrophages, and CD4⁺ Th17 cell-mediated pathogenic cytotoxicity. The fifth step is the cumulative failure of CD4⁺ and CD8⁺ Tregs and Bregs to control autoantigen-specific effector mechanisms causing hepatic injury.⁽⁵³⁾ Moreover, exposure of CD4⁺ iTregs to specific cytokines can transform them from regulatory cells into pathogenic CD4⁺ Th17 cells.⁽⁵²⁾ The sixth step is the generation of complex portal inflammatory infiltrates of effector cells that cause cytotoxicity of periportal and lobular hepatocytes. Necroinflammatory destruction of hepatocytes results in activation of periportal stellate cells, which amplify local immune responses through contact-dependent and independent mechanisms and cause progressive portal fibrosis, culminating in cirrhosis in the absence of effective immunosuppressive therapy. Abbreviations: Ag, antigen; IFN, interferon; TGF, transforming growth factor.

Th9, Th17, iTregs, and T follicular helper (Tfh) cell subsets in the presence of costimulatory signaling.⁽⁵⁰⁾ CD4 Th1 cells secrete cytokines that promote proliferation of autoantigen-specific CD8 CTLs and activation of macrophages. CD4 Th2 cytokines augment immunoglobulin production by B cells, while cytokines produced by Tfh cells induce their conversion to

immunoglobulin G (IgG)-secreting plasma cells. CD4 Th17 cells intensify inflammation and tissue injury.

Autoantigen-specific iTregs can down-regulate the proliferation and functions of all CD4 Th subtypes, and inadequate numbers and/or dysfunction of CD4 iTregs may play a key role in AIH.^(52,53) Cytokine-mediated transformation of CD4 iTregs into pathogenic CD4

Th17 cells also promotes perpetuation of AIH. Low doses of IL-2 preferentially stimulate proliferation and function of CD4 iTregs, while high doses promote production of other pathogenic CD4 Th subsets.

Mucosal invariant T (MAIT) cells that react with bacterially processed vitamin B antigens presented by major histocompatibility complex class I-related molecules congregate in the peribiliary region in AIH.⁽⁵⁴⁾ MAIT cells can express characteristics of CD4 Th1 and Th17 cells, and they may transform CD4 iTregs into proinflammatory CD4 Th17 cells. Inflammatory infiltrates composed of CD4 Th subsets, CD8 CTLs, MAIT cells, B cells, plasma cells, and innate immune cells, including natural killer (NK) and NK T cells and activated macrophages, can accumulate within the portal tracts.

Adhesion molecules and chemokines mediate transendothelial migration of immune cells into tissues.^(50,55) Extension of inflammation into periportal hepatocytes (interface hepatitis) and lobular hepatitis causes apoptosis of hepatocytes and fibrogenesis in untreated patients with AIH. Uptake and processing of immune complexes of autoantigen and immunoglobulin by antigen-presenting cells greatly increases activation of autoantigen-specific CD8 CTLs, and autoantibodies may enhance CD8 CTL cytotoxicity of hepatocytes.

Diagnosis

DIAGNOSTIC REQUISITES AND SUBTYPES

The diagnosis of AIH is based on histological abnormalities (interface hepatitis), characteristic clinical and laboratory findings (elevated serum aspartate aminotransferase [AST] and alanine aminotransferase [ALT] levels and increased serum IgG concentration), and the presence of one or more characteristic autoantibodies.^(2,56) AIH lacks a signature diagnostic marker, and the diagnosis requires characteristic features and the exclusion of other diseases that may resemble it (e.g., viral hepatitis, drug-induced liver injury, Wilson's disease, hereditary hemochromatosis).⁽⁵⁶⁾

There are two types of AIH, based on the specific autoantibodies that are present. Type 1 is characterized by antinuclear antibodies (ANA) and/or smooth muscle antibodies (SMA)/anti-actin antibodies, and type 2 is characterized by antibodies to liver kidney microsome

type 1 (anti-LKM1), usually in the absence of ANA and SMA.⁽⁵⁷⁾ The characteristic clinical features of these two types are presented in Table 3. In addition, up to 20% of AIH cases are negative for ANA, SMA, and LKM1 autoantibodies, despite the presence of other characteristic features of AIH (seronegative AIH). If seronegative AIH is suspected, other autoantibodies may be sought, as indicated in Table 4 and Fig. 2. Classification of AIH into types assists in management and aids in predicting outcomes in children, but it may be less informative in adults.⁽⁵⁸⁻⁶⁰⁾

AUTOANTIBODIES

ANA, SMA, and anti-LKM1 constitute the conventional serological repertoire for the diagnosis of AIH (Table 4).^(2,60) ANA are detected in 80% of white North American adults with AIH at presentation, SMA are present in 63%, and anti-LKM1 are present in 3%.⁽⁶¹⁾ Forty-nine percent of patients with AIH have ANA, SMA, or anti-LKM1 as an isolated serological finding at presentation; and 51% have multiple autoantibodies.⁽⁶¹⁾ ANA can also occur as an isolated serological finding in primary sclerosing cholangitis (PSC; 29%), chronic hepatitis C (26%), chronic hepatitis B (32%), nonalcoholic fatty liver disease (NAFLD; 34%), and chronic alcohol-associated liver disease (21%); and SMA can occur as an isolated serological finding in PSC (6%), chronic hepatitis C (6%), and chronic alcohol-associated liver disease (4%). ANA and SMA are concurrent in <10% of liver diseases outside of AIH, and the diagnostic accuracy for AIH improves from ~58% to 74% if two autoantibodies are detected at presentation.⁽⁶¹⁾

Anti-LKM1 are commonly detected in the absence of ANA and SMA, and this observation has justified their assessment after first testing for ANA and SMA⁽⁵⁷⁾ (Fig. 2). Furthermore, anti-LKM1 have a low sensitivity for AIH in North American adults (1%),⁽⁶¹⁾ and their assessment after first demonstrating the absence of ANA and SMA is appropriate in these patients. Anti-LKM1 are detected in 13%-38% of British and Canadian children with AIH,^(13,16,62) and determinations of ANA, SMA, and anti-LKM1 are usually made together at presentation. Autoantibody titers in adults and children roughly reflect disease severity and treatment response,^(63,64) but they are not established biomarkers of disease activity or treatment outcome.⁽⁶³⁾

Antibodies to soluble liver antigen (anti-SLA) are present in 7%-22% of patients with type 1 AIH, and

TABLE 3. Characteristic Features of Type 1 and Type 2 AIH

Features	Type 1 AIH	Type 2 AIH
Frequency	US adults, 96% ^(61,554)	US children, 9%-12% ⁽¹⁴⁻¹⁶⁾ UK children, 38% ⁽¹³⁾
Age at presentation	Peripubertal and adults	Usually under 14 years ⁽¹⁵³⁾
Mode of presentation	Chronic symptoms common Ascites or GI bleeding rare Asymptomatic in 25%-34% Acute in 25%-75% Acute severe in 2%-6%	Acute onset (~40%) Acute liver failure possible ^(555,556) Relapse frequent ⁽¹⁰⁸⁾
Laboratory features	Hypergammaglobulinemia	IgA levels may be reduced ⁽¹⁵³⁾
Autoantibodies	ANA SMA, anti-actin SLA	Anti-LKM1 [Anti-LC1, Anti-LKM3]
Concurrent immune diseases	Autoimmune thyroiditis Rheumatic diseases IBD	Autoimmune thyroiditis Diabetes mellitus Vitiligo
Autoimmune overlap with PSC (ASC in children)	Common in children Atypical pANCA-positive	Rare Atypical pANCA-negative
Overlap with PBC	Seen in adults (not children)	Not reported
Cirrhosis at presentation	Adults, 28%-33% (especially elderly) Children, ≤33%	Rare
Remission after drug withdrawal	Possible	Rare, usually need long-term immunosuppression

Abbreviations: GI, gastrointestinal; IgA, serum immunoglobulin A.

TABLE 4. Autoantibodies in the Diagnosis of AIH

Antibody	Target Antigen	Diagnostic Value
ANA	Chromatin, ribonucleoproteins ⁽⁵⁵⁷⁾	Type 1 AIH ⁽⁵⁶⁾
SMA	Filamentous actin (F-actin), vimentin, desmin ^(81,558)	Type 1 AIH ⁽⁵⁶⁾
LKM1	Cytochrome P450 2D6 (CYP2D6) ⁽⁵⁵⁹⁾	Type 2 AIH ⁽¹⁵³⁾
SLA	Sep (O-phosphoserine) transfer RNA:Sec (selenocysteine) transfer RNA synthase ⁽⁵⁶⁰⁻⁵⁶⁴⁾	Type 1 AIH ⁽⁶⁹⁾ Severe AIH ^(70,72) Predicts relapse after treatment ⁽⁷³⁾ Associated with poor outcome ⁽⁷⁰⁾
p-ANCA (atypical)	B-tubulin isotype 5 ⁽⁷⁷⁾ Nuclear lamina proteins ⁽⁵⁶⁵⁾	Type 1 AIH ^(75,76,566) PSC ^(566,567) ASC ⁽¹⁰⁸⁾
Actin	Filamentous (F) actin ⁽⁸¹⁾	Type 1 AIH ^(81,83)
α-Actinin	Filamentous actin cross-linking proteins ⁽⁵⁶⁸⁾	Investigational ⁽⁸⁴⁾ Type 1 AIH ⁽⁸⁵⁾ Prognostic biomarker ^(85,86)
LKM3	UDP glucuronosyltransferase family 1 ^(90,93)	Type 2 AIH ⁽⁹⁰⁾ Hepatitis D ⁽⁹⁰⁾
LC-1	Formiminotransferase cyclodeaminase ^(569,570)	Type 2 AIH ^(569,571)
LM	Cytochrome P450 1A2 ^(572,573)	Dihydralazine-induced hepatitis ⁽⁵⁷⁴⁾ APECED hepatitis ⁽⁵⁷⁵⁾
AMA	E2-subunits of pyruvate dehydrogenase complex ⁽⁵⁷⁶⁾	PBC ⁽⁵⁷⁶⁾ PBC-AIH overlap syndrome ⁽¹⁷⁷⁾ Type 1 AIH ^(183,577,578)

Abbreviations: APECED, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy; UDP, uridine diphosphate.




FIG. 2. Diagnostic algorithm for the evaluation of suspected AIH after exclusion of viral, drug-induced, hereditary, and metabolic diseases. ANA and SMA should be assessed in adults (green panel), and antibodies to LKM1 should be assessed later if ANA and SMA are absent. ANA, SMA, and LKM1 should be assessed in all pediatric patients at presentation (green panel). The findings of the liver biopsy (dark blue panels) could support the diagnosis of AIH (dark red panel) or suggest alternative diagnoses that might include an overlap syndrome, PBC, PSC, AIH with NAFLD, or NASH (brown panels). The absence of ANA, SMA, and LKM1 justifies additional serological tests (green panel) that can include antibodies to SLA, atypical pANCA, tissue transglutaminase, and AMA. Seropositivity for one of these autoantibodies could support the diagnosis of AIH (dark red panels) or suggest other diagnoses including celiac disease (dark brown panels). Abbreviations: Peds, pediatric patients; tTG, tissue transglutaminase.

they have high specificity (99%) for the diagnosis⁽⁶⁵⁻⁷¹⁾ (Table 4). Anti-SLA have been the sole markers of AIH in 14%-20% of patients,^(65,67,68) and they have been associated with severe disease and relapse after drug withdrawal.^(68,70,72-74) Atypical perinuclear antineutrophil cytoplasmic antibodies (pANCA) are frequently present in patients with type 1 AIH (50%-92%),⁽⁷⁵⁻⁷⁷⁾ but they lack diagnostic specificity, occurring in PSC, AIH-PSC overlap syndrome, ulcerative colitis (UC), and minocycline-related liver injury.^(76,78) Occasionally atypical pANCA may be the only autoantibodies detected.^(56,79,80)

Antibodies against filamentous (F) actin (anti-actin) are a subset of SMA, and they are present in 86%-100% of patients with AIH and SMA⁽⁸¹⁻⁸³⁾

(Table 4). Antibody to alpha-actinin (anti- α -actinin) is an investigational marker that is present in 42% of patients with AIH and 66% of patients with anti-actin.⁽⁸⁴⁾ Dual reactivity to anti-actin and anti- α -actinin has been associated with severe acute AIH, incomplete treatment response, and relapse.⁽⁸⁴⁻⁸⁶⁾

Antibodies to liver cytosol type 1 (anti-LC1) are present in 32% of patients with anti-LKM1,⁽⁸⁷⁾ and they occur mainly in children with severe liver disease^(87,88) (Table 4). Anti-LKM3 are present in 17% of patients with type 2 AIH⁽⁸⁹⁾ and may be useful in evaluating otherwise seronegative patients.⁽⁹⁰⁻⁹³⁾ Anti-LC1 and anti-LKM3 have not been rigorously assessed in the United States.⁽⁹⁴⁾

Antibody determinations should be selective and consistent with the clinical phenotype being assessed. Additional serological markers may be sought depending on results of the earlier tests and in accordance with the evolving diagnostic possibilities (Fig. 2).

HISTOLOGICAL FINDINGS

The diagnosis of AIH cannot be made without liver biopsy and compatible histological findings. Interface hepatitis is the histological hallmark of AIH, accompanied by plasma cell infiltration in 66% and lobular hepatitis in 47%.⁽⁹⁵⁾ Centrilobular necrosis is also found in 29%,⁽⁹⁶⁻¹⁰⁰⁾ and it occurs with similar frequency in patients with and without cirrhosis.⁽⁹⁹⁾ Emperipolesis is the penetration of one intact cell into another intact cell, with both cells retaining viability (as opposed to phagocytosis).^(101,102) Emperipolesis is present in 65% of patients with

AIH, and hepatocyte rosettes are present in 33%⁽¹⁰³⁾ (Fig. 3). None of the individual histological findings is specific for AIH, but the findings of interface hepatitis with portal lymphocytic or lymphoplasmacytic cells extending into the lobule, emperipolesis, and rosettes are considered typical of AIH.⁽¹⁰³⁾

Cirrhosis is present in 28%-33% of adults at presentation, especially in the elderly,^(9,104-107) as well as in 38% of children.^(13,108) Cirrhosis develops in 40% of adults with multilobular necrosis or bridging necrosis.^(105,109,110) The histological examination at presentation is essential to exclude alternative or concurrent diagnoses, grade the severity of inflammatory activity, and indicate the stage of fibrosis.⁽¹¹¹⁻¹¹⁴⁾ IgG4-positive plasma cells may be present in some patients with AIH,⁽¹¹⁵⁻¹¹⁷⁾ but the clinical impact of this finding remains unclear. Histological findings of NAFLD/nonalcoholic steatohepatitis (NASH) are present in 17%-30% of patients with AIH,^(118,119) and liver tissue examination may




FIG. 3. Histological features characteristic of AIH. (A) Lymphoplasmacytic inflammatory infiltration of the portal tract and interface hepatitis involving >50% of the portal tract circumference (arrows; hematoxylin and eosin; magnification, $\times 200$). (B) Plasma cell predominance in a portal inflammatory infiltrate (hematoxylin and eosin; magnification, $\times 600$). (C) Perivenulitis of a central vein (hematoxylin and eosin; magnification, $\times 400$). (D) A hepatocyte undergoing emperipolesis (arrows; hematoxylin and eosin; magnification, $\times 600$). (E) Rosettes of regenerating hepatocytes (arrows; hematoxylin and eosin; magnification, $\times 600$). Photomicrographs are courtesy of Sadhna Dhingra, M.D., Department of Pathology, Baylor College of Medicine, Houston, TX.

identify patients with AIH and NASH who are at increased risk of liver-related mortality (relative risk, 7.65) and adverse outcome (relative risk, 2.55).⁽¹¹⁸⁾

The histological features of AIH with ALF predominate in the centrilobular zone and consist of four principal features.⁽¹⁰⁰⁾ Central perivenulitis is present in 65%, plasma cell-enriched inflammatory infiltrate in 63%, massive hepatic necrosis in 42%, and lymphoid follicles in 32%. Sixty-six percent of patients with ALF will have two (21%), three (26%), or all four (19%) of these features.⁽¹⁰⁰⁾

DIAGNOSTIC SCORING SYSTEMS

The diagnostic scoring system of the International Autoimmune Hepatitis Group (IAIHG) was created by an international panel in 1993,⁽¹²⁰⁾ revised in 1999,⁽⁵⁶⁾ and simplified in 2008⁽¹²¹⁾ (Supporting Table S2). The original revised scoring system has greater sensitivity for AIH compared to the simplified scoring system (100% versus 95%), whereas the simplified scoring system has superior specificity (90% versus 73%) and accuracy (92% versus 82%), using clinical judgment as the gold standard.⁽¹²²⁾ The revised diagnostic scoring system is preferable for patients with complex or unusual features, whereas the simplified scoring system is most accurate for typical patients.⁽¹²²⁾

Reassessment of patients with the revised scoring system should be considered whenever the simplified system yields a low score. In children, a meta-analysis of four studies pertaining to the accuracy of the simplified criteria revealed a sensitivity of 77% and a specificity of 95%.⁽¹²³⁾ In that study, false-negative scores (~17%) were associated with seronegative AIH.

The revised original diagnostic scoring system can be applied to children and accepts lower autoantibody titers than in adults as having diagnostic significance.⁽⁵⁶⁾ Substitution of the serum gamma-glutamyltransferase (GGT) level for the serum alkaline phosphatase level in the ratio with the serum ALT or AST level may improve the specificity of the revised original scoring system for children by indicating the likelihood of biliary disease.⁽¹²⁴⁾

Limitations to the revised original and simplified scoring systems include (1) lack of validation by prospective studies; (2) lack of accuracy in the setting of concurrent PSC, primary biliary cholangitis (PBC), NAFLD/NASH, LT, or fulminant liver failure^(125,126);

(3) failure to include other serological markers, such as anti-SLA^(56,121); and (4) dependence on autoantibody determinations by indirect immunofluorescence (titers) rather than by enzyme-linked immunoassay (units).⁽¹²⁷⁾ Diagnostic scoring systems can aid in establishing a diagnosis of AIH in challenging cases, but they are most useful in defining cohorts of patients with AIH for clinical studies.⁽⁵⁶⁾

GUIDANCE STATEMENTS

- The diagnosis of AIH requires compatible *histological findings* and is further supported by the following features: (1) *elevated serum aminotransaminase levels*; (2) *elevated serum IgG level and/or positive serological marker(s)*; (3) *exclusion* of viral, hereditary, metabolic, cholestatic, and drug-induced diseases that may resemble AIH.
- Initial serological testing should include determinations of ANA and SMA in adults and ANA, SMA, and anti-LKM1 in children; consider additional autoantibody tests if warranted to secure the diagnosis.
- Diagnostically challenging cases should be reviewed by or referred to an experienced liver center prior to initiating therapy.

Clinical Manifestations

PRESENTATIONS

Symptomatic

Most patients with AIH present after the development of chronic nonspecific symptoms (fatigue, malaise, arthralgias, or amenorrhea). Easy fatigability is the main complaint in 85% of patients, and jaundice may be present.⁽¹²⁸⁾ Presence of pruritus or hyperpigmentation is inconsistent with the diagnosis,⁽⁵⁶⁾ and weight loss suggests a serious complication (malignancy). Physical signs are usually absent, apart from signs of advanced chronic liver disease (spider nevi, caput medusa, splenomegaly, ascites, palmar erythema) or manifestations of extrahepatic autoimmune disease (vitiligo, inflammatory bowel disease [IBD]).⁽¹²⁹⁾

Asymptomatic

AIH is asymptomatic in 25%-34% of patients.^(60,104,130) Asymptomatic patients infrequently achieve spontaneous laboratory improvement (12%),⁽¹³¹⁾ may have histological findings similar to those of symptomatic patients,⁽¹³⁰⁾ frequently develop symptoms within 2-120 months (mean interval, 32 months; 26%-70%),^(104,130) and experience a 10-year survival that is less than that of treated patients with more severe disease (67% versus 98%).⁽¹³¹⁾ The absence of symptoms should not discourage treatment.⁽¹³⁰⁻¹³²⁾

Acute Severe Hepatitis and ALF

AIH presents with an acute onset (duration, <30 days) in 25%-75% of patients.⁽¹³³⁻¹³⁶⁾ ALF associated with hepatic encephalopathy occurs in 3%-6% of North American and European patients^(100,137) (see definitions in Table 2). Spontaneous exacerbation or a superimposed viral, toxic, or drug-induced liver injury on previously undiscovered AIH (acute-on-chronic liver disease) must be excluded.^(138,139) ANA are absent or weakly positive in 29%-39% of patients with acute severe AIH, and the serum IgG level is normal in 25%-39%.^(140,141) Histological assessment is a key diagnostic test.⁽¹⁴¹⁾ Lobular hepatitis, lymphoplasmacytic infiltrate, and interface hepatitis support the diagnosis of acute AIH; and similar features in the presence of cirrhosis suggest exacerbated chronic disease.⁽¹³⁸⁾ Central perivenulitis, lymphoplasmacytic infiltrate, lymphoid follicles, and massive hepatic necrosis can be found in AIH with ALF.⁽¹⁰⁰⁾ Unenhanced computed tomography demonstrates heterogeneous hypoattenuated regions within the liver in 65% of patients with acute severe AIH and may be disease-specific.⁽¹⁴²⁾

Autoantibody-Negative Hepatitis

ANA, SMA, and anti-LKM1 are absent in 19%-34% of North American and German patients originally diagnosed as cryptogenic hepatitis and then reclassified as AIH by the revised original diagnostic scoring system.^(143,144) Lower frequencies of autoantibody-negative AIH have been reported in other ethnicities⁽¹⁴⁵⁾ and by other diagnostic criteria, including clinical judgment and glucocorticoid responsiveness.^(146,147) ANA and SMA may be

expressed later in the course of the disease,⁽⁶³⁾ or the demonstration of SLA and atypical pANCA may direct the diagnosis to AIH⁽¹⁴⁸⁾ (Fig. 2).

GUIDANCE STATEMENT

- The diagnosis of AIH must be considered in all patients presenting with acute or chronic liver disease, including patients with asymptomatic liver test abnormalities, ALF, and autoantibody-negative hepatitis.

CONCURRENT IMMUNE DISEASES

Concurrent autoimmune diseases are present in 14%-44% of patients with AIH,^(129,149-152) and they have been recognized with similar frequencies in patients with type 1 and type 2 disease.⁽¹⁴⁹⁾ Autoimmune thyroid disease has been the most common concurrent autoimmune disease in type 1 AIH (10%-18%),^(129,150-152) whereas type 1 diabetes,⁽¹⁵³⁾ autoimmune thyroid disease,⁽¹⁵³⁾ and autoimmune skin diseases (vitiligo, leukocytoclastic vasculitis, urticaria, alopecia areata) have been most common in type 2 AIH.⁽¹⁵²⁾

Concurrent immune disease is commonly associated with few or no symptoms, but in rare instances, the severity of symptoms may obscure the underlying liver disease.⁽¹²⁹⁾ In 10%-15% of children with APS-1, AIH may accompany at least two of the three components of the syndrome (mucocutaneous candidiasis, hypoparathyroidism, and adrenocortical insufficiency).^(154,155)

Extrahepatic autoimmune disease occurs most frequently in women,⁽¹⁵²⁾ and the type varies by age group.⁽¹⁵⁶⁾ Patients aged ≥60 years have autoimmune thyroid and rheumatic diseases more commonly than adults ≤30 years (42% versus 13%), whereas young adults more often have IBD and autoimmune hemolytic anemia (13% versus 0%).⁽¹⁵⁶⁾ Furthermore, concurrent autoimmune disease is more common in patients with HLA DRB1*04:01⁽¹⁵⁶⁻¹⁵⁸⁾ or a family history of autoimmune disease in first-degree relatives.^(152,159)

The frequency of celiac disease in patients with AIH is higher than that in the general population (2.8%-3.5%).^(160,161) Among Italian children with AIH, celiac disease was present in 16%.⁽¹⁶²⁾ Both laboratory and serological features associated with celiac disease can be confused with AIH, and concurrent celiac disease may contribute to the degree of liver

dysfunction in AIH.^(160,161,163-167) Pediatric patients with AIH and celiac disease who avoided gluten had higher frequencies of sustained remission after withdrawal of glucocorticoids than AIH children without celiac disease (33% versus 8%).⁽¹⁶⁶⁾

GUIDANCE STATEMENTS

- AIH patients should be screened for celiac and thyroid diseases at diagnosis.
- AIH patients should be assessed for rheumatoid arthritis, IBD, autoimmune hemolytic anemia, diabetes, and other extrahepatic autoimmune diseases based on symptomatology and medical provider concern.

OVERLAP SYNDROMES OR CHOLESTATIC VARIANTS

Overlap syndromes between AIH and PBC or PSC are clinical descriptions and not validated pathological entities.^(126,168-173) Their major clinical value is to identify individuals who may not respond to conventional treatment for AIH.⁽¹⁷³⁻¹⁷⁶⁾

AIH–PBC Overlap Syndrome

The “Paris criteria” identify patients with overlapping features of AIH and PBC.⁽¹⁷⁷⁾ Two of the following three criteria for PBC should be met: (1) serum alkaline phosphatase level ≥ 2 -fold the upper limit of normal (ULN) range or serum GGT level ≥ 5 -fold ULN, (2) presence of antimitochondrial antibodies (AMA), and (3) florid bile duct lesions on histological examination.^(126,178,179) Criteria for AIH in the setting of PBC (in addition to the presence of interface hepatitis) are (1) serum ALT level ≥ 5 -fold ULN and (2) serum IgG level ≥ 2 -fold ULN or presence of SMA.^(126,177,180) A single-center comparison of the Paris criteria and the AIH scoring systems found that the Paris criteria were more reliable (sensitivity, 92%; specificity, 97%).⁽¹⁸¹⁾ Importantly, the Paris criteria may not capture all patients with the AIH–PBC overlap syndrome who have less pronounced cholestatic laboratory features.^(173,175,182)

The IAIHG has emphasized that the criteria for the diagnosis of AIH–PBC have not been independently validated and that it is difficult to interpret the reported high sensitivity and specificity of the Paris criteria.⁽¹²⁶⁾ They have also emphasized that the diagnostic scoring

systems for AIH were not developed or validated for the diagnosis of the overlap syndromes and that they should not be used for this purpose.⁽¹²⁶⁾

Antibodies to pyruvate dehydrogenase-E2 (AMA) are present in 8%–12% of patients with AIH in the absence of histological features of bile duct injury or loss.^(65,183) These patients respond well to glucocorticoid therapy, and they do not evolve into PBC.⁽¹⁸³⁾ Liver tissue examination is required to exclude the AIH–PBC overlap syndrome, and the presence of AMA in patients with AIH is insufficient to make this diagnosis.

AIH–PSC Overlap Syndrome

Criteria for the diagnosis of AIH–PSC overlap syndrome (also known as autoimmune sclerosing cholangitis [ASC] in children⁽¹⁰⁸⁾) include the presence of typical features of AIH, absence of AMA, and evidence of large-duct PSC by endoscopic or magnetic resonance cholangiography or evidence of small-duct PSC based on “onion skinning” periductal fibrosis on histology.⁽¹⁷³⁾ Chronic UC is present in 16% of adults with AIH, and 42% of patients with AIH and concurrent UC have cholangiographic changes of PSC.⁽¹⁸⁴⁾ UC is present in 20% of children with AIH, and it affects up to 45% with AIH–PSC overlap syndrome.⁽¹⁰⁸⁾ Patients with cholestatic laboratory abnormalities, absence of AMA, histological features compatible with PSC or PBC, and normal cholangiograms may have small-duct PSC⁽¹⁸⁵⁾ or AMA-negative PBC, respectively.⁽¹⁸⁶⁾ The diagnosis of AIH–PSC overlap syndrome should be considered in all patients with AIH and chronic UC, unexplained cholestatic laboratory findings, or non-response to conventional glucocorticoid therapy.⁽¹⁷³⁾

GUIDANCE STATEMENTS

- Patients with AIH, cholestatic laboratory/histological findings consistent with PBC, and a positive AMA should be considered to have AIH–PBC overlap syndrome.
- Patients with AIH, cholestatic laboratory findings, histological features of bile duct injury or loss, and concurrent chronic UC should be evaluated for large-duct PSC by cholangiography to determine whether they have the AIH–PSC overlap syndrome.
- The Paris criteria can aid in diagnosing the AIH–PBC overlap syndrome, but the criteria may exclude

patients with AIH-PBC who have less severe cholestatic features.

- Neither the revised nor the simplified IAIHG diagnostic scoring systems for AIH should be used for assessing overlap syndromes.

DRUG-INDUCED AIH-LIKE INJURY

Drug-induced liver injury can mimic AIH,⁽¹⁸⁷⁻¹⁹¹⁾ and an unpredictable idiosyncratic or hypersensitivity drug reaction has been implicated in 2%-17% of patients with classical features of AIH.^(187,189,191) Minocycline,^(187,192-198) nitrofurantoin,^(187,199-205) and infliximab⁽²⁰⁶⁻²²¹⁾ have been most commonly incriminated; and multiple other agents have been implicated (Table 5). Immune-related adverse events, including hepatitis, have been reported with the use of immune activating agents, such as the checkpoint

inhibitors.⁽²²²⁻²²⁴⁾ The liver injuries associated with the checkpoint inhibitors have usually improved with glucocorticoid therapy, but they have lacked the laboratory and histological features characteristic of AIH.⁽²²⁵⁻²²⁹⁾ Furthermore, some cases have been resistant to glucocorticoid therapy and associated with bile duct injury.⁽²³⁰⁾ The liver injuries associated with the checkpoint inhibitors should not be confused with AIH.

The clinical phenotype of drug-induced AIH-like injury is summarized in Table 6.^(56,188,190) The latency interval from drug exposure to disease onset ranges from 1-8 weeks to 3-12 months,⁽²³¹⁻²³³⁾ but nitrofurantoin and minocycline can have latency periods that exceed 12 months.⁽²³⁴⁾ The clinical history should detail all previous exposures to drugs and supplements.

The histological findings of interface hepatitis with portal and periportal infiltrates of lymphocytes, lobular hepatitis, plasma cells, and eosinophils are similar to

TABLE 5. Drugs Associated with Liver Injuries Resembling AIH

Definite Association	Probable Association	Possible Association
Minocycline ^(187,192-198)	Propylthiouracil ^(579,580)	Ipilimumab (anti-CTLA-4) ⁽⁵⁸¹⁾
Nitrofurantoin ^(187,199-205)	Isoniazid ⁽⁵⁸²⁾	Tremelimumab (anti-CTLA-4) ⁽⁵⁸¹⁾
Infliximab ⁽²⁰⁶⁻²²¹⁾	Diclofenac ^(583,584)	Nivolumab (anti-PD-1) ⁽⁵⁸¹⁾
Alpha-methyl dopa ⁽⁵⁸⁵⁻⁵⁸⁷⁾	Etanercept ^(216,432,433)	Pembrolizumab (anti-PD-1) ^(230,588)
Adalimumab ^(216,433,589-591)	Atorvastatin ⁽⁵⁹²⁻⁵⁹⁵⁾	Atezolizumab (anti-PD-L1) ⁽⁵⁸¹⁾
Halothane ^(596,597)	Rosuvastatin ⁽⁵⁹⁸⁾	Black cohosh (herbal medicine) ^(599,600)
Oxyphenisatin ⁽⁶⁰¹⁾	Clometacine ^(602,603)	Dai-saiko-to (herbal medicine) ⁽⁶⁰⁴⁾
Dihydralazine ^(573,574,605)		Germander (herbal medicine) ⁽⁶⁰⁶⁾
Tienilic acid ⁽⁶⁰⁷⁾		Hydroxycut (nutritional supplement) ⁽⁶⁰⁸⁾
		Trichloroethylene (toxin) ⁽⁶⁰⁹⁾
		Papaverine ⁽⁶¹⁰⁾
		Indomethacin ⁽⁶¹¹⁾
		Imatinib ⁽⁶¹²⁾

*Removed from marketplace.

Abbreviation: anti-PD-L1, antibody to programmed death protein ligand 1.

TABLE 6. Features of Drug-Induced AIH-Like Injury and AIH

Clinical Features	Drug Induced AIH-Like Injury	AIH
Gender	Mainly women ⁽¹⁸⁷⁾	Female predominance, but men also affected ^(2,384,467)
Acute onset	Majority (>60%) ⁽²³¹⁾	<20% ^(2,136)
Hypersensitivity (fever, rash, eosinophilia)	Up to 30% ^(231,232,613)	Unusual ^(2,384,467)
Temporal relationship with drug	Positive ⁽²³¹⁻²³⁴⁾	Negative ^(2,56,188)
HLA DRB1*03:01 or DRB1*04:01 association	None ⁽²³⁶⁾	Common ⁽²⁹⁾
Concurrent autoimmune diseases	Unusual ⁽¹⁸⁷⁾	Present in 14%-44% ^(129,149-152)
Cirrhosis at presentation	Rare ⁽¹⁸⁷⁾	28%-33% ^(9,104-107)
Management	Stop offending drug ± glucocorticoids ^(187,231,232)	Glucocorticoids with AZA ^(2,384,467)
Relapse after drug withdrawal	Rare ⁽¹⁸⁷⁾	60%-87% ^(243,244)
Progression to cirrhosis	Rare ⁽¹⁸⁷⁾	7%-40% ⁽¹⁰⁵⁾
Survival without transplantation	90%-100% ^(187,232)	10-year survival, 89%-91% ^(105,451)

those of classical AIH, except for the absence of advanced fibrosis or cirrhosis in most instances.^(187,190,231,232,235,236) Centrilobular zone 3 necrosis may be present,^(187,233) and bridging fibrosis (Ishak score ≥ 4) is rare.⁽²³⁷⁾

The diagnosis is supported by an acute onset, features of hypersensitivity, published literature on the implicated drug, latency period from drug exposure to liver injury, and absence of advanced fibrosis or cirrhosis at presentation.⁽¹⁸⁸⁾ Liver tissue examination is warranted if the diagnosis is uncertain, laboratory findings indicate severe injury, or the institution of glucocorticoid therapy is being considered.

Treatment requires withdrawal of the offending agent with close monitoring until complete and sustained resolution of clinical and laboratory findings^(187,231,232) (Table 6). Resolution typically occurs within 1 month (rarely 3 months).^(187,231,238,239) In accordance with "Hy's law," serum aminotransferase levels >3 -fold ULN and total serum bilirubin level >2 -fold ULN increase the risk of death or need for LT in 9%-12% of patients.⁽²⁴⁰⁻²⁴²⁾ Satisfaction of criteria for Hy's law supports the institution of glucocorticoid therapy.⁽¹⁸⁷⁾ Other reasons to consider glucocorticoid management are failure of the laboratory tests to improve after discontinuation of the medication or worsening of symptoms or laboratory tests at any time during the observation period.

Sustained biochemical resolution after glucocorticoid withdrawal strengthens the diagnosis of a self-limited drug-induced liver injury, whereas recrudescence of laboratory abnormalities is consistent with AIH.^(187,188) Recrudescence should be managed as AIH with immunosuppressive therapy.^(243,244) An algorithm based on the serum ALT level >17.3 ULN, total serum bilirubin level >6.6 ULN, and AST:ALT >1.5 has a sensitivity of 80% and specificity of 82% for drug-induced ALF; this algorithm is a promising enhancement of Hy's law.⁽²⁴²⁾

The outcome of drug-induced AIH-like injury has been excellent^(187,231,232) (Table 6). The infrequent exceptions have been reported mainly as case reports or abstracts,⁽²⁴⁵⁾ and idiosyncratic drug reactions do have a mortality of 5% and need for LT in 4.5%.^(234,246) The LiverTox website (<https://livertox.nlm.nih.gov/aboutus.html>) of the US Drug-Induced Liver Injury Network is a valuable resource for evaluating suspected drug-induced liver injury. It is a joint effort of the Liver Disease Research Branch of the National Institute of Diabetes and Digestive and Kidney Diseases and the Division of Specialized

Information Services of the National Library of Medicine, National Institutes of Health.

GUIDANCE STATEMENTS

- Drug-induced AIH-like liver injury must always be considered in the differential diagnosis of AIH.
- The offending agent must be withdrawn and monitoring maintained to ensure laboratory resolution.
- Glucocorticoid therapy for drug-induced AIH-like injury should be instituted when symptoms or disease activity are severe (e.g., fulfill Hy's law) or if symptoms and laboratory tests fail to improve or worsen after discontinuation of the offending drug.
- Laboratory flare after glucocorticoid withdrawal suggests underlying AIH and the need for immunosuppressive therapy.

Noninvasive Fibrosis Assessment

NONINVASIVE ASSESSMENT OF HEPATIC FIBROSIS BY SERUM BIOMARKER PANELS

Among 14 serum-based biomarker panels for hepatic fibrosis, the FibroTest,⁽²⁴⁷⁻²⁴⁹⁾ the serum AST/platelet ratio index (APRI),⁽²⁵⁰⁾ the Fibrosis-4 index (FIB-4),^(251,252) and the enhanced liver fibrosis test^(253,254) have emerged as the better candidates in AIH.⁽²⁵⁵⁻²⁵⁸⁾ However, their role in AIH and their relative merit in assessing the progression or reversal of hepatic fibrosis, immediate and long-term prognosis, risk of hepatocellular carcinoma (HCC), and treatment outcome remain unknown.⁽²⁵⁹⁾

NONINVASIVE ASSESSMENT OF HEPATIC FIBROSIS BY LIVER STIFFNESS

Vibration-Controlled Transient Elastography (or FibroScan)

Vibration-controlled transient elastography (VCTE) or FibroScan correlates strongly with the histological stage of fibrosis in AIH,⁽²⁶⁰⁻²⁶²⁾ but its accuracy in quantifying fibrosis is impaired when

undertaken within the first 3 months of treatment.⁽²⁶⁰⁾ Because liver stiffness estimated by VCTE is affected by both inflammation and fibrosis,^(260,263,264) the VCTE results at presentation correlate with histological grade of inflammation rather than stage of fibrosis.⁽²⁶⁰⁾ After at least 6 months of successful immunosuppressive therapy to reduce hepatic inflammation, VCTE can accurately diagnose cirrhosis and distinguish advanced stages of fibrosis (F3, F4) from less severe stages (F0-F2).⁽²⁶⁰⁾ The cutoff values that best predicted fibrosis stages (defined as the highest sum of sensitivity plus specificity) were 5.8 kPa for $F \geq 2$, 10.5 kPa for $F \geq 3$, and 16 kPa for $F \geq 4$.⁽²⁶⁰⁾ Improvements in liver stiffness correlate with biochemical remission, regression of fibrosis, and favorable prognosis when assessed after 6 months of treatment.⁽²⁶⁵⁾

Magnetic Resonance Elastography

The findings of magnetic resonance elastography (MRE) correlate strongly with fibrosis stage, and MRE appears to outperform VCTE for staging hepatic fibrosis in some studies performed in other liver diseases.⁽²⁶⁶⁻²⁶⁹⁾ Furthermore, MRE assessment of splenic stiffness can have prognostic value for predicting portal hypertension and esophageal varices.⁽²⁷⁰⁾ In AIH, the accuracy (97%), sensitivity (90%), specificity (100%), positive predictive value (100%), and negative predictive value (90%) of MRE for advanced hepatic fibrosis are excellent.⁽²⁶⁹⁾

MRE has outperformed conventional magnetic resonance imaging, the fibrosis scoring systems (FIB-4, APRI), and the conventional laboratory tests (AST, ALT, international normalized ratio [INR], platelet count) for the diagnosis of cirrhosis in AIH.⁽²⁶⁹⁾ In one study, liver inflammation affected the assessment of fibrosis stage by MRE when the grade of fibrosis was $\leq F2$.⁽²⁷¹⁾ In another study, liver stiffness in untreated patients with AIH was higher than that in treated patients (3.83 kPa versus 3.7 kPa, $P =$ non-significant).⁽²⁶⁹⁾ This trend was seen at each fibrosis stage from F0 to F3 (F0, 3.1 kPa versus 2.61 kPa; F1, 2.94 kPa versus 2.74 kPa; F2, 3.2 kPa versus 2.63 kPa; F3, 4.1 kPa versus 3.99 kPa) and reversed in F4 (6.5 kPa versus 5.9 kPa).⁽²⁶⁹⁾ Differences in liver stiffness detected by MRE in untreated and treated patients with AIH have not been statistically significant, but the findings suggest that liver stiffness

assessed by MRE can be influenced by therapy, possibly by reducing liver inflammation or hepatic fibrosis. MRE and VCTE have not been compared head-to-head in AIH.

Acoustic Radiation Force Impulse Imaging

Acoustic radiation force impulse imaging (ARFI) assesses liver stiffness by measuring changes in wave propagation speed, and displacements of short-duration bursts of radiated sound waves are interpreted as changes in liver stiffness.^(256,272,273) The accuracy of ARFI for cirrhosis exceeds 90% (sensitivity, 93%; specificity, 85%),⁽²⁷⁴⁾ and results by meta-analysis of 13 studies have been comparable to VCTE in predicting fibrosis stage ≥ 2 and cirrhosis.⁽²⁷⁵⁾ Splenic stiffness by ARFI has also correlated with the grade of esophageal varices, and ARFI may evolve as a method to assess manifestations of portal hypertension.^(276,277) ARFI can overestimate hepatic fibrosis in patients with massive hepatic necrosis, cholestasis, severe inflammation, and hepatic congestion.⁽²⁷⁸⁾

GUIDANCE STATEMENTS

- Serum-based biomarker panels for hepatic fibrosis are unestablished in AIH and should not be used.
- VCTE can identify advanced fibrosis or cirrhosis in patients with AIH with reasonable accuracy, but it should be deferred for at least 6 months after successful treatment of AIH in order to avoid the confounding effects of hepatic inflammation.

Pretreatment Evaluation

The aims of the pretreatment evaluation of patients with AIH are to limit treatment-related complications and ensure an optimal therapeutic response.

PRETREATMENT ASSESSMENT OF THIOPURINE METHYLTRANSFERASE ACTIVITY

Pretreatment testing of thiopurine methyltransferase (TPMT) activity identifies those rare patients with zero or near-zero TPMT activity who are at risk for severe myelosuppression when treated with AZA

or mercaptopurine (MP).^(279,280) Absent or near-absent TPMT activity occurs in only 0.3%-0.5% of the normal population,⁽²⁸¹⁻²⁸⁴⁾ but the possibility of preventing severe bone marrow toxicity may warrant its use without an analysis of cost-effectiveness.⁽²⁸⁵⁻²⁸⁸⁾ Genotypic and phenotypic screening for blood TPMT activity does not reduce the frequency of other common AZA or 6-MP side effects such as nausea, rash, and arthralgias,⁽²⁸⁹⁻²⁹¹⁾ and normal TPMT activity does not preclude the occurrence of dose-dependent toxicities (including cytopenia) in AIH.^(291,292)

GUIDANCE STATEMENT

- Consider screening patients with AIH for absent or near-absent TPMT activity prior to initiating treatment with AZA.

VACCINATIONS

Vaccination status should be reviewed and updated, ideally prior to the institution of immunosuppressive therapy.⁽²⁹³⁻²⁹⁵⁾ Live, attenuated vaccines are not recommended in persons on high doses of immunosuppression, whereas recombinant and inactivated vaccines are considered safe. Response rates to vaccines are lower in immunosuppressed patients but not so low as to preclude their use.

Patients unprotected against infections with hepatitis A virus (HAV) and hepatitis B virus (HBV) should undergo vaccination prior to immunosuppressive treatment if possible.⁽²⁹⁴⁾ Susceptibility to HAV infection (51%) and HBV infection (86%) has been demonstrated in most patients with autoimmune liver diseases, and the incidence of infection has been 1.3 (HAV infection) and 1.4 (HBV infection) per 1,000 person-years.⁽²⁹⁴⁾ Protective antibodies have developed in all patients vaccinated for HAV and in 76% of patients vaccinated for HBV, with vaccination failures attributed mainly to concomitant immunosuppressive therapy.⁽²⁹⁴⁾

GUIDANCE STATEMENTS

- Vaccines should be administered to all susceptible patients with AIH according to the age-specific guidelines of the Centers for Disease Control and Prevention (<https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html>)

- Patients unprotected against HAV and HBV infection should undergo vaccination, preferably before immunosuppressive therapy.

DETECTION AND PREVENTION OF REACTIVATION OF HBV INFECTION

Patients on immunosuppressive agents are at risk for reactivation of HBV infection, and guidelines have been developed recommending routine pretreatment screening of patients for hepatitis B surface antigen (HBsAg) and antibodies to hepatitis B core antigen (anti-HBc).⁽²⁹⁶⁻²⁹⁹⁾ Based on the serological profile (HBsAg-positive versus HBsAg-negative/anti-HBc-positive) and the type, dose, and duration of immunosuppressive therapy, the risk of HBV reactivation during treatment can be estimated as high ($\geq 10\%$), moderate (1%-10%), and low ($< 1\%$).⁽²⁹⁸⁾ Depending on the risk category, a preemptive treatment or monitoring strategy with the intent of on-demand therapy can be developed.^(298,299) Prophylactic antiviral therapy, preferably with entecavir or tenofovir, during immunosuppressive treatment and for at least 6 months after treatment (or at least 12 months after treatment with anti-CD20 agents) has been recommended for individuals at high to moderate risk of HBV reactivation. Watchful monitoring with intent of on-demand therapy has been recommended for patients at low risk.^(298,299)

The risk of HBV reactivation in patients with AIH who are treated with conventional regimens of prednisone or prednisolone in combination with AZA is unknown. Furthermore, the reported risk levels in glucocorticoid-treated patients relate mainly to individuals with HBsAg who are at risk of developing viremia detected by HBV DNA.⁽³⁰⁰⁾ These patients warrant antiviral prophylaxis, but they constitute a small percentage of patients with AIH who would be considered for glucocorticoid therapy.^(296-298,300)

HBsAg-negative patients with anti-HBc constitute another risk category for reactivation, but reverse seroconversion (appearance of HBsAg and HBV DNA in a previously HBsAg-negative patient) has occurred mainly in patients treated with B cell-depleting agents, TNF inhibitors, and chemotherapeutic agents.⁽³⁰⁰⁾ Traditional immunosuppressive agents (AZA, 6-MP) have been associated with a low

risk (<1%) of reverse seroconversion, as has glucocorticoid therapy for ≥ 4 weeks for autoimmune disorders.^(296,298) Risk increases with the dose and duration of glucocorticoids, and moderate (10–20 mg daily) to high (>20 mg daily) doses of glucocorticoids for ≥ 4 weeks have been associated with a risk of reverse seroconversion of 1%–10%.⁽²⁹⁸⁾

Patients with AIH typically undergo serological testing for HBV (HBsAg, anti-HBc, and antibodies to HBsAg) during the diagnostic phase of their evaluation, and individuals requiring close monitoring for HBV reactivation during glucocorticoid therapy can be identified prior to treatment. The goal of management is to achieve clinical and biochemical remission on low-dose glucocorticoid regimens in combination with AZA, and close serological monitoring for reverse seroconversion is justified in these low-risk patients. Assessments of serum HBV DNA and HBsAg at intervals of 1–3 months has been suggested by the AASLD.⁽²⁹⁹⁾ High-dose therapy or the institution of B cell–depleting agents, cytokine antagonists, calcineurin inhibitors, or other immune inhibitory agents may increase the risk of reverse seroconversion; and it is best avoided in these patients. Otherwise, the institution of preemptive antiviral therapy in these patients should be considered.

GUIDANCE STATEMENTS

- Patients with AIH who are HBsAg-negative/anti-HBc-positive during the diagnostic phase of their evaluation should undergo periodic serological testing (HBsAg, HBV DNA) during conventional therapy with prednisone or prednisolone in conjunction with AZA to detect HBV reactivation and the need for on-demand antiviral therapy.
- Patients with serological evidence of previous HBV infection who are treated with high-dose glucocorticoids or other immune modulators, especially B cell–depleting agents, are at moderate risk for HBV reactivation and should be considered for preemptive antiviral therapy.

BONE MAINTENANCE

Bone density assessments by dual-energy X-ray absorptiometry of lumbar vertebrae and hips should be performed at baseline in patients with risk factors for osteoporosis and every 2–3 years in adult patients with

ongoing risk factors for osteoporosis.^(301–303) The most common risk factors are past or prolonged use of glucocorticoids, postmenopausal status, history of low-trauma fracture, and age (>65 years for women and >70 years for men).⁽³⁰³⁾ Elemental calcium (1,000–1,200 mg daily) and vitamin D (at least 400–800 IU daily) has been recommended for patients on glucocorticoid therapy.^(301,304)

Vitamin D insufficiency (serum 25-hydroxyvitamin D level, ≤ 29 ng/mL) occurs in 68%–81% of patients with AIH,^(305,306) and severe vitamin D deficiency (serum 25-hydroxyvitamin D level, <20 ng/mL) occurs in 20%.⁽³⁰⁶⁾ These findings justify assessment of the serum 25-hydroxyvitamin D level in all patients at diagnosis and vitamin D supplementation as indicated clinically.⁽³⁰⁷⁾ Similar dosing and monitoring strategies are used in children.

Clinical trials support the use of bisphosphonates when osteoporosis is present.^(301,308,309) Regular weight-bearing exercise can help control weight and eliminate immobility as a basis for bone loss.⁽³⁰¹⁾

METABOLIC SYNDROME

The metabolic syndrome is defined by a cluster of risk factors for cardiovascular disease and type 2 diabetes mellitus that may be aggravated or induced by prolonged glucocorticoid therapy, and its presence should be assessed prior to the institution of such therapy. The five principal components of the metabolic syndrome are hypertension, hypertriglyceridemia, low high-density lipoprotein cholesterol level, fasting hyperglycemia, and central obesity (waist–hip ratio or body mass index >30 kg/m²).^(310,311) Three abnormal findings of the five possible manifestations justify the diagnosis. The presence of metabolic syndrome at presentation or during treatment might require modification of the glucocorticoid regimen and supplemental therapies and lifestyle adjustments (exercise, weight reduction).⁽³¹¹⁾

GUIDANCE STATEMENTS

- Bone mineral densitometry should be performed at baseline in all adult patients with AIH who have risk factors for osteoporosis, and it should be repeated every 2–3 years of continuous glucocorticoid treatment.
- Serum levels of 25-hydroxyvitamin D should be determined at diagnosis and annually thereafter.

- Supplementation with elemental calcium (1,000–1,200 mg daily) and vitamin D (at least 400–800 IU daily) should be provided while on glucocorticoid therapy and supplemented as clinically indicated in patients with vitamin D insufficiency.
- Bisphosphonate therapy is indicated for patients with AIH and documented osteoporosis.
- Assessment for all features of metabolic syndrome should be performed prior to and during therapy, and its presence may require individualized treatment adjustments and lifestyle modifications.

PRETREATMENT COUNSELING

Sufficient time should be spent prior to initiating treatment to ensure that patients understand not only the potential side effects of the medication but also the positive benefits of achieving therapeutic remission and the comparative risks associated with inadequately treated disease.⁽³¹²⁾ Noncompliance or problematic adherence are commonplace among patients with chronic diseases, particularly among adolescents.⁽³¹²⁻³¹⁴⁾

Depression and anxiety are more common in patients with AIH than in the general population,^(314,315) mainly because of concerns about disease progression.⁽³¹⁶⁻³¹⁸⁾ Depression is moderate in 19% and moderately severe in 10% of patients, and it correlates strongly with physical fatigue.⁽³¹⁵⁾ Anxiety relates mainly to misconceptions about the nature and outcome of the disease and its treatment, and it can predispose to nonadherence.^(312,314)

Low scores on health-related quality of life assessments have been strongly associated with glucocorticoid use.⁽³¹⁹⁻³²²⁾ Pretreatment psychological disturbances, especially depression, may be intensified during glucocorticoid treatment.⁽³²¹⁾ The combined effects of depression, anxiety, and glucocorticoid-related emotional lability may impact on treatment outcome.^(322,323) Manifestations of depression and changes in the quality of life should be monitored throughout management of AIH as they may justify targeted counseling, individualized adjustments in the doses of glucocorticoids, or adjunctive antidepressive or anti-anxiety interventions.⁽³¹⁷⁾ These manifestations can be assessed by structured, validated questionnaires such as the 12-Item Short Form Survey, the depression module of the Patient Health Questionnaire, and the Generalized Anxiety Disorders Screener.^(316,317)

GUIDANCE STATEMENTS

- Potential barriers to long-term medication compliance should be identified proactively and addressed at the start of treatment and monitored thereafter.
- Manifestations of depression and changes in the quality of life should be monitored throughout management of AIH, and they can be assessed objectively by structured, validated questionnaires.

Pregnancy Counseling

The effects of AIH and its medications on fetal-maternal health should be discussed before pregnancy if possible. Data on risks and outcomes of pregnancy in AIH are derived from recent case series (2002–2012) encompassing 142 conceptions.⁽³²⁴⁻³²⁷⁾ Amenorrhea and decreased fertility occur when AIH is poorly controlled,⁽³²⁸⁾ whereas menstruation signals improved overall health. Exact fertility rates are not known, but in 53 British women with AIH (81 pregnancies), 41% had cirrhosis.⁽³²⁴⁾

FETAL COMPLICATIONS

The live birth rate is 73% in mothers with AIH.⁽³²⁴⁾ The fetal loss and stillbirth rate of 27% is higher than that for the general population (7%–15%) but similar to that for women with chronic disease (24%–29%). Antiphospholipid antibodies are strongly associated with AIH,⁽³²⁵⁾ and they may be a separate, but related, cause of preterm delivery. Premature births occur in ~20% of pregnancies,⁽³²⁴⁾ but there are no specific birth defects associated with AIH.

MATERNAL COMPLICATIONS

The overall maternal complication rate during the pregnancy or within 12 months of delivery is 38%.^(324,326) Prematurity is primarily due to a flare in AIH. Flares occur mainly in patients who are not on therapy or who have not been in remission during the year prior to conception. Patients with AIH who are pregnant or planning pregnancy within the next year should be continued on treatment to reduce the risk of flare and hepatic decompensation. Flares are 3 times more common postpartum,⁽³²⁷⁾ and the low rate of flare during pregnancy may relate in part to the effects of pregnancy implantation factor.^(329,330)

TABLE 7. Safety of Medications Commonly Used in the Pregnant Patient with AIH

Medication	Safety Reports in Pregnancy
Terlipressin	Uterine ischemia
Octreotide	No harmful effects noted
Beta-blockers	Fetal bradycardia, fetal growth retardation
Lactulose	No harmful effects noted
Rifaximin	No harmful effects noted but limited data
Corticosteroids	Inconsistent association with cleft abnormalities
AZA	Premature birth
MMF	Birth defects, spontaneous abortion
TAC	Premature birth, transient neonatal renal dysfunction

In pregnant patients with cirrhosis, progressive increase in blood volume can lead to an increased risk of variceal bleeding. Preemptive identification and eradication of varices with variceal ligation is necessary as β -blockers and terlipressin have potential adverse effects in pregnancy (Table 7). The safety of endoscopy during pregnancy has been addressed in other guidelines.⁽³³¹⁾

MEDICATION SAFETY IN PREGNANCY

Glucocorticoids

Whereas data from 1997-2002 suggested an increased risk of cleft lip and palate during the first trimester of pregnancy in glucocorticoid-treated women, data from 2003-2009 reported by the US National Birth Defects Prevention case-control study showed no association, presumably because of lower doses given in the latter era⁽³³²⁾ (Table 7). The placental enzyme 11-beta-hydroxysteroid dehydrogenase 2 converts prednisolone (the active drug) into prednisone (the inactive prodrug), and it may protect the fetus from high levels of glucocorticoids.

AZA

AZA-related adverse events have not been reported in the pregnancy or baby. Initial concerns about possible teratogenicity were derived from animal studies that used supratherapeutic doses.⁽³³³⁾ A systematic review and meta-analysis of 3,000 pregnant patients with IBD⁽³³⁴⁾ found no increase in the risk of low birth weight or birth defects in mothers taking AZA. However, the risk of preterm birth was increased

(OR, 1.45) (Table 7). Small amounts of AZA are detectable in the milk of lactating mothers, and low levels of 6-thioguanine nucleotide (6-TGN) have been detected in newborns.⁽³³⁵⁾

Mycophenolate Mofetil

Data from the National Transplantation Pregnancy Registry and postmarketing surveillance indicate that mycophenolate mofetil (MMF) use during pregnancy is associated with first-trimester pregnancy loss and birth defects, most commonly ear, heart, and cleft defects⁽³³⁶⁾ (Table 7). Thus, MMF should be avoided during pregnancy. The Food and Drug Administration recommends a negative pregnancy test within 1 week of starting MMF and use of two effective methods of birth control for 4 weeks prior to and 6 weeks after use of MMF. Small amounts of MMF are detectable in the milk of lactating mothers.⁽³³⁶⁾

GUIDANCE STATEMENTS

- Family planning should include the goal of achieving biochemical remission of AIH for 1 year prior to conception.
- Women of reproductive potential should receive prenatal counseling on the significant adverse effect of active AIH on pregnancy and the risk of flares during and after pregnancy.
- Maintenance doses of glucocorticoids and/or AZA should be continued throughout pregnancy.
- MMF is contraindicated during pregnancy, and women should be counseled about the adverse effects of MMF on pregnancy prior to initiating MMF treatment.
- Women with cirrhosis who are pregnant or plan to become pregnant within the next year should be screened for varices by endoscopy either prior to conception or during the second trimester of gestation and treated with band ligation.
- Women with AIH should be monitored closely for the first 6 months postpartum for early detection of a flare.

First-Line Treatments

The objectives of first-line therapy are to improve symptoms, control hepatic inflammation, achieve

biochemical remission, prevent disease progression, and promote the regression of fibrosis at the lowest risk of drug-induced complication. The ideal laboratory response is normalization of serum ALT, AST, and IgG levels.^(2,337,338) All patients with AIH are candidates for therapy except individuals with inactive disease by clinical, laboratory, and histological assessment.

PREDNISONE OR PREDNISOLONE WITH AND WITHOUT AZA

Prednisone alone, 40-60 mg daily in adults and 1-2 mg/kg daily in children (maximum dose 40-60 mg daily), or a lower dose of prednisone, 20-40 mg daily, in combination with AZA (AZA adult dosing: United States, 50-150 mg daily; Europe, 1-2 mg/kg daily; pediatric, 1-2 mg/kg daily), is administered with an antacid during an induction phase (Fig. 4). Some centers advocate using prednisone 1 mg/kg for adult

patients and then reducing the dose once a response is documented. In Europe, prednisolone is preferred over prednisone, and equivalent or weight-based doses of prednisolone (1 mg/kg daily) are administered in conjunction with weight-based doses of AZA (1-2 mg/kg daily). In some centers, AZA is started at the same time as glucocorticoids, whereas most centers recommend waiting 2 weeks before starting AZA to confirm steroid responsiveness, evaluate TPMT status, and assess treatment response by excluding the rare possibility of AZA-induced hepatitis.

Once a biochemical remission has been achieved (see definition in Table 2), response-guided therapy is advocated. The dose of prednisone or prednisolone is reduced gradually to 20 mg daily or a dose sufficient to achieve biochemical remission while monitoring laboratory tests every 2 weeks. Thereafter, a gradual taper is recommended (2.5-5 mg every 2-4 weeks) to achieve a lower dose of 5-10 mg daily that maintains




FIG. 4. First-line treatment of AIH in adults and children, recognizing adjustments based on the presence of cirrhosis or an acute severe presentation.

laboratory remission. Prednisone or prednisolone may then be discontinued completely, leaving the patient on only AZA or alternative glucocorticoid-sparing drugs. Alternate-day predniso(lo)ne is advocated by some because of fewer side effects, but this regimen may also reduce immunosuppression.^(339,340) In children, the goals of therapy are to eventually be glucocorticoid-free and to prevent the multiple long-term complications of glucocorticoids.

Treatment of AIH with prednisone monotherapy is appropriate for patients in whom the duration of treatment is expected to be <6 months (e.g., suspected drug-induced AIH-like injury) or AZA is contraindicated (known AZA intolerance or complete TPMT deficiency). In the setting of AZA intolerance, MMF is an acceptable alternative therapy to maintain remission. Prolonged prednisone monotherapy, especially at doses >10 mg daily, is frequently associated with well-known drug toxicities and should be avoided⁽³⁴¹⁾ (Table 8).

The typical starting dose of AZA is 50-100 mg daily in adults and 1-2 mg/kg daily in children. Evolving leukopenia or thrombocytopenia warrants dose reduction or drug withdrawal. AZA should be discontinued if the cytopenia does not recover in 1-2 weeks. Most cases of cytopenia in AZA-treated patients with AIH are associated with cirrhosis.^(290,291)

The AZA dose can be further adjusted to achieve a therapeutic range and avoid toxicity by monitoring thiopurine metabolite levels.⁽³⁴²⁻³⁴⁵⁾ In children with

AIH, the 6-TGN level is titrated between 100 and 300 pmol/8 × 10⁸ red blood cells (RBCs) to avoid bone marrow toxicity, and the 6-methyl-mercaptopurine level is kept <5700 pmol/8 × 10⁸ RBCs to prevent hepatotoxicity.^(342,346) Nonadherence to treatment should be suspected in patients who fail to respond to induction therapy or in those who relapse. Text messaging⁽³⁴⁷⁾ and electronic monitoring⁽³⁴⁸⁾ may also be useful in reducing nonadherence in children. AZA should not be used in patients with active malignancy because it acts synergistically with ultraviolet light to enhance mutational damage.⁽³⁴⁹⁾

In adults with AIH, routine measurement of 6-TGN levels in unselected patients has had limited value because 6-TGN levels have been similar between patients with normalized serum aminotransferase levels and those with partial improvement.⁽³⁴⁴⁾ 6-TGN determinations might prove useful in assessing treatment compliance in adults and in developing management strategies for adults with an incomplete response (e.g., increasing the dose of AZA or adding allopurinol to the regimen).⁽³⁴⁴⁾

BUDESONIDE AND AZA

The efficacy and safety of budesonide (which has a 90% first-pass effect on the liver) in combination with AZA was demonstrated in a randomized trial of newly diagnosed AIH which targeted laboratory remission after 6 months. Patients receiving

TABLE 8. Side Effects Associated with Prolonged First-Line Treatment Drugs in AIH

Drug	Side Effects	Management Options
Predniso(lo)ne	<ul style="list-style-type: none"> Cosmetic: Facial rounding, hirsutism, alopecia, dorsal hump, striae Systemic: Weight gain, glucose intolerance/diabetes, hypertension, fatty liver, osteoporosis, vertebral compression, cataracts, glaucoma, opportunistic infections Quality of life: Emotional instability, psychosis, depression, anxiety 	<ul style="list-style-type: none"> Actively taper to the lowest steroid dose needed for remission and attempt withdrawal after remission Eye examinations for cataract and glaucoma Lifestyle interventions for metabolic syndrome Bone density monitoring Vitamin D and calcium administration Proactive screening and management for quality of life and mental health symptoms
Budesonide	<ul style="list-style-type: none"> Reduced intensity of the side effects from prednisone is possible despite first-pass metabolism Unable to reach the liver with portal hypertensive shunts Portal vein thrombosis in cirrhosis 	<ul style="list-style-type: none"> Taper budesonide to the lowest effective dose and attempt withdrawal after remission Do not prescribe in cirrhosis and acute severe AIH
AZA	<ul style="list-style-type: none"> Hematologic: Mild cytopenia, severe leukopenia or bone marrow failure (rare) Gastrointestinal: Nausea, emesis, pancreatitis Neoplastic: Nonmelanoma skin cancer Cholestatic liver damage (rare) 	<ul style="list-style-type: none"> Check TPMT metabolizer status prior to prescribing Monitor cell counts at least every 6 months Reduce dose if mild cytopenia occurs Discontinue in severe cytopenia Discontinue in gastrointestinal intolerance Avoid direct sunlight and have yearly dermatologic screening for skin cancer Not recommended in decompensated cirrhosis or acute severe AIH

budesonide (3 mg thrice daily, reduced to twice daily following remission) combined with weight-based AZA (1-2 mg/kg daily) achieved laboratory remission after 6 months more frequently (60% versus 39%) and with fewer steroid-specific side effects (SSSE; 28% versus 53%) compared to prednisone (40 mg daily tapered to 10 mg daily) combined with weight-based AZA.⁽³⁵⁰⁾ A potential long-term benefit of budesonide therapy is preservation of the bone mineral density.^(351,352)

Patients with ALF or cirrhosis were not included in this randomized trial of budesonide. Patients with cirrhosis should not receive budesonide because portosystemic shunting may reduce drug efficacy and promote SSSE by allowing budesonide to bypass the liver.^(353,354) Portal vein thrombosis has also been reported in patients with cirrhosis taking budesonide, albeit portal vein thrombosis is a known complication of cirrhosis independent of budesonide use⁽³⁵⁵⁾ (Table 8). Patients who fail to normalize their laboratory tests on prednisone therapy are also less likely to respond to budesonide treatment,⁽³⁵¹⁾ and therefore the drug should not be used as a rescue therapy for steroid-refractory AIH.^(352,356) The role of budesonide as first-line treatment in acute severe AIH or ALF is unknown, and thus it is not recommended in these settings.

In a subgroup analysis, children receiving budesonide and AZA achieved laboratory remission after 6 months as frequently as those receiving prednisone and AZA. The occurrence of SSSE was lower but not statistically different between the groups, with the notable exception of lower weight gain in budesonide-treated children.⁽³⁵⁷⁾ Budesonide with AZA may be considered in children with AIH, particularly if the disease is mild or if there are concerns that prednisone may worsen concurrent obesity, depression, or acne, thus potentially jeopardizing medication adherence.

SYSTEMATIC REVIEW AND META-ANALYSIS OF FIRST-LINE REGIMENS

We performed a systematic review and meta-analysis to investigate whether first-line treatment with prednisone or prednisolone alone or in combination with AZA was superior to budesonide in combination with AZA in patients with newly diagnosed

AIH. Outcomes were frequency of remission, interval to remission, frequency and type of medication-associated side effects, and the frequency of death or LT. Out of 1,712 records that were identified in a database search, 578 were fully assessed for eligibility, five were included in a qualitative meta-analysis,^(20,350,357-359) and two were included in a quantitative meta-analysis.^(20,350)

The meta-analysis revealed that biochemical remission was more likely with the use of budesonide and AZA compared to prednisone and AZA (OR, 2.19; 95% confidence interval [CI], 1.30-3.67) (high grade of evidence) (Table 9), but the analysis was based on a single randomized clinical trial.⁽³⁵⁰⁾ None of the studies reported on the time to remission or outcomes such as histological resolution, progression to cirrhosis, death, and transplantation. Furthermore, only one study reported a lower frequency of steroid-related side effects in patients treated with budesonide and AZA (low grade of evidence).⁽³⁵⁰⁾ The individual determinants that constituted the strength assessment for the recommendation of either budesonide and AZA or prednisone and AZA as first-line therapy (systematic review 1 [SR1]) are shown in Table 10.

GUIDELINE RECOMMENDATIONS

1. For children and adults who present with AIH who do not have cirrhosis or acute severe AIH, the AASLD suggests that budesonide and AZA or prednisone/prednisolone and AZA be used as first-line treatment.
2. For children and adults with AIH who have cirrhosis or who present with acute severe AIH, the AASLD suggests that budesonide not be used (conditional recommendation, very low certainty).

ALTERNATIVE FIRST-LINE REGIMENS

MMF has been used in place of AZA as a front-line therapy in combination with prednisolone.⁽³⁶⁰⁾ A single-center experience with MMF as front-line treatment in combination with prednisone reported a remission rate of ~75% after 24 months.⁽³⁶¹⁾ A recent meta-analysis found few evaluable studies

TABLE 9. Evidence Profile and Results of Systematic Review and Meta-analysis of First-line Therapies for AIH

Budesonide + AZA versus Predniso(ol)ne + AZA

Outcome	Results	Grade of Evidence Quality
Biochemical remission	Two studies (one RCT ⁽³⁵¹⁾ and one non-RCT ⁽²⁰⁾)	High
Rapidity of response	No studies reported rapidity of response	
Side effects (bone disease, cytopenia, weight gain, portal vein thrombosis)	One study ⁽³⁵¹⁾ reported more steroid-specific side effects in prednisone group compared to budesonide group	Low
Death	No studies reported death	
Liver transplantation	No studies reported LT	
Meta-analysis: I^2 test of heterogeneity	$I^2 = 0.0\%$, $P = 0.495$	
Meta-analysis for biochemical remission	OR, 2.19; 95% CI, 1.30-3.67	
Meta-analysis: Conclusions	Few qualified studies Homogeneous test results between studies Current evidence insufficient to assess patient selection and long-term outcome Budesonide and AZA favored for biochemical remission Conditional recommendation with low certainty for use of budesonide and AZA in children and adults without cirrhosis, acute severe hepatitis, or ALF	

Abbreviation: RCT, randomized clinical trial.

comparing MMF and prednisone with prednisone and AZA.⁽³⁶²⁾ MMF/prednisone was superior to prednisone/AZA in the normalization of serum ALT, AST, and IgG levels and in the rate of nonresponse. First-line treatment with MMF seemed to be at least as effective as AZA when each was combined with prednisone, but data are insufficient to recommend its first-line use.

Calcineurin inhibitors have been used to a limited extent as first-line agents in AIH.^(16,363-367) Cyclosporine (CsA) has induced biochemical remission in children with AIH⁽³⁶⁴⁾ with good results during long-term follow-up.^(368,369) Trough levels of CsA are typically maintained higher initially (i.e., 150-200 ng/mL) and then tapered to 50-70 ng/mL after 1 year, providing the disease is in remission.⁽³⁶⁸⁾ Tacrolimus (TAC) reduced serum AST and ALT levels by 70% and 80% after 3 months,⁽³⁶³⁾ but this early promise has not been developed further. At this time, there are insufficient data to recommend calcineurin inhibitors as front-line agents.

SPECIAL CONSIDERATION: ACUTE SEVERE AIH OR ALF DUE TO AIH

Patients presenting with acute severe AIH⁽³⁷⁰⁾ or ALF^(100,136,371) (see definitions in Table 2) constitute a management dilemma in which the potential

advantages of glucocorticoid therapy must be balanced against the risks of the treatment, namely infection⁽³⁷²⁾ and delay of LT.^(373,374) Glucocorticoid therapy (usually prednisone or prednisolone alone, 0.5-1 mg/kg daily in adults and up to 2 mg/kg in children) has been effective in 20%-100% of patients with acute severe AIH and has not been associated with an increase in sepsis.^(136,370,372,375-377) In patients with AIH and ALF, glucocorticoid therapy has not been associated with improved overall survival, and survival has been less in treated patients with Model for End-Stage Liver Disease scores >40.⁽³⁷¹⁾ Reports of improvement in patients with ALF and mild encephalopathy have been sparse, and glucocorticoid therapy may be deleterious in patients with severe decompensation.^(370,372)

The key to success in managing acute severe AIH is to abandon ineffective treatment quickly (within 1-2 weeks depending on clinical status and treatment response) and to proceed to LT.^(370,373,374,376,378) Failure to improve any laboratory test reflective of liver inflammation or function, especially hyperbilirubinemia, or any evidence of clinical deterioration or hepatic encephalopathy during treatment justifies immediate consideration of LT.^(370,376,378) Hepatic encephalopathy at presentation defines AIH with ALF, and LT is more likely to improve survival than protracted glucocorticoid treatment.^(370,372,376)

TABLE 10. Determinants of Recommendation Strength by GRADE Assessment of Clinical Studies

Strength Determinant	SR1: "First-Line Treatment" (budesonide/AZA versus predniso(lo)ne/AZA)	SR2: "Second-Line Treatment" (MMF versus TAC)	SR3: "Steroid Withdrawal Post-LT" (pred versus no pred)
1. Benefits versus harms	Budesonide > pred	MMF > TAC	No pred > pred
2. Certainty	Limited	Limited	Limited
3. Cost	High cost/copay for budesonide	+MMF	No pred
4. Patient values	Budesonide	+MMF (ease of use) +TAC (pregnancy)	No pred
5. Feasibility	Copay may make it harder to get budesonide	Equal	Equal
6. Accessibility	Copay may make it harder to get budesonide	Equal	Equal
7. Equity	Equal	Equal	Equal

Abbreviations: no pred, no predniso(lo)ne; pred, predniso(ol)ne.

GUIDANCE STATEMENTS

- Patients with acute severe AIH should receive a treatment trial with prednisone or prednisolone alone, whereas patients with AIH and ALF should be evaluated directly for LT.
- Patients with acute severe AIH who do not improve laboratory tests or clinically worsen within 1-2 weeks of glucocorticoid therapy should be evaluated for LT.

PUTATIVE PREDICTORS OF TREATMENT RESPONSE

The rapidity of response to treatment is the most important index of outcome, and the serum aminotransferase levels should improve within 2 weeks.⁽³⁷⁸⁾ Elderly patients (≥ 60 years old) respond more quickly to treatment than young adults, and they are characterized by HLA DRB1*04:01.^(379,380) Biochemical remission that is achieved within 6 months is associated with a significantly lower frequency of progression to cirrhosis or need for LT, and individualized adjustments in therapy may be justified to improve the speed of response.⁽³⁷⁹⁾ Laboratory manifestations of cholestasis (increased serum alkaline phosphatase or GGT levels) have been associated with incomplete or delayed response and may indicate an alternative diagnosis (e.g., overlap syndrome).⁽¹⁷³⁾

Other biomarkers predictive of response are evolving. In type 1 AIH, persistent production of SMA or antiactin in the setting of biochemical remission have been associated with histological features of active liver inflammation.⁽³⁸¹⁾ Elevated ferritin levels (>2.1 -fold

ULN) at the time of diagnosis have been associated with subsequent biochemical remission, and the predictive value of remission has increased when both elevated serum ferritin and low IgG values (<1.9 -fold ULN) have been present at baseline.⁽³⁸²⁾ Vitamin D deficiency at presentation has been associated with histological severity, poor treatment response, progression to cirrhosis, and increased mortality or need for LT⁽³⁰⁵⁻³⁰⁷⁾; and increased serum levels of angiotensin-converting enzyme have correlated with fibrosis scores.⁽³⁸³⁾

TREATMENT WITHDRAWAL

Sustained normal serum levels of AST, ALT, and IgG for at least 2 years have been proposed as requisites before attempting treatment withdrawal.^(384,385) Patients with cirrhosis may have chronic elevation of the serum IgG level, and they are not excluded from treatment withdrawal if other tests are normal during a prolonged (≥ 2 years) period of stability.^(386,387) Restoration of the liver tissue to normal reduces the risk of subsequent relapse to 28%,⁽³⁸⁶⁾ and liver biopsy prior to drug withdrawal has been the preferred strategy.⁽³⁸⁶⁻³⁸⁸⁾ Liver biopsy, however, may not be mandatory before treatment withdrawal in all adults.⁽³⁸⁴⁾

In adult patients with and without prewithdrawal liver biopsy, the frequency of relapse (30% versus 21%, $P = 0.57$) was similar after treatment for at least 2 years, during which serum AST and ALT levels had been normal or near-normal.⁽³⁸⁹⁾ Of 28 treated patients with AIH who were in biochemical remission for at least 2 years before withdrawal, 15 (54%) remained in biochemical remission after treatment withdrawal during a median follow-up of 28 months

(range, 17-57 months).⁽³⁸⁵⁾ These patients were characterized by a serum ALT level <50% ULN and a normal serum IgG level <1,200 mg/dL.⁽³⁸⁵⁾ Liver biopsy was performed in 13 patients prior to drug withdrawal, and of the 11 patients with normal liver tests and normal liver tissue, 46% subsequently relapsed. These findings suggest that sustained normal liver tests during treatment may have gradations within the normal range that predict outcome, possibly better than liver tissue examination. Prewithdrawal liver biopsy is still strongly advised in children to ensure resolution of inflammation.⁽¹⁰⁸⁾ In a retrospective study of 35 children with AIH, 16 (46%) had lack of inflammation on prewithdrawal liver biopsy after 2 years of biochemical remission and were weaned off of immunosuppression.⁽³⁸⁴⁾ Fourteen of these 16 patients (87%) had a sustained remission off immunosuppression, with a median follow-up of 3.4 years.

VCTE is emerging as a noninvasive method that may also aid in the withdrawal decision.^(260,265) Patients achieving a complete biochemical remission decreased their liver stiffness by 7.5%/year ($P = 0.003$), whereas patients not achieving biochemical remission showed a slight but nonsignificant increase in liver stiffness by 1.7%/year.⁽²⁶⁵⁾ Patients achieving biochemical remission had an average liver stiffness measurement of 6.4 ± 3.2 kPa compared to the average liver stiffness measurement of 9.2 ± 9.1 kPa in the patients who did not achieve biochemical remission ($P = 0.06$).⁽²⁶⁵⁾ A liver stiffness threshold below which biochemical remission was expected was not determined. The findings of VCTE have not been correlated with outcome after treatment withdrawal or compared with histological examination in predicting sustained remission after treatment, and its role in predicting relapse after drug withdrawal is unknown.

Laboratory surveillance for relapse must be continued indefinitely at regular intervals of increasing length depending on test stability.⁽³⁹⁰⁾ Long-term follow-up studies in adults and children of at least 3 years' duration have indicated that the frequency of achieving a treatment-free remission is 19%-40%.⁽³⁹¹⁻³⁹³⁾

RELAPSE

Relapse occurs in 50%-87% of adults and 60%-80% of children after drug withdrawal.^(244,338,387,394,395) In patients satisfying the remission criterion of

biochemical normality for ≥ 2 years during treatment, the relapse frequency is 46% in adults⁽³⁸⁵⁾ and 80% in children.⁽¹⁰⁸⁾ Long-term biochemical remission has been possible in 20% of children with type 1 AIH but rarely in children with type 2 AIH.^(62,108)

Relapse is typically asymptomatic, manifested by mild increases in serum AST or ALT level, and rapidly responsive to retreatment.⁽³⁹⁴⁾ Its main risks relate to delayed or failed detection, resulting in increased hepatic fibrosis in 10%⁽²⁴³⁾ and clinical deterioration in 3%.⁽²⁴³⁾ Fifty percent of all relapses occur within the first 3 months after drug withdrawal, and the frequency of relapse decreases after the first year to 3% per year over the next 3 years.⁽³⁹⁰⁾ Ninety percent of relapses occur within 28 months (mean interval, 5 ± 0.6 months; median, 3 months; range, 1-28 months), but late relapses are possible (range, 49-265 months after drug withdrawal).⁽³⁹⁰⁾

The principal predisposing factors for relapse are the duration and completeness of inactive disease prior to treatment withdrawal.^(385,389) Various other factors have been proposed, including psychological stress,⁽³²³⁾ concurrent autoimmune disease,⁽²⁴⁴⁾ treatment with multiple agents,⁽²⁴⁴⁾ increased serum ALT and IgG levels at drug withdrawal,^(106,338,385) portal plasma cells in the liver tissue prewithdrawal,^(106,388) delayed biochemical remission,⁽³⁹⁶⁾ and prednisolone monotherapy.⁽³⁹⁷⁾

Patients who relapse almost invariably respond to retreatment with the original regimen.^(244,394) Ninety-four percent achieve laboratory resolution in 4 ± 1 months, and 59% achieve histological resolution in 8 ± 2 months.^(391,394) Subsequent attempts at drug withdrawal are commonly followed by another relapse,⁽³⁹⁴⁾ and adult patients should be treated long-term after their first relapse. Cirrhosis develops more commonly in patients with repeated relapses after drug withdrawal than in patients who have relapsed once and been retreated (38% versus 10%, $P = 0.02$), and liver-related death or LT is also more common (20% versus 3%, $P = 0.02$).⁽²⁴³⁾

Complete drug withdrawal has been possible in 12% of patients who have relapsed previously after 69 ± 8 months of retreatment, and it can be attempted in individuals with inactive disease for at least 24 months.⁽³⁸⁷⁾ In children with relapse and subsequent biochemical remission on retreatment, a second assessment to gauge histological remission

and treatment withdrawal can be considered after an additional 2 years of normal laboratory tests.

Biochemical remission is induced with the standard glucocorticoid and AZA regimen, and then the dose of AZA is adjusted up to 2 mg/kg daily as the dose of prednisone or prednisolone is reduced to the lowest dose possible or fully withdrawn.^(398,399) Patients intolerant of AZA can be treated with MMF, or in adults, low-dose predniso(lo)ne (≤ 7.5 mg daily) only can be instituted.^(400,401)

GUIDANCE STATEMENTS

- Drug withdrawal and achievement of a long-term treatment-free remission of AIH are possible in a minority of patients and should be considered in patients who have normalized serum aminotransferase and IgG levels for at least 2 years.
- Liver tissue examination prior to drug withdrawal is valuable in excluding unsuspected inflammation and reducing the frequency of relapse, but it is not mandatory in adults.
- Patients must be closely monitored for relapse with regular laboratory assessments during the first 12 months after treatment withdrawal and annually thereafter to cover for lifelong risk.
- Relapse requires prompt reinstatement of the original treatment until biochemical remission and subsequent transition to a long-term maintenance regimen.

Second-Line Treatments

Second-line therapies have been used to manage treatment failure, incomplete response, and drug intolerance^(402,403) (see definitions in Table 2). Treatment failure occurs in 7%–9% of adults and is associated with increased risk of progression to cirrhosis and liver failure, with mortality rates as high as 30%.⁽⁴⁰³⁾ Second-line therapies for treatment failure include MMF,^(404–410) calcineurin inhibitors (CsA^(411–416), TAC^(417–420)), mercaptopurine^(421,422) and biologics (rituximab,⁽⁴²³⁾ infliximab⁽⁴²⁴⁾).

Incomplete response manifests as an improvement in laboratory findings but without complete normalization of serum AST, ALT, or IgG levels. Incomplete response occurs in ~15% of adults and children. Patients unable to normalize liver tests and liver tissue

within 36 months have a higher frequency of cirrhosis and need for LT.^(379,403) Second-line therapies for incomplete response include MMF and calcineurin inhibitors.

Treatment intolerance indicates the inability to continue therapy due to side effects of the drug.^(341,350) Treatment-ending side effects occur in 13%. Some patients who cannot tolerate AZA will tolerate MP to maintain remission.^(421,422) Other therapies to consider are MMF and TAC.

MMF

MMF has been given to patients with AIH who are intolerant of AZA or have an incomplete response or treatment failure with glucocorticoid/AZA. In a meta-analysis involving five studies and 309 patients,⁽⁴²⁵⁾ the pooled overall response rate was 58% (82% for AZA intolerance and 32% for treatment failure). MMF-based therapies were well tolerated, with a pooled adverse event rate of 14%, leading to discontinuation in 8%. Another meta-analysis⁽⁴²⁶⁾ based on 15 out of 1,532 studies indicated that the combination of MMF and prednisone was the most widely used second-line treatment. The MMF regimen reduced serum AST and ALT levels in 79% and achieved histological remission in 89%.

The effectiveness of MMF as second-line therapy has also been supported by a recent study indicating the induction of biochemical remission in 60%.⁽⁴²⁷⁾ As in previous studies, MMF therapy was more frequently effective in patients intolerant of primary therapy than in those with treatment failure to primary therapy (62% versus 38%). Predictors of a favorable response included older age and lower levels of IgG and INR.

Similar findings have been reported in pediatric patients with treatment failure.⁽⁴¹⁶⁾ Normalization of serum ALT and AST levels by month 6 was achieved in 36% of children treated with MMF and 83% treated with CsA and in 50% of patients treated with TAC. MMF was well tolerated, and adverse events occurred in 45% compared to 78% treated with CsA and 42% treated with TAC.

CALCINEURIN INHIBITORS

Multiple studies on the use of TAC in the setting of treatment failure, incomplete response, and AZA intolerance have confirmed its moderate-to-high efficacy.

TABLE 11. Evidence Profile and Results of Systematic Review and Meta-analysis of Second-Line Therapies for AIH

MMF versus TAC

Outcome	Results	Grade of Evidence Quality
Biochemical remission	Two retrospective studies ^(418,430) reported no significant difference in frequency of biochemical remission	Low
Drug intolerance	One study ⁽⁴¹⁸⁾ reported drug intolerance and showed no significant difference between MMF and TAC in frequency of side effects	Very low
Death or LT	One study ⁽⁴¹⁸⁾ reported death or LT (together) and showed no significant difference in frequencies between MMF and TAC	Very low
Meta-analysis: I^2 test of heterogeneity	$I^2 = 59.6\%$, $P = 0.116$	
Meta-analysis: For biochemical remission	OR, 1.95; 95% CI, 0.18-20.81	
Meta-analysis: Conclusions	Few qualified studies Heterogeneous test results between studies Low-quality evidence to assess differences in frequency of biochemical remission Very low-quality evidence to assess differences in frequency of side effects, mortality, or need for LT Conditional recommendation with very low certainty that MMF be used over TAC based on ease of use and side effect profile	

TAC has been administered in combination with prednisone, budesonide, AZA, or MMF, with serum trough levels ranging from 1 to 10 ng/mL. Two single-center studies reported normalization of serum aminotransferases in response to TAC in 91%-92% of adult cases,^(417,428) and a third single-center study showed normalization of either serum ALT or IgG level in 79%.⁽⁴²⁰⁾ A multicentered study of patients with either AZA intolerance or incomplete response/treatment failure documented normalization of serum aminotransferases in 73% (94% with AZA intolerance and 57% with incomplete response or treatment failure).⁽⁴¹⁸⁾

Two meta-analyses on the use of TAC in adults as second-line therapy revealed improvement or normalization of serum aminotransferases in 75%-94%.^(426,429) Similar response rates have been reported in single-center studies in children.^(366,419) Side effects necessitating decreased dose or cessation of TAC occurred in ~25%. The most frequently reported side effects were neurologic symptoms (tremors, headaches), renal complications (hypertension, insufficiency), and hair loss. CsA may be considered as the second-line therapy of choice for patients with concurrent diabetes when compared to TAC as diabetes can develop as a side effect of TAC.

Systematic Review and Meta-Analysis of Second-Line Regimens

We performed a systematic review to answer the question of whether 6-MP, MMF, or a calcineurin

inhibitor demonstrated superior efficacy in the setting of treatment failure or incomplete response in adults and children. A comprehensive search of several databases identified 1,712 records. After screening and exclusion of articles for various methodological reasons, four articles were included in a qualitative analysis and two in a quantitative meta-analysis.^(407,418,419,430)

Based on the available studies, a direct comparison was performed between MMF and TAC. There were insufficient data to evaluate the use of mercaptopurine as a second-line therapy. No significant differences in outcome (remission rate, frequency of transplant or death) were reported between MMF and TAC therapies (Table 11). The individual determinants that constituted the strength assessment for the recommendation of preferred second-line therapy (SR2) are shown in Table 10.

GUIDELINE RECOMMENDATIONS

- In children or adults with AIH who have treatment failure, incomplete response, or drug intolerance to first-line agents, the AASLD suggests the use of MMF or TAC to achieve and maintain biochemical remission (conditional recommendation, low certainty).
- Based on a superior ease of use and side-effect profile, the AASLD suggests a trial of MMF over TAC as the initial second-line agent in patients with AIH (conditional recommendation, very low certainty).

Evolving Salvage Therapies

ANTIBODIES TO TNF- α

Monoclonal antibodies to TNF- α (infliximab) are known to cause liver injury and may even cause drug-induced AIH-like injury.^(208,431-433) Anti-TNF antibodies may also have a therapeutic role in AIH. In the largest single-center retrospective analysis of infliximab therapy in AIH, 11 difficult-to-treat adult patients, including 7 with cirrhosis, received infusions of infliximab (5 mg/kg).⁽⁴²⁴⁾ Six patients normalized serum aminotransferase and IgG levels, 7 patients developed infectious complications, and 1 patient stopped treatment due to an allergic reaction and incomplete response.

Another single-center retrospective analysis in 11 pediatric and adolescent patients with IBD and autoimmune liver disease included 2 patients with type 1 AIH and 9 with AIH-PSC overlap.⁽⁴³⁴⁾ Infliximab (5 mg/kg) was infused to treat the IBD, and 3 patients were later treated with adalimumab after infliximab intolerance or failure. The IBD improved in most patients, and liver enzymes improved in 5. The heterogeneity of the population and its principal goal of treating the IBD precluded conclusions about the role of anti-TNF- α agents in AIH. The weak evidence on efficacy and the increased risk of infection, especially in patients with cirrhosis, do not justify the use of anti-TNF- α agents as second-line treatments.

ANTIBODIES TO CD20

Rituximab, a monoclonal antibody directed against the B-cell surface receptor CD20, has been used to treat 2 children with AIH who were not responding to glucocorticoids/AZA; and both normalized serum AST and ALT levels.⁽⁴³⁵⁾ Rituximab has also been infused in 6 adult patients with AIH, including 3 with AZA intolerance and 3 who were nonresponders to glucocorticoids/AZA and MMF.⁽⁴²³⁾ Serum aminotransferases and IgG levels improved significantly in all patients, and biochemical remission was achieved in 67%. Evidence favoring the use of B cell-depleting antibodies is limited and does not justify their use as second-line treatments. A prospective randomized clinical trial is ongoing that evaluates inatumumab (VAY736) in patients with AIH who are

nonresponders or intolerant to glucocorticoids/AZA (NCT03217422).

THIOGUANINE

Thioguanine is directly metabolized to 6-TGN, which is the metabolically active metabolite of AZA.^(436,437) The 6-thioguanine metabolites are responsible for the therapeutic immunosuppressive effect of AZA, but they can also cause myelosuppression, especially in the presence of TPMT deficiency. The methylated metabolites associated with the conversion of AZA to 6-TGN have been associated with AZA intolerance, and the production of these methylated metabolites may be reduced by treatment with thioguanine.

Thioguanine has normalized serum aminotransferases in 64% of patients with AIH unresponsive to AZA, and the frequency of side effects (11%) has been less than those reported with the second-line therapies of MMF or 6-MP (12%-50%).⁽⁴³⁸⁾ Of 38 patients treated for intolerable side effects of AZA, 29 (76%) were able to continue treatment with thioguanine and 24 (83%) achieved biochemical remission.⁽⁴³⁹⁾ Seven of 11 patients (64%) in one study⁽⁴³⁹⁾ and all 3 patients in another study⁽⁴⁴⁰⁾ with insufficient response to AZA improved after receiving thioguanine. The major concern about treatment with thioguanine has been liver toxicity, especially the development of nodular regenerative hyperplasia⁽⁴⁴¹⁾; but dosing schedules of thioguanine not exceeding 25 mg daily have minimized this risk in patients with IBD.⁽⁴⁴²⁾

Thioguanine has been proposed as a second-line treatment for patients with AIH who are intolerant of AZA, and it may also be considered in patients with nonresponse to thiopurine therapy (AZA, 6-MP).⁽⁴³⁸⁻⁴⁴⁰⁾ The inclusion of thioguanine as a second-line treatment for AIH awaits further demonstration of its safety and efficacy in a multicenter collaborative treatment trial.

GUIDANCE STATEMENTS

- In children or adults with AIH who have nonresponse to first-line treatment, the accuracy of the original diagnosis and medication adherence should be reevaluated.
- Anti-TNF and anti-CD20 are possible alternative therapies after first-line and second-line regimens have failed, but the data supporting their use are limited.

Treatment of Overlap Syndromes

Management of the overlap syndromes has been empiric and includes glucocorticoids, glucocorticoids in combination with AZA, ursodeoxycholic acid (UDCA), and glucocorticoids in combination with UDCA.^(126,173,176,443) The IAIHG advises that management be directed at the predominant manifestations of the overlap syndrome,⁽¹²⁶⁾ and regimens directed at a single component of the overlap syndrome have been able to improve liver tests in patients with a predominant AIH or cholestatic phenotype. Patients with AIH-PBC who have not satisfied the Paris criteria^(175,182) have improved with conventional immunosuppressive therapy for AIH, and patients with predominantly PBC and background features of AIH have improved with UDCA alone.⁽⁴⁴⁴⁾ Early reports of the AIH-PSC overlap syndrome described responses to conventional immunosuppressive therapy for AIH.⁽⁴⁴⁵⁾ Regimens directed at a single predominant component of the overlap syndrome are based on the premise that these syndromes are single diseases with mixed atypical clinical features rather than concurrent diseases.⁽⁴⁴⁶⁾

Most reports have described combination regimens directed at both the AIH and cholestatic components. Prednisone or prednisolone (30 mg daily tapered over 4 weeks to 10 mg daily) in combination with UDCA (13-15 mg/kg daily) has been superior to glucocorticoids alone and UDCA alone in patients satisfying the Paris criteria,⁽¹⁷⁷⁾ and combination therapy has been advocated for patients satisfying the Paris criteria for the AIH-PBC overlap syndrome.^(126,177,179) Combination therapy has improved laboratory tests, stabilized hepatic fibrosis, and preserved the 5-year transplant-free (100%) and 10-year overall survival (92%) in patients with AIH-PBC.⁽¹⁸¹⁾

Prednisone or prednisolone (0.5 mg/kg daily tapered to 10-15 mg daily) with UDCA (13-15 mg/kg daily) has improved survival and reduced frequency of transplantation compared to classical PSC,⁽⁴⁴⁷⁾ and this regimen has been advocated by the European and American liver societies for the AIH-PSC overlap syndrome.^(179,448) UDCA, 10 mg/kg twice daily (dose not exceeding 1.5-2 g daily), in conjunction with prednisone or prednisolone has been used in children with AIH-ASC.⁽⁶²⁾ Treatment outcomes have been variable

in adults with AIH-PSC, and laboratory resolution has been less common than in AIH (22% versus 64%). Furthermore, treatment failure (33% versus 10%) and death from liver failure or need for LT (33% versus 8%) have been more common than in AIH.^(126,449,450)

GUIDANCE STATEMENT

- Consider adding UDCA to prednisone or prednisolone in combination with AZA in adults and children with AIH and overlap syndromes.

Long-Term Outcomes

The overall 10- and 20-year survival rates of treated AIH in a nontransplant center are 91% and 70%, respectively; and the standardized mortality ratio is 1.63 for all-cause death (95% CI, 1.25-2.02) and 1.86 after inclusion of LT as "death" (95% CI, 1.49-2.26).⁽⁴⁵¹⁾ The 10-year liver-related mortalities in the United States range from 6.2% to 7.5%,^(105,452,453) and they are similar to those in the United Kingdom (9%)⁽⁴⁵¹⁾ and Denmark (10.2%).⁽¹¹⁾ Cirrhosis is present in 28%-33% of patients at presentation, especially in patients aged ≥ 60 years⁽¹⁵⁶⁾; and it may develop in 10%-40% of treated patients.^(9,104-107) Cirrhosis has been associated with reduced survival,^(11,23,451) and LT has been necessary in 21% of steroid-refractory patients.⁽⁴⁵⁴⁾ Factors that may affect the treatment response and long-term outcome are age at onset, ethnicity, and malignancy.

AGE-RELATED IMPACT

Elderly patients with AIH frequently have advanced hepatic fibrosis at presentation, commonly have concurrent thyroid or rheumatic diseases, and tend to respond better to glucocorticoid therapy than adult patients aged < 30 years.⁽¹⁵⁶⁾ AIH occurs with similar frequency in all adult age groups, and the propensity for better treatment response among the elderly may be associated with immunosenescence and their higher frequency of HLA DRB1*04 (47% versus 13%).^(156,455) The findings suggest that AIH is undiagnosed at early fibrotic stages in the elderly and that age-related genetic susceptibilities affect outcome.

ETHNICITY

Clinical phenotype, treatment response, and outcome can vary in different ethnic groups within the same geographical region.^(17,456) African American patients have more advanced stages of hepatic fibrosis at presentation than white American patients.⁽⁴⁵²⁾ They are younger at presentation, commonly have cirrhosis (57%-85% versus 38%), have higher frequencies of liver failure (38% versus 9%), require LT more commonly (52% versus 23%), and have greater mortality (24% versus 6%).^(452,457) Asian Americans with AIH have a higher mortality (29%) than Hispanic Americans (5%) and white Americans (8%) with AIH, and hospitalizations for AIH have been more frequent for African Americans and Hispanics than for whites.⁽⁴⁵⁸⁾ In Europe, black patients with AIH have similar differences from white patients with AIH (younger age at presentation, increased risk of LT, and greater risk of liver-related death). They differ by having similar responses to standard therapy and higher frequency of systemic lupus erythematosus.⁽⁴⁵⁹⁾

HCC AND EXTRAHEPATIC MALIGNANCIES

HCC develops in 1%-9% of patients with AIH and cirrhosis (annual incidence, 1.1-1.9%).^(111,112,114,460,461) The standardized incidence ratio is 23.3 (95% CI, 7.5-54.3),⁽⁴⁶²⁾ and the standardized mortality ratio is 42.3 (95% CI, 20.3-77.9).⁽⁴⁶³⁾ Risk factors for HCC are cirrhosis ≥ 10 years, portal hypertension, continuous inflammation, and immunosuppressive therapy ≥ 3 years.⁽¹¹³⁾ Five percent of treated patients with AIH develop extrahepatic malignancies of diverse cell types (cervix, lymphatic tissue, breast, bladder, soft tissue, and skin).⁽⁴⁶⁴⁾ Nonmelanoma skin cancers are most common,⁽⁴⁶⁵⁾ and the standardized incidence ratio for extrahepatic malignancy is 2.7 (95% CI, 1.8-3.9).⁽⁴⁶³⁾ These risks justify surveillance strategies that include hepatic ultrasonography, with or without serum alpha-fetoprotein (AFP) level, every 6 months in patients with cirrhosis⁽⁴⁶⁶⁻⁴⁶⁸⁾ and adherence to standard guidelines for detection of extrahepatic malignancy.⁽²⁸⁸⁾

GUIDANCE STATEMENT

- Cancer surveillance should include hepatic ultrasonography, with or without serum AFP level, every

6 months in patients with cirrhosis and adherence to standard guidelines for detection of extrahepatic malignancy.

LT

AIH is the indication for LT in 2%-3% of recipients in Europe^(469,470) and approximately 5% of recipients in the United States.⁽⁴⁷¹⁾ The number of new listings for LT for AIH in the United States is 0.5 per million population per year, but this number reflects an ongoing decrease in AIH listings of 0.012 listings per million population per year.⁽⁴⁷²⁾ Patient and graft survivals in European adults from 2000 to 2009 have been 88% and 84% at 1 year and 80% and 72% at 5 years, respectively.⁽⁴⁷⁰⁾ In the United States, patient and graft survivals for children transplanted from 2002 to 2012 have been 95% and 91% at 1 year and 91% and 84% at 5 years, respectively.⁽⁴⁷³⁾ The 5-year patient and graft survivals for AIH in American adults are 80%-90% and 74%, respectively.⁽⁴⁷⁴⁾ Patient survivals have been similar in pediatric and adult patients up to 50 years of age.⁽⁴⁷⁵⁾ Infection has been the most frequent cause of death within 30-180 days after LT,⁽⁴⁷⁶⁾ especially during the early postoperative period for patients >50 years old.⁽⁴⁷⁵⁾

Acute (81% versus 47%) and steroid-resistant (38% versus 13%) rejection after LT have occurred more frequently in adult patients transplanted for AIH than in patients transplanted for alcohol-associated cirrhosis.⁽⁴⁷⁷⁾ Furthermore, the incidence of chronic rejection has been higher in patients transplanted for AIH (16%) than in patients transplanted for PBC (8.2%), PSC (5.2%), or alcohol-associated cirrhosis (2%).⁽⁴⁷⁸⁾ More recent experience (2000-2010) has demonstrated a frequency of late acute rejection of 9% in AIH.^(470,479) The frequency of chronic rejection has varied from 14% to 17% in AIH (versus 2% in alcohol-associated cirrhosis).^(478,480) These findings continue to suggest an increased frequency of acute and chronic rejection in AIH compared to other liver diseases.

Continuation of glucocorticoid therapy after LT, rather than weaning patients to achieve a glucocorticoid-free immunosuppressive regimen, has been touted to protect against rejection and recurrence of AIH.^(477,481-484) However, discontinuation of steroids after LT has been advocated to reduce risks of infection and steroid-related side effects.⁽⁴⁸⁵⁻⁴⁹⁶⁾ The topic of long-term use of corticosteroids after LT remains

controversial, but the literature suggests that some patients can be safely weaned off of corticosteroids.

SYSTEMATIC REVIEW AND META-ANALYSIS OF GLUCOCORTICOID USE AFTER LT

We performed a systematic review and meta-analysis to investigate whether continuous glucocorticoid treatment after LT was associated with fewer episodes of acute cellular rejection, recurrent AIH, graft loss, retransplantation, and better graft and patient survival compared to steroid withdrawal after LT. Out of 1,712 records that were identified in a database search, 578 were fully assessed for eligibility as full-text articles, four were judged suitable for qualitative synthesis, and two were judged suitable for quantitative synthesis. The meta-analysis was unable to establish a significant difference between each management strategy (Table 12). The individual determinants that constitute the strength assessment for the recommendation of glucocorticoid withdrawal versus continued glucocorticoid treatment (SR3) are shown in Table 10.

GUIDELINE RECOMMENDATION

5. Based on limited data to support long-term administration of glucocorticoids to prevent

posttransplant rejection, graft loss, recurrent AIH, and reduced patient and graft survival in adults, the AASLD suggests that a gradual withdrawal of glucocorticoids be considered after LT (conditional recommendation, very low certainty).

RECURRENT AIH AFTER LT

AIH recurs in 8%-12% of patients within the first year after LT and 36%-68% after 5 years.^(471,491,497-501) The frequency of recurrent AIH has been similar (20%) in recipients of grafts from living-related, living-unrelated, and deceased donors.⁽⁵⁰²⁾ The diagnostic criteria for recurrent AIH are the same as for the original disease, albeit some features may be less pronounced or absent because of concurrent immunosuppressive therapy or short duration of disease.^(498,501) Recurrent AIH can sometimes be difficult to distinguish from alloimmune rejection. The laboratory profile and characteristic histological changes required for the diagnosis of recurrent AIH are detailed in Table 13. Histological features classically seen in rejection, including endothelialitis and bile duct damage, are usually absent in recurrent AIH. Standard glucocorticoid-based therapy is used to treat recurrent AIH, along with the possible addition of AZA or MMF.

TABLE 12. Evidence Profile and Results of Systematic Review and Meta-analysis for Continuation versus Discontinuation of Steroids after LT for AIH

Continuation versus Discontinuation of Steroids After LT

Outcome	Results	Grade of Evidence Quality
Recurrent autoimmune hepatitis	Two retrospective studies ^(488,491) and one RCT ⁽⁴⁸⁹⁾ reported no significant difference in recurrence of AIH after LT	Low
Acute cellular rejection	No studies reported frequencies of acute cellular rejection	
Graft loss	No studies reported frequencies of graft loss	
Death	One RCT ⁽⁴⁸⁹⁾ reported no significant difference between the two groups	Very low
Re-transplantation	No studies reported retransplantation	
Meta-analysis: I^2 test of heterogeneity	$I^2 = 38.6\%$, $P = 0.202$	
Meta-analysis: For biochemical remission	OR, 0.62; 95% CI, 0.19-1.96	
Meta-analysis: Conclusions	Few qualified studies Heterogeneous test results between studies Low-quality evidence to assess differences in frequency of recurrent AIH after LT Very low-quality evidence to assess differences in mortality after LT Conditional recommendation of very low certainty that steroids be discontinued after LT	

Abbreviation: RCT, randomized clinical trial.

DE NOVO AIH

De novo AIH denotes the development of AIH in a patient transplanted for a disease other than AIH⁽⁵⁰³⁾ (Table 13). It was originally described in 4% of British children (median age, 10.3 years; range, 2-19.4 years) who developed clinical and histological features of AIH 6-45 months after LT for extrahepatic biliary atresia, Alagille syndrome, drug-induced acute liver failure, and alpha 1-antitrypsin deficiency.⁽⁵⁰³⁾ It has been reported subsequently in North American, South American, Japanese, and Korean children from 0.1 to 9 years after LT representing 1%-7% of pediatric recipients.⁽⁵⁰³⁻⁵⁰⁹⁾ *De novo* AIH has been described in adults after LT,⁽⁵¹⁰⁾ especially in recipients transplanted for PBC⁽⁵¹¹⁻⁵¹⁶⁾ or chronic hepatitis C.⁽⁵¹⁷⁻⁵¹⁹⁾ The estimated frequency of *de novo* AIH in transplanted adults ranges from 1% to 3% with an overall incidence of 4 cases per 1,000 patient-years.⁽⁵²⁰⁾

The clinical features of *de novo* AIH are similar to those required for the diagnosis of AIH and recurrent AIH.^(2,56,384,521) The term “plasma cell hepatitis” was coined to describe the inflammatory

infiltrates observed in adult LT recipients with recurrence of hepatitis C virus infection.⁽⁵²²⁾ The plasmacytic nature of the inflammation was thought to resemble AIH or “*de novo* AIH.”⁽⁵²²⁾ IgG4⁺ plasma cells have been identified in the infiltrates associated with severe portal, periportal, and perivenular necro-inflammatory activity and fibrosis in adult patients, which could indicate alloimmune and/or autoimmune responses.⁽⁵²³⁾

The Banff working group on liver allograft pathology has proposed that “plasma cell-rich rejection” replace the terms “plasma cell hepatitis” and “*de novo* autoimmune hepatitis,” for graft dysfunction occurring >6 months after transplantation in association with severe lymphocytic cholangitis, plasma cell-rich central perivenulitis, and portal microvascular deposition of complement component 4d.^(524,525) This form of graft dysfunction has been described mainly in adult interferon-treated recipients with chronic hepatitis C^(522,526,527) and distinguishes adults from children with *de novo* AIH.⁽⁵²¹⁾ It may be prudent to separate *de novo* AIH from plasma cell hepatitis/rejection.^(521,524,525) Keys to the diagnosis and management of *de novo* AIH are provided in Table 13.

TABLE 13. Diagnostic Features, Treatment, and Outcome of Recurrent and *De Novo* AIH

Categories	Recurrent AIH	<i>De Novo</i> AIH
Clinical findings	Graft dysfunction at 2 months-12 years ^(471,491,497) Asymptomatic to graft failure ^(614,615) May be detected only by liver biopsy ^(500,616)	Indication for LT other than AIH ^(503,521) Exclude plasma cell-rich rejection/plasma cell hepatitis ^(521,522,524-526)
Laboratory findings	Increased serum AST, ALT, IgG levels ⁽⁵⁰¹⁾	Increased serum AST, ALT, IgG levels ^(503,521)
Serological markers	Same antibodies as pre-LT AIH ⁽⁶¹⁷⁻⁶¹⁹⁾ ANA, SMA common ⁽⁶¹⁷⁾ Anti-LKM1 rare ⁽⁶¹⁸⁾	ANA, SMA, anti-LKM1 ^(503,521)
Histologic findings	Lobular hepatitis, focal necrosis, pseudorosettes (early) ⁽⁶²⁰⁻⁶²³⁾ Interface hepatitis, lymphoplasmacytic infiltration (late) ⁽⁶²³⁾ Lobular collapse, confluent/bridging necrosis (severe) ⁽⁶²¹⁻⁶²³⁾	Interface hepatitis ⁽⁵²¹⁾ Lymphoplasmacytic infiltrates ⁽⁵²¹⁾
Treatment	Predniso(lo)ne, 30 mg daily, and AZA, 1-2 mg/kg daily ^(499,501) Predniso(lo)ne dose reduction to 5-10 mg daily in 4-8 weeks ⁽⁶²⁴⁾ Predniso(lo)ne and AZA maintenance ^(501,624) Continue calcineurin inhibitor ^(624,625)	Children ^(501,503,624) • Predniso(lo)ne (1-2 mg/kg, <60 mg daily) and AZA (1-2 mg/kg daily) • Otherwise same as recurrent AIH adults ^(501,624,626) • Same as recurrent AIH
Rescue regimens (empiric)	MMF for AZA ⁽⁶²⁷⁾ Switch calcineurin inhibitor ^(498,625) Rapamycin ⁽⁶²⁸⁾	MMF for AZA ⁽⁴¹⁹⁾ Rapamycin ⁽⁶²⁹⁾
Outcomes	5-year patient survival, 86%-100% ^(500,614) Graft failure, 8%-50% ^(614,630-632) Retransplantation, 33%-60% ^(614,615,631) Recurrent AIH in retransplanted liver, 33%-100% ^(614,615,631)	Better in children than adults ^(503,509,521,522,526) Biochemical remission, 86% ⁽⁵⁰³⁾ Retransplantation, 8% ⁽⁵⁰⁸⁾ Patient survival, 95% ⁽⁶²⁶⁾

TABLE 14. Current and Potential Therapies for AIH Based on Evolving Knowledge of Immunopathogenic Mechanisms

Goal	Treatment	Mechanism of Action	Status of Development
Decrease the numbers and/or functions of autoimmune effector cells and pathogenic autoantibodies	Immunosuppressive drugs: CNI, mTOR, antiproliferative agents	Inhibit proliferation of autoantigen-activated CD4 and CD8 T cells by reducing the amount and/or signaling of mitogenic IL-2 or block completion of T-cell division	SOC in multiple AI diseases. Combination therapies using subtoxic doses of two or more agents attractive. Ongoing research into prevention and management of toxicities
	Anti-CD20	B-cell depletion	
	Anti-BAFF	B-cell depletion followed by mobilization of memory B cells from lymphoid tissue. Potent inhibition of BAFF signaling in activated T cells	Off-label use as alternative therapy in AIH
	Anti-BAFF, followed by anti-CD20		SOC in SLE. Ongoing clinical trial in AIH
	Anti-CD40	Depletion of memory B cells mobilized from lymphoid tissues by anti-BAFF	Clinical trials planned in AI diseases
	Efgartigimod	Block CD40-CD40L (CD154) costimulation of T cells and B cells	POC. Clinical trial initiated in liver transplantation
	Inhibition of sphingosine-1-phosphate receptors	First in class antibody fragment to block FcRn to increase IgG clearance and prevent IgG recycling	POC to reduce pathogenic autoantibodies and Ig–autoantigen immune complexes
Decrease and/or inhibit proinflammatory cytokines	Myeloid-derived suppressor cells	Prevent egress of activated T cells from lymph nodes into blood	SOC in MS, new agents in development for other AI diseases
		Inhibit autoreactive T-cell activation and proliferation	POC in preclinical models. Clinical trials planned in RA
	Anti-TNF α or TNF α -receptor	Reduce TNF α -mediated tissue injury and proinflammatory signaling pathways	SOC in multiple AI diseases. Studied as an alternative therapy in AIH
	Anti-IL-6 or anti-IL-6R	Reduce pathogenic effects of proinflammatory IL-6 signaling in innate and adaptive immune responses	SOC in RA, clinical trials ongoing in other AI diseases
	Anti-IL-12 (p40 subunit)	Reduce pathogenic effects of proinflammatory IL-12 signaling in innate and adaptive immune responses	SOC in psoriasis and Crohn's disease. Also blocks IL-23 signaling
	Anti-IL-17a or Anti-17R	Reduce pathogenic effects of IL-17	SOC for psoriasis and psoriatic arthritis. Clinical trials planned in other AI diseases
	Anti-IL-21	Reduce multiple pathogenic effects of IL-21 in innate and adaptive immune responses	Ongoing clinical trials in RA, T1DM, and Crohn's disease
	Anti-IL-23 (p19 or p40 subunits)	Reduce pathogenic effects of proinflammatory IL-23 stimulation of Th17 cells	SOC in psoriasis and Crohn's disease
	Anti-Blys	Reduce pathogenic B-cell selection, differentiation, and homeostasis	SOC in SLE
	Inhibit signaling of proinflammatory cytokines	mTOR inhibition	Decrease proliferation of activated CD4 and CD8 T cells by inhibiting signaling of IL-2
Tofacitinib (JAK3 inhibitor of IL-2 signaling)		Decrease proliferation of activated CD4 and CD8 T cells by inhibiting signaling of IL-2	SOC in RA. Clinical trials planned
Baricitinib (JAK1/2 inhibitor of IL-6 and IFN γ signaling)		Reduce pathogenic effects of proinflammatory IL-6 signaling through IL-6R in innate and adaptive immune responses and pathogenic effects of IFN γ signaling in NK, NK T, CD4, and CD8 T cells	SOC in RA. Ongoing clinical trial in PBC
Pacritinib (JAK2 inhibitor of IL-12/IL-23 signaling)		Reduce proinflammatory IL-12 and IL-23 signaling that polarizes increases CD4 Th1 polarization, secretion of IFN γ and TNF α , cytotoxic activity of NK and CD8 CTLs, and differentiation of pathogenic Th17 cells	POC established. Ongoing clinical trials
Filotinib (JAK1 inhibitor of IFN α /IFN β signaling)		Reduce immunopathogenic gene expression induced by type 1 IFNs	POC established. Ongoing clinical trials
Upadacitinib (selective JAK1 inhibitor of IFN α /IFN β signaling)		Reduce immunopathogenic gene expression	SOC for refractory RA
Augment effects of immunosuppressant cytokines	rHuIL-10	Reduce immunopathogenic effects of activated CD4 Th1 cells	SOC to prevent pancreatitis post-ERCP Trial in UC terminated for concern of Guillain-Barré syndrome

TABLE 14. Continued

Goal	Treatment	Mechanism of Action	Status of Development
Inhibit transendothelial migration of effector cells from blood into tissues	Inhibition of chemokine receptors or integrins	Prevent tissue inflammation and injury by blocking transendothelial entry of effector cells from blood into target tissues	SOC inhibition of $\alpha 4/\beta 7$ integrin in UC. Clinical trial in PSC ineffective
		Prevent chemokine-induced terminal differentiation of effector cells	Potential for clinical trials of other Food and Drug Administration–approved chemokine/integrin inhibitors
Establish immunoregulatory control	Low-dose IL-2 infusion to increase autoantigen-specific iTregs	Expansion of preexisting autoantigen-specific iTregs <i>in vivo</i> requires exposure to low concentrations of IL-2	POC established Clinical trials ongoing
	Infusion of autoantigen-specific iTregs generated <i>ex vivo</i>	<i>Ex vivo</i> generation of autologous autoantigen-specific iTregs followed by infusion to immunologically control autoantigen-specific CD4 Th-cell subset responses	POC of iTreg generation <i>ex vivo</i> established. Future clinical trials planned in AIH. Viability, function, and distribution of iTregs after infusion unknown
	Inhibition of bromodomain and extraterminal family of proteins	Inhibition of disease-specific epigenetic transcriptional enhancers, superenhancers, and enhancer RNA production to decrease autoimmune reactions	POC established. Clinical trials ongoing
	Mesenchymal stem cells	Inhibition of innate immune cells, effector T cells Induction of antigen-specific iTregs Reduction of TNF α secretion	POC established. Clinical trials ongoing
Establish physiologic immunoregulatory state of pregnancy	PIF	Creation of immunosuppressive and immunomodulatory environment of pregnancy	Phase 1b trial of synthetic PIF in AIH completed. Ongoing clinical trial

Abbreviations: AI, autoimmune; BAFF, B cell–activating factor; Blys, B lymphocyte stimulator; CNI, calcineurin inhibitor; ERCP, endoscopic retrograde cholangiopancreatography; IFN, interferon; JAK, Janus kinase; MS, multiple sclerosis; mTOR, mechanistic target of rapamycin; PIF, preimplantation factor; POC, proof of concept; RA, rheumatoid arthritis; rHuIL-10, recombinant, human IL-10; SLE, systemic lupus erythematosus; SOC, standard of care regulatory approval; T1DM, type 1 diabetes mellitus.

GUIDANCE STATEMENTS

- Recurrent AIH or *de novo* AIH and plasma cell hepatitis/rejection must be suspected in LT recipients with laboratory changes of allograft injury.
- Liver biopsy, serum IgG level, and autoantibodies should be obtained to distinguish immune-mediated disease from other causes of allograft dysfunction.
- Predniso(lo)ne with AZA should be added to the calcineurin inhibitor to achieve biochemical remission in recurrent AIH or *de novo* AIH.

Future Directions and Unmet Needs

The unmet clinical needs in AIH will drive studies that improve the outcomes of current management, enhance quality of life, prevent disease recurrence, improve management of atypical populations (especially overlap syndromes), and increase

understanding of the epidemiology and pathophysiology of AIH through real-world international databases.⁽⁵²⁸⁾

Pharmacological and biological agents that can restore homeostatic mechanisms that modulate immune responses,^(224,529–531) reduce oxidative and nitrosative stresses,⁽⁵³²⁾ or inhibit hepatic fibrosis⁽⁵³³⁾ will be evaluated to supplement or replace current treatments (Table 14). The ability to correct deficient immune cell mediators by the transfer of autologous expanded populations (Tregs, mesenchymal stromal cells, or myeloid-derived suppressor cells) will be another promising investigational front.^(534,535)

Prognostic biomarkers that predict the risk of treatment failure, relapse, or progression to cirrhosis and therapeutic biomarkers that reflect biochemical and histological response are needed to individualize management strategies and establish endpoints of treatment.⁽⁵³⁶⁾ Antibodies to programmed cell death-1 protein (PD-1),⁽⁵³⁷⁾ soluble circulating PD-1 levels,⁽⁵³⁸⁾ macrophage migration inhibitory

factor,^(539,540) micro-RNA-21,⁽⁵⁴¹⁾ and soluble CD163⁽⁵⁴²⁾ are evolving biomarkers that may guide future management. Similarly, metabolomic profiling may emerge as a means of distinguishing AIH from other liver diseases (drug-induced liver injury, PBC)^(543,544) and assessing treatment outcome.⁽⁵⁴⁵⁾

Population-based epidemiological studies that have demonstrated an increasing incidence of AIH in Spain, Denmark, and the Netherlands⁽¹⁷⁾ must energize efforts to understand the environmental risk factors for AIH in different geographical regions by promoting highly targeted, population-based investigations. Key epitopes that might trigger the disease must be sought among environmental agents (infections, pharmaceuticals, diet, and pollutants)⁽⁵⁴⁶⁾ and within the intestinal microbiome.⁽⁵⁴⁷⁾

The intestinal microbiome is an undervalued source of microbial antigens and activated immune cells that is actively being evaluated in diverse immune-mediated diseases, including AIH.⁽⁵⁴⁷⁾ Intestinal dysbiosis, circulating gut-derived lipopolysaccharides, and weakening of the intestinal mucosal barrier have already been described in patients with AIH^(548,549); and changes in the intestinal microbiome have been associated with female bias in autoimmune disease.⁽⁵⁵⁰⁻⁵⁵²⁾ Future investigations that reinforce and extend these observations in AIH may identify interventions that can reduce risk, severity, and relapse.^(547,553)

The management and outcome of AIH and the overall well-being of patients with AIH will continue to improve as understanding of its pathogenic mechanisms evolves, molecular interventions that counter its homeostatic disruptions emerge, and adjunctive measures tailored by greater awareness and responsiveness to individual need are instituted.

Acknowledgment: This work was produced in tandem with a *de novo* systematic review that was written by the same writing group, including M. Hassan Murad, M.D., M.P.H., who participated in the selection of the clinical questions and provided expertise regarding the GRADE approach. The AASLD Practice Guidelines Committee approved the scope, directed the development of the practice guideline and guidance, and provided the peer review that was led by Elizabeth C. Verna, M.D., M.S. Members of the AASLD Practice Guidelines Committee include George Ioannou, M.D., F.A.A.S.L.D. (chair); Rabab Ali, M.B.B.S.; Alfred Sidney Barritt IV, M.D., M.S.C.R.; James R. Burton,

Jr., M.D.; Roniel Cabrera, M.D., M.S.; Michael F. Chang, M.D., M.Sc., M.B.A., F.A.A.S.L.D.; Udem Ekong, M.D., F.A.A.S.L.D.; Ruben Hernaez, M.D., M.P.H., Ph.D.; Whitney E. Jackson, M.D.; Binu John, M.D., M.P.H.; Patricia D. Jones, M.D., M.S.C.R.; Patrick S. Kamath, M.D.; David G. Koch, M.D.; Cynthia Levy, M.D., F.A.A.S.L.D.; Lopa Mishra, M.D., F.A.A.S.L.D. (board liaison); Daniel S. Pratt, M.D., F.A.A.S.L.D.; David J. Reich, M.D., F.A.C.S.; Barry Schlansky, M.D., M.P.H.; Amit G. Singal, M.D., M.S. (vice-chair); James R. Spivey, M.D.; and Elizabeth C. Verna, M.D., M.S.

REFERENCES

- Merriman RB, Tran TT. AASLD practice guidelines: the past, the present, and the future. *HEPATOLOGY* 2016;63:31-34.
- Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, et al. Diagnosis and management of autoimmune hepatitis. *HEPATOLOGY* 2010;51:2193-2213.
- Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;336:924-926.
- Goldet G, Howick J. Understanding GRADE: an introduction. *J Evid Based Med* 2013;6:50-54.
- Gatselis NK, Zachou K, Koukoulis GK, Dalekos GN. Autoimmune hepatitis, one disease with many faces: etiopathogenic, clinico-laboratory and histological characteristics. *World J Gastroenterol* 2015;21:60-83.
- Palle SK, Naik KB, McCracken CE, Kolachala VL, Romero R, Gupta NA. Racial disparities in presentation and outcomes of paediatric autoimmune hepatitis. *Liver Int* 2019;39:976-984.
- Czaja AJ, Carpenter HA, Santrach PJ, Moore SB, Taswell HF, Homburger HA. Evidence against hepatitis viruses as important causes of severe autoimmune hepatitis in the United States. *J Hepatol* 1993;18:342-352.
- Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. *Scand J Gastroenterol* 1998;33:99-103.
- Werner M, Prytz H, Ohlsson B, Almer S, Bjornsson E, Bergquist A, et al. Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. *Scand J Gastroenterol* 2008;43:1232-1240.
- Ngu JH, Bechly K, Chapman BA, Burt MJ, Barclay ML, Geary RB, et al. Population-based epidemiology study of autoimmune hepatitis: a disease of older women? *J Gastroenterol Hepatol* 2010;25:1681-1686.
- Gronbaek L, Vilstrup H, Jepsen P. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. *J Hepatol* 2014;60:612-617.
- van Gerven NM, Verwer BJ, Witte BI, van Erpecum KJ, van Buuren HR, Maijers I, et al. Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands. *Scand J Gastroenterol* 2014;49:1245-1254.
- Gregorio GV, Portmann B, Reid F, Donaldson PT, Doherty DG, McCartney M, et al. Autoimmune hepatitis in childhood: a 20-year experience. *HEPATOLOGY* 1997;25:541-547.

- 14) Radhakrishnan KR, Alkhoury N, Worley S, Arrigain S, Hupertz V, Kay M, et al. Autoimmune hepatitis in children—impact of cirrhosis at presentation on natural history and long-term outcome. *Dig Liver Dis* 2010;42:724-728.
- 15) Deneau M, Jensen MK, Holmen J, Williams MS, Book LS, Guthery SL. Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in Utah children: epidemiology and natural history. *HEPATOLOGY* 2013;58:1392-1400.
- 16) Jimenez-Rivera C, Ling SC, Ahmed N, Yap J, Aglipay M, Barrowman N, et al. Incidence and characteristics of autoimmune hepatitis. *Pediatrics* 2015;136:e1237-e1248.
- 17) Czaja AJ. Global disparities and their implications in the occurrence and outcome of autoimmune hepatitis. *Dig Dis Sci* 2017;62:2277-2292.
- 18) McFarlane IG. The relationship between autoimmune markers and different clinical syndromes in autoimmune hepatitis. *Gut* 1998;42:599-602.
- 19) McFarlane IG. Autoimmune hepatitis: clinical manifestations and diagnostic criteria. *Can J Gastroenterol* 2001;15:107-113.
- 20) Delgado JS, Vodonos A, Malnick S, Kriger O, Wilkof-Segev R, Delgado B, et al. Autoimmune hepatitis in southern Israel: a 15-year multicenter study. *J Dig Dis* 2013;14:611-618.
- 21) Primo J, Merino C, Fernandez J, Moles JR, Llorca P, Hinojosa J. Incidence and prevalence of autoimmune hepatitis in the area of the Hospital de Sagunto (Spain). *Gastroenterol Hepatol* 2004;27:239-243.
- 22) Primo J, Maroto N, Martinez M, Anton MD, Zaragoza A, Giner R, et al. Incidence of adult form of autoimmune hepatitis in Valencia (Spain). *Acta Gastroenterol Belg* 2009;72:402-406.
- 23) Danielsson Borssen A, Marschall HU, Bergquist A, Rorsman F, Weiland O, Kechagias S, et al. Epidemiology and causes of death in a Swedish cohort of patients with autoimmune hepatitis. *Scand J Gastroenterol* 2017;52:1022-1028.
- 24) Hurlburt KJ, McMahon BJ, Deubner H, Hsu-Trawinski B, Williams JL, Kowdley KV. Prevalence of autoimmune liver disease in Alaska natives. *Am J Gastroenterol* 2002;97:2402-2407.
- 25) Lee YM, Teo EK, Ng TM, Khor C, Fock KM. Autoimmune hepatitis in Singapore: a rare syndrome affecting middle-aged women. *J Gastroenterol Hepatol* 2001;16:1384-1389.
- 26) Chung HV, Riley M, Ho JK, Leung B, Jevon GP, Arbour LT, et al. Retrospective review of pediatric and adult autoimmune hepatitis in two quaternary care centres in British Columbia: increased prevalence seen in British Columbia's First Nations community. *Can J Gastroenterol* 2007;21:565-568.
- 27) Price P, Witt C, Alcock R, Sayer D, Garlepp M, Kok CC, et al. The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. *Immunol Rev* 1999;167:257-274.
- 28) Fainboim L, Marcos Y, Pando M, Capucchio M, Reyes GB, Galoppo C, et al. Chronic active autoimmune hepatitis in children. Strong association with a particular HLA-DR6 (DRB1*1301) haplotype. *Hum Immunol* 1994;41:146-150.
- 29) Strettell MD, Donaldson PT, Thomson LJ, Santrach PJ, Moore SB, Czaja AJ, et al. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. *Gastroenterology* 1997;112:2028-2035.
- 30) Goldberg AC, Bittencourt PL, Mouglin B, Cancado EL, Porta G, Carrilho F, et al. Analysis of HLA haplotypes in autoimmune hepatitis type 1: identifying the major susceptibility locus. *Hum Immunol* 2001;62:165-169.
- 31) Djilali-Saiah I, Fakhfakh A, Louafi H, Caillat-Zucman S, Debray D, Alvarez F. HLA class II influences humoral autoimmunity in patients with type 2 autoimmune hepatitis. *J Hepatol* 2006;45:844-850.
- 32) van Gerven NM, de Boer YS, Zwiers A, Verwer BJ, Drenth JP, van Hoek B, et al. HLA-DRB1*03:01 and HLA-DRB1*04:01 modify the presentation and outcome in autoimmune hepatitis type-1. *Genes Immun* 2015;16:247-252.
- 33) Agarwal K, Czaja AJ, Jones DE, Donaldson PT. Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. *HEPATOLOGY* 2000;31:49-53.
- 34) Cookson S, Constantini PK, Clare M, Underhill JA, Bernal W, Czaja AJ, et al. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. *HEPATOLOGY* 1999;30:851-856.
- 35) Qin B, Li J, Liang Y, Yang Z, Zhong R. The association between cytotoxic T lymphocyte associated antigen-4, Fas, tumour necrosis factor-alpha gene polymorphisms and autoimmune hepatitis: a meta-analysis. *Dig Liver Dis* 2014;46:541-548.
- 36) Hiraide A, Imazeki F, Yokosuka O, Kanda T, Kojima H, Fukai K, et al. Fas polymorphisms influence susceptibility to autoimmune hepatitis. *Am J Gastroenterol* 2005;100:1322-1329.
- 37) Agarwal K, Czaja AJ, Donaldson PT. A functional Fas promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterized by early development of cirrhosis. *Tissue Antigens* 2007;69:227-235.
- 38) Vogel A, Strassburg CP, Manns MP. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. *HEPATOLOGY* 2002;35:126-131.
- 39) Fan L, Tu X, Zhu Y, Zhou L, Pfeiffer T, Feltens R, et al. Genetic association of vitamin D receptor polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in the Chinese. *J Gastroenterol Hepatol* 2005;20:249-255.
- 40) Migita K, Nakamura M, Abiru S, Jiuchi Y, Nagaoka S, Komori A, et al. Association of STAT4 polymorphisms with susceptibility to type-1 autoimmune hepatitis in the Japanese population. *PLoS ONE* 2013;8:e71382.
- 41) Paladino N, Flores AC, Fainboim H, Schroder T, Cuarterolo M, Lezama C, et al. The most severe forms of type I autoimmune hepatitis are associated with genetically determined levels of TGF-beta1. *Clin Immunol* 2010;134:305-312.
- 42) Bucala R. MIF, MIF alleles, and prospects for therapeutic intervention in autoimmunity. *J Clin Immunol* 2013;33(Suppl. 1):S72-S78.
- 43) de Boer YS, van Gerven NM, Zwiers A, Verwer BJ, van Hoek B, van Erpecum KJ, et al. Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. *Gastroenterology* 2014;147:443-452.
- 44) Liu M, Zhu W, Wang J, Zhang J, Guo X, Wang J, et al. Interleukin-23 receptor genetic polymorphisms and ulcerative colitis susceptibility: a meta-analysis. *Clin Res Hepatol Gastroenterol* 2015;39:516-525.
- 45) Nagamine K, Peterson P, Scott HS, Kudoh J, Minoshima S, Heino M, et al. Positional cloning of the APECED gene. *Nat Genet* 1997;17:393-398.
- 46) Christen U, Hintermann E. Pathogen infection as a possible cause for autoimmune hepatitis. *Int Rev Immunol* 2014;33:296-313.
- 47) Floreani A, Leung PS, Gershwin ME. Environmental basis of autoimmunity. *Clin Rev Allergy Immunol* 2016;50:287-300.
- 48) Oo YH, Hubscher SG, Adams DH. Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and management. *Hepatol Int* 2010;4:475-493.
- 49) Trivedi PJ, Adams DH. Mucosal immunity in liver autoimmunity: a comprehensive review. *J Autoimmun* 2013;46:97-111.
- 50) Floreani A, Restrepo-Jimenez P, Secchi MF, De Martin S, Leung PSC, Krawitt E, et al. Etiopathogenesis of autoimmune hepatitis. *J Autoimmun* 2018;95:133-143.

- 51) Sakkas LI, Daoussis D, Mavropoulos A, Lioussis SN, Bogdanos DP. Regulatory B cells: new players in inflammatory and autoimmune rheumatic diseases. *Semin Arthritis Rheum* 2019;48:1133-1141.
- 52) Kitz A, Singer E, Hafler D. Regulatory T cells: from discovery to autoimmunity. *Cold Spring Harb Perspect Med* 2018;8:a029041.
- 53) Saligrama N, Zhao F, Sikora MJ, Serratelli WS, Fernandes RA, Louis DM, et al. Opposing T cell responses in experimental autoimmune encephalomyelitis. *Nature* 2019;572:481-487.
- 54) Chiba A, Murayama G, Miyake S. Mucosal-associated invariant T cells in autoimmune diseases. *Front Immunol* 2018;9:1333.
- 55) Oo YH, Adams DH. The role of chemokines in the recruitment of lymphocytes to the liver. *J Autoimmun* 2010;34:45-54.
- 56) Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. *J Hepatol* 1999;31:929-938.
- 57) Czaja AJ, Manns MP. The validity and importance of subtypes in autoimmune hepatitis: a point of view. *Am J Gastroenterol* 1995;90:1206-1211.
- 58) Muratori P, Granito A, Quarneti C, Ferri S, Menichella R, Cassani F, et al. Autoimmune hepatitis in Italy: the Bologna experience. *J Hepatol* 2009;50:1210-1218.
- 59) Muratori P, Lalanne C, Fabbri A, Cassani F, Lenzi M, Muratori L. Type 1 and type 2 autoimmune hepatitis in adults share the same clinical phenotype. *Aliment Pharmacol Ther* 2015;41:1281-1287.
- 60) Czaja AJ. Diagnosis and management of autoimmune hepatitis: current status and future directions. *Gut Liv* 2016;10:177-203.
- 61) Czaja AJ. Performance parameters of the conventional serological markers for autoimmune hepatitis. *Dig Dis Sci* 2011;56:545-554.
- 62) Gregorio GV, Portmann B, Karani J, Harrison P, Donaldson PT, Vergani D, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. *HEPATOLOGY* 2001;33:544-553.
- 63) Czaja AJ. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. *J Hepatol* 1999;30:394-401.
- 64) Gregorio GV, McFarlane B, Bracken P, Vergani D, Mieli-Vergani G. Organ and non-organ specific autoantibody titres and IgG levels as markers of disease activity: a longitudinal study in childhood autoimmune liver disease. *Autoimmunity* 2002;35:515-519.
- 65) Czaja AJ, Carpenter HA, Manns MP. Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis. *Gastroenterology* 1993;105:1522-1528.
- 66) Kanzler S, Weidemann C, Gerken G, Lohr HF, Galle PR, Meyer zum Buschenfelde KH, et al. Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. *J Hepatol* 1999;31:635-640.
- 67) Ballot E, Homberg JC, Johanet C. Antibodies to soluble liver antigen: an additional marker in type 1 auto-immune hepatitis. *J Hepatol* 2000;33:208-215.
- 68) Baeres M, Herkel J, Czaja AJ, Wies I, Kanzler S, Cancado EL, et al. Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. *Gut* 2002;51:259-264.
- 69) Eyraud V, Chazouilleres O, Ballot E, Corpechot C, Poupon R, Johanet C. Significance of antibodies to soluble liver antigen/liver pancreas: a large French study. *Liver Int* 2009;29:857-864.
- 70) Montano-Loza AJ, Shums Z, Norman GL, Czaja AJ. Prognostic implications of antibodies to Ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis. *Liver Int* 2012;32:85-92.
- 71) Efe C, Ozaslan E, Wahlin S, Purnak T, Muratori L, Quarneti C, et al. Antibodies to soluble liver antigen in patients with various liver diseases: a multicentre study. *Liver Int* 2013;33:190-196.
- 72) Ma Y, Okamoto M, Thomas MG, Bogdanos DP, Lopes AR, Portmann B, et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. *HEPATOLOGY* 2002;35:658-664.
- 73) Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. *Am J Gastroenterol* 2002;97:413-419.
- 74) Czaja AJ. Autoantibodies as prognostic markers in autoimmune liver disease. *Dig Dis Sci* 2010;55:2144-2161.
- 75) Targan SR, Landers C, Vidrich A, Czaja AJ. High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. *Gastroenterology* 1995;108:1159-1166.
- 76) Bansi D, Chapman R, Fleming K. Antineutrophil cytoplasmic antibodies in chronic liver diseases: prevalence, titre, specificity and IgG subclass. *J Hepatol* 1996;24:581-586.
- 77) Terjung B, Sohne J, Lechtenberg B, Gottwein J, Muennich M, Herzog V, et al. p-ANCA in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ. *Gut* 2010;59:808-816.
- 78) Elkayam O, Levartovsky D, Brautbar C, Yaron M, Burke M, Vardinon N, et al. Clinical and immunological study of 7 patients with minocycline-induced autoimmune phenomena. *Am J Med* 1998;105:484-487.
- 79) Czaja AJ. Cryptogenic chronic hepatitis and its changing guise in adults. *Dig Dis Sci* 2011;56:3421-3438.
- 80) Zachou K, Rigopoulou E, Dalekos GN. Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease. *J Autoimmune Dis* 2004;1:2.
- 81) Czaja AJ, Cassani F, Cataleta M, Valentini P, Bianchi FB. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. *HEPATOLOGY* 1996;24:1068-1073.
- 82) Chretien-Leprince P, Ballot E, Andre C, Olsson NO, Fabien N, Escande A, et al. Diagnostic value of anti-F-actin antibodies in a French multicenter study. *Ann N Y Acad Sci* 2005;1050:266-273.
- 83) Frenzel C, Herkel J, Luth S, Galle PR, Schramm C, Lohse AW. Evaluation of F-actin ELISA for the diagnosis of autoimmune hepatitis. *Am J Gastroenterol* 2006;101:2731-2736.
- 84) Gueguen P, Dalekos G, Nousbaum JB, Zachou K, Putterman C, Youinou P, et al. Double reactivity against actin and alpha-actinin defines a severe form of autoimmune hepatitis type 1. *J Clin Immunol* 2006;26:495-505.
- 85) Zachou K, Oikonomou K, Renaudineau Y, Chauveau A, Gatselis N, Youinou P, et al. Anti-alpha actinin antibodies as new predictors of response to treatment in autoimmune hepatitis type 1. *Aliment Pharmacol Ther* 2012;35:116-125.
- 86) Renaudineau Y, Dalekos GN, Gueguen P, Zachou K, Youinou P. Anti-alpha-actinin antibodies cross-react with anti-ssDNA antibodies in active autoimmune hepatitis. *Clin Rev Allergy Immunol* 2008;34:321-325.
- 87) Martini E, Abuaf N, Cavalli F, Durand V, Johanet C, Homberg JC. Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2. *HEPATOLOGY* 1988; 8:1662-1666.
- 88) Abuaf N, Johanet C, Chretien P, Martini E, Soulier E, Laperche S, et al. Characterization of the liver cytosol antigen type 1 reacting with autoantibodies in chronic active hepatitis. *HEPATOLOGY* 1992;16:892-898.
- 89) Bachrich T, Thalhammer T, Jager W, Haslmayer P, Alihodzic B, Bakos S, et al. Characterization of autoantibodies against uridine-diphosphate glucuronosyltransferase in patients with inflammatory liver diseases. *HEPATOLOGY* 2001;33:1053-1059.
- 90) Obermayer-Straub P, Manns MP. Cytochromes P450 and UDP-glucuronosyl-transferases as hepatocellular autoantigens. *Baillieres Clin Gastroenterol* 1996;10:501-532.

- 91) Strassburg CP, Obermayer-Straub P, Alex B, Durazzo M, Rizzetto M, Tukey RH, et al. Autoantibodies against glucuronosyltransferases differ between viral hepatitis and autoimmune hepatitis. *Gastroenterology* 1996;111:1576-1586.
- 92) Obermayer-Straub P, Manns MP. Cytochrome P450 enzymes and UDP-glucuronosyltransferases as hepatocellular autoantigens. *Mol Biol Rep* 1996;23:235-242.
- 93) Fabien N, Desbos A, Bienvenu J, Magdalou J. Autoantibodies directed against the UDP-glucuronosyltransferases in human autoimmune hepatitis. *Autoimmun Rev* 2004;3:1-9.
- 94) Czaja AJ, Shums Z, Norman GL. Nonstandard antibodies as prognostic markers in autoimmune hepatitis. *Autoimmunity* 2004;37:195-201.
- 95) Czaja AJ, Carpenter HA. Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. *Gastroenterology* 1993;105:1824-1832.
- 96) Pratt DS, Fawaz KA, Rabson A, Dellelis R, Kaplan MM. A novel histological lesion in glucocorticoid-responsive chronic hepatitis. *Gastroenterology* 1997;113:664-668.
- 97) Kessler WR, Cummings OW, Eckert G, Chalasani N, Lumeng L, Kwo PY. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. *Clin Gastroenterol Hepatol* 2004;2:625-631.
- 98) Misdraji J, Thiim M, Graeme-Cook FM. Autoimmune hepatitis with centrilobular necrosis. *Am J Surg Pathol* 2004;28:471-478.
- 99) Miyake Y, Iwasaki Y, Terada R, Onishi T, Okamoto R, Takaguchi K, et al. Clinical features of Japanese type 1 autoimmune hepatitis patients with zone III necrosis. *Hepatol Res* 2007;37:801-805.
- 100) Stravitz RT, Lefkowitz JH, Fontana RJ, Gershwin ME, Leung PS, Sterling RK, et al. Autoimmune acute liver failure: proposed clinical and histological criteria. *HEPATOLOGY* 2011;53:517-526.
- 101) Humble JG, Jayne WH, Pulvertaft RJ. Biological interaction between lymphocytes and other cells. *Br J Haematol* 1956;2:283-294.
- 102) Rastogi V, Sharma R, Misra SR, Yadav L, Sharma V. Emperipolesis—a review. *J Clin Diagn Res* 2014;8:ZM01-ZM02.
- 103) Balitzer D, Shafizadeh N, Peters MG, Ferrell LD, Alshak N, Kakar S. Autoimmune hepatitis: review of histologic features included in the simplified criteria proposed by the international autoimmune hepatitis group and proposal for new histologic criteria. *Mod Pathol* 2017;30:773-783.
- 104) Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR, Heathcote EJ. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. *HEPATOLOGY* 2005;42:53-62.
- 105) Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. *Gastroenterology* 1996;110:848-857.
- 106) Verma S, Gunuwan B, Mendler M, Govindrajana S, Redeker A. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. *Am J Gastroenterol* 2004;99:1510-1516.
- 107) Liberal R, Grant CR. Cirrhosis and autoimmune liver disease: current understanding. *World J Hepatol* 2016;8:1157-1168.
- 108) Mieli-Vergani G, Vergani D, Baumann U, Czubkowski P, Debray D, Dezsofi A, et al. Diagnosis and management of pediatric autoimmune liver disease: ESPGHAN Hepatology Committee position statement. *J Pediatr Gastroenterol Nutr* 2018;66:345-360.
- 109) Schalm SW, Korman MG, Summerskill WH, Czaja AJ, Baggenstoss AH. Severe chronic active liver disease. Prognostic significance of initial morphologic patterns. *Am J Dig Dis* 1977;22:973-980.
- 110) Davis GL, Czaja AJ, Ludwig J. Development and prognosis of histologic cirrhosis in corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis. *Gastroenterology* 1984;87:1222-1227.
- 111) Wang KK, Czaja AJ. Hepatocellular carcinoma in corticosteroid-treated severe autoimmune chronic active hepatitis. *HEPATOLOGY* 1988;8:1679-1683.
- 112) Park SZ, Nagorney DM, Czaja AJ. Hepatocellular carcinoma in autoimmune hepatitis. *Dig Dis Sci* 2000;45:1944-1948.
- 113) Montano-Loza AJ, Carpenter HA, Czaja AJ. Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis. *Am J Gastroenterol* 2008;103:1944-1951.
- 114) Yeoman AD, Al-Chalabi T, Karani JB, Quaglia A, Devlin J, Mieli-Vergani G, et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: implications for follow-up and screening. *HEPATOLOGY* 2008;48:863-870.
- 115) Chung H, Watanabe T, Kudo M, Maenishi O, Wakatsuki Y, Chiba T. Identification and characterization of IgG4-associated autoimmune hepatitis. *Liver Int* 2010;30:222-231.
- 116) Umemura T, Zen Y, Hamano H, Joshita S, Ichijo T, Yoshizawa K, et al. Clinical significance of immunoglobulin G4-associated autoimmune hepatitis. *J Gastroenterol* 2011;46 (Suppl. 1):48-55.
- 117) Yada N, Kudo M, Chung H, Watanabe T. Autoimmune hepatitis and immunoglobulin G4-associated autoimmune hepatitis. *Dig Dis* 2013;31:415-420.
- 118) De Luca-Johnson J, Wangenstein KJ, Hanson J, Krawitt E, Wilcox R. Natural history of patients presenting with autoimmune hepatitis and coincident nonalcoholic fatty liver disease. *Dig Dis Sci* 2016;61:2710-2720.
- 119) Takahashi A, Arinaga-Hino T, Ohira H, Abe K, Torimura T, Zeniya M, et al. Non-alcoholic fatty liver disease in patients with autoimmune hepatitis. *JGH Open* 2018;2:54-58.
- 120) Johnson PJ, McFarlane IG. Meeting report: international autoimmune hepatitis group. *HEPATOLOGY* 1993;18:998-1005.
- 121) Hennes EM, Zeniya M, Czaja AJ, Pares A, Dalekos GN, Krawitt EL, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. *HEPATOLOGY* 2008;48:169-176.
- 122) Czaja AJ. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. *HEPATOLOGY* 2008;48:1540-1548.
- 123) Arcos-Machancoses JV, Molera Busoms C, Julio Tatis E, Bovo MV, Martín de Carpi J. Accuracy of the simplified criteria for autoimmune hepatitis in children: systematic review and decision analysis. *J Clin Exp Hepatol* 2019;9:147-155.
- 124) Ebbeson RL, Schreiber RA. Diagnosing autoimmune hepatitis in children: is the International Autoimmune Hepatitis Group scoring system useful? *Clin Gastroenterol Hepatol* 2004;2:935-940.
- 125) Yatsui S, Hashimoto E, Kaneda H, Taniai M, Tokushige K, Shiratori K. Diagnosing autoimmune hepatitis in nonalcoholic fatty liver disease: is the International Autoimmune Hepatitis Group scoring system useful? *J Gastroenterol* 2005;40:1130-1138.
- 126) Boberg KM, Chapman RW, Hirschfield GM, Lohse AW, Manns MP, Schrupf E, et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. *J Hepatol* 2011;54:374-385.
- 127) Vergani D, Alvarez F, Bianchi FB, Cancado EL, Mackay IR, Manns MP, et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. *J Hepatol* 2004;41:677-683.
- 128) Czaja AJ. Natural history, clinical features, and treatment of autoimmune hepatitis. *Semin Liver Dis* 1984;4:1-12.
- 129) Muratori P, Fabbri A, Lalanne C, Lenzi M, Muratori L. Autoimmune liver disease and concomitant extrahepatic

- autoimmune disease. *Eur J Gastroenterol Hepatol* 2015;27:1175-1179.
- 130) Kogan J, Safadi R, Ashur Y, Shouval D, Ilan Y. Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients. *J Clin Gastroenterol* 2002;35:75-81.
 - 131) Czaja AJ. Features and consequences of untreated type 1 autoimmune hepatitis. *Liver Int* 2009;29:816-823.
 - 132) Muratori P, Lalanne C, Barbato E, Fabbri A, Cassani F, Lenzi M, et al. Features and progression of asymptomatic autoimmune hepatitis in Italy. *Clin Gastroenterol Hepatol* 2016;14:139-146.
 - 133) Nikias GA, Batts KP, Czaja AJ. The nature and prognostic implications of autoimmune hepatitis with an acute presentation. *J Hepatol* 1994;21:866-871.
 - 134) Ferrari R, Pappas G, Agostinelli D, Muratori P, Muratori L, Lenzi M, et al. Type 1 autoimmune hepatitis: patterns of clinical presentation and differential diagnosis of the "acute" type. *QJM* 2004;97:407-412.
 - 135) Seo S, Toutounjian R, Conrad A, Blatt L, Tong MJ. Favorable outcomes of autoimmune hepatitis in a community clinic setting. *J Gastroenterol Hepatol* 2008;23:1410-1414.
 - 136) Czaja AJ. Acute and acute severe (fulminant) autoimmune hepatitis. *Dig Dis Sci* 2013;58:897-914.
 - 137) Lee WS, McKiernan P, Kelly DA. Etiology, outcome and prognostic indicators of childhood fulminant hepatic failure in the United Kingdom. *J Pediatr Gastroenterol Nutr* 2005;40:575-581.
 - 138) Burgart LJ, Batts KP, Ludwig J, Nikias GA, Czaja AJ. Recent-onset autoimmune hepatitis. Biopsy findings and clinical correlations. *Am J Surg Pathol* 1995;19:699-708.
 - 139) Anand L, Choudhury A, Bihari C, Sharma BC, Kumar M, Maiwall R, et al. Flare of autoimmune hepatitis causing acute on chronic liver failure: diagnosis and response to corticosteroid therapy. *HEPATOLOGY* 2019;70:587-596.
 - 140) Yasui S, Fujiwara K, Yonemitsu Y, Oda S, Nakano M, Yokosuka O. Clinicopathological features of severe and fulminant forms of autoimmune hepatitis. *J Gastroenterol* 2011;46:378-390.
 - 141) Fujiwara K, Fukuda Y, Yokosuka O. Precise histological evaluation of liver biopsy specimen is indispensable for diagnosis and treatment of acute-onset autoimmune hepatitis. *J Gastroenterol* 2008;43:951-958.
 - 142) Yasui S, Fujiwara K, Okitsu K, Yonemitsu Y, Ito H, Yokosuka O. Importance of computed tomography imaging features for the diagnosis of autoimmune acute liver failure. *Hepatol Res* 2012;42:42-50.
 - 143) Heringlake S, Schutte A, Flemming P, Schmiegel W, Manns MP, Tillmann HL. Presumed cryptogenic liver disease in Germany: high prevalence of autoantibody-negative autoimmune hepatitis, low prevalence of NASH, no evidence for occult viral etiology. *Z Gastroenterol* 2009;47:417-423.
 - 144) Mehendiratta V, Mitroo P, Bombonati A, Navarro VJ, Rossi S, Rubin R, et al. Serologic markers do not predict histologic severity or response to treatment in patients with autoimmune hepatitis. *Clin Gastroenterol Hepatol* 2009;7:98-103.
 - 145) Miyake Y, Yamamoto K. Current status of autoimmune hepatitis in Japan. *Acta Med Okayama* 2008;62:217-226.
 - 146) Czaja AJ, Carpenter HA, Santrach PJ, Moore SB, Homburger HA. The nature and prognosis of severe cryptogenic chronic active hepatitis. *Gastroenterology* 1993;104:1755-1761.
 - 147) Gassert DJ, Garcia H, Tanaka K, Reinus JF. Corticosteroid-responsive cryptogenic chronic hepatitis: evidence for seronegative autoimmune hepatitis. *Dig Dis Sci* 2007;52:2433-2437.
 - 148) Czaja AJ. Autoantibody-negative autoimmune hepatitis. *Dig Dis Sci* 2012;57:610-624.
 - 149) Bittencourt PL, Farias AQ, Porta G, Cancado EL, Miura I, Pugliese R, et al. Frequency of concurrent autoimmune disorders in patients with autoimmune hepatitis: effect of age, gender, and genetic background. *J Clin Gastroenterol* 2008;42:300-305.
 - 150) Teufel A, Weinmann A, Kahaly GJ, Centner C, Piendl A, Worns M, et al. Concurrent autoimmune diseases in patients with autoimmune hepatitis. *J Clin Gastroenterol* 2010;44:208-213.
 - 151) Efe C, Wahlin S, Ozaslan E, Berlot AH, Purnak T, Muratori L, et al. Autoimmune hepatitis/primary biliary cirrhosis overlap syndrome and associated extrahepatic autoimmune diseases. *Eur J Gastroenterol Hepatol* 2012;24:531-534.
 - 152) Wong GW, Yeong T, Lawrence D, Yeoman AD, Verma S, Heneghan MA. Concurrent extrahepatic autoimmunity in autoimmune hepatitis: implications for diagnosis, clinical course and long-term outcomes. *Liver Int* 2017;37:449-457.
 - 153) Homberg JC, Abuaf N, Bernard O, Islam S, Alvarez F, Khalil SH, et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis. *HEPATOLOGY* 1987;7:1333-1339.
 - 154) Clemente MG, Meloni A, Obermayer-Straub P, Frau F, Manns MP, De Virgili S. Two cytochromes P450 are major hepatocellular autoantigens in autoimmune polyglandular syndrome type 1. *Gastroenterology* 1998;114:324-328.
 - 155) Lankisch TO, Jaeckel E, Strassburg CP. The autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy or autoimmune polyglandular syndrome type 1. *Semin Liver Dis* 2009;29:307-314.
 - 156) Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. *HEPATOLOGY* 2006;43:532-538.
 - 157) Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Significance of HLA DR4 in type 1 autoimmune hepatitis. *Gastroenterology* 1993;105:1502-1507.
 - 158) Czaja AJ, Strettell MD, Thomson LJ, Santrach PJ, Moore SB, Donaldson PT, et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. *HEPATOLOGY* 1997;25:317-323.
 - 159) Fogel R, Comerford M, Chilukuri P, Orman E, Chalasani N, Lammert C. Extrahepatic autoimmune diseases are prevalent in autoimmune hepatitis patients and their first-degree relatives: survey study. *Interact J Med Res* 2018;7:e18.
 - 160) Volta U, De Franceschi L, Molinaro N, Cassani F, Muratori L, Lenzi M, et al. Frequency and significance of anti-gliadin and anti-endomysial antibodies in autoimmune hepatitis. *Dig Dis Sci* 1998;43:2190-2195.
 - 161) van Gerven NM, Bakker SF, de Boer YS, Witte BI, Bontkes H, van Nieuwkerk CM, et al. Seroprevalence of celiac disease in patients with autoimmune hepatitis. *Eur J Gastroenterol Hepatol* 2014;26:1104-1107.
 - 162) Caprai S, Vajro P, Ventura A, Sciveres M, Maggiore G, SIGENP Study Group for Autoimmune Liver Disorders in Celiac Disease. Autoimmune liver disease associated with celiac disease in childhood: a multicenter study. *Clin Gastroenterol Hepatol* 2008;6:803-806.
 - 163) Volta U, De Franceschi L, Lari F, Molinaro N, Zoli M, Bianchi FB. Coeliac disease hidden by cryptogenic hypertransaminasaemia. *Lancet* 1998;352:26-29.
 - 164) Volta U, Granito A, De Franceschi L, Petrolini N, Bianchi FB. Anti tissue transglutaminase antibodies as predictors of silent coeliac disease in patients with hypertransaminasaemia of unknown origin. *Dig Liver Dis* 2001;33:420-425.
 - 165) Volta U. Pathogenesis and clinical significance of liver injury in celiac disease. *Clin Rev Allergy Immunol* 2009;36:62-70.
 - 166) Nastasio S, Sciveres M, Riva S, Filippeschi IP, Vajro P, Maggiore G. Celiac disease-associated autoimmune hepatitis in childhood: long-term response to treatment. *J Pediatr Gastroenterol Nutr* 2013;56:671-674.
 - 167) Marciano F, Savoia M, Vajro P. Celiac disease-related hepatic injury: insights into associated conditions and underlying pathomechanisms. *Dig Liver Dis* 2016;48:112-119.

- 168) Domschke W, Klein R, Terracciano LM, Jung P, Kirchner T, Berg PA, et al. Sequential occurrence of primary sclerosing cholangitis and autoimmune hepatitis type III in a patient with ulcerative colitis: a follow up study over 14 years. *Liver* 2000;20:340-345.
- 169) Abdo AA, Bain VG, Kichian K, Lee SS. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: a sequential syndrome. *HEPATOLOGY* 2002;36:1393-1399.
- 170) Poupon R, Chazouilleres O, Corpechot C, Chretien Y. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. *HEPATOLOGY* 2006;44:85-90.
- 171) Gossard AA, Lindor KD. Development of autoimmune hepatitis in primary biliary cirrhosis. *Liver Int* 2007;27:1086-1090.
- 172) Lindgren S, Glaumann H, Almer S, Bergquist A, Bjornsson E, Broome U, et al. Transitions between variant forms of primary biliary cirrhosis during long-term follow-up. *Eur J Intern Med* 2009;20:398-402.
- 173) Czaja AJ. Cholestatic phenotypes of autoimmune hepatitis. *Clin Gastroenterol Hepatol* 2014;12:1430-1438.
- 174) Czaja AJ. The variant forms of autoimmune hepatitis. *Ann Intern Med* 1996;125:588-598.
- 175) Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. *HEPATOLOGY* 1998;28:360-365.
- 176) Czaja AJ, Carpenter HA. Autoimmune hepatitis overlap syndromes and liver pathology. *Gastroenterol Clin North Am* 2017;46:345-364.
- 177) Chazouilleres O, Wendum D, Serfaty L, Montebault S, Rosmorduc O, Poupon R. Primary biliary cirrhosis–autoimmune hepatitis overlap syndrome: clinical features and response to therapy. *HEPATOLOGY* 1998;28:296-301.
- 178) Farias AQ, Goncalves LL, Bittencourt PL, De Melo ES, Abrantes-Lemos CP, Porta G, et al. Applicability of the IAIHG scoring system to the diagnosis of antimitochondrial/anti-M2 seropositive variant form of autoimmune hepatitis. *J Gastroenterol Hepatol* 2006;21:887-893.
- 179) Beuers U, Boberg KM, Chapman RW, Chazouilleres O, Invernizzi P, Jones DEJ, et al. EASL clinical practice guidelines: management of cholestatic liver diseases. *J Hepatol* 2009;51:237-267.
- 180) Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, et al. Changing nomenclature for PBC: from “cirrhosis” to “cholangitis.” *HEPATOLOGY* 2015;62:1620-1622.
- 181) Kuiper EM, Zondervan PE, van Buuren HR. Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome. *Clin Gastroenterol Hepatol* 2010;8:530-534.
- 182) Bonder A, Retana A, Winston DM, Leung J, Kaplan MM. Prevalence of primary biliary cirrhosis–autoimmune hepatitis overlap syndrome. *Clin Gastroenterol Hepatol* 2011;9:609-612.
- 183) O'Brien C, Joshi S, Feld JJ, Guindi M, Dienes HP, Heathcote EJ. Long-term follow-up of antimitochondrial antibody–positive autoimmune hepatitis. *HEPATOLOGY* 2008;48:550-556.
- 184) Perdigoto R, Carpenter HA, Czaja AJ. Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. *J Hepatol* 1992;14:325-331.
- 185) Olsson R, Glaumann H, Almer S, Broome U, Lebrun B, Bergquist A, et al. High prevalence of small duct primary sclerosing cholangitis among patients with overlapping autoimmune hepatitis and primary sclerosing cholangitis. *Eur J Intern Med* 2009;20:190-196.
- 186) Muratori P, Muratori L, Gershwin ME, Czaja AJ, Pappas G, MacCariello S, et al. “True” antimitochondrial antibody–negative primary biliary cirrhosis, low sensitivity of the routine assays, or both? *Clin Exp Immunol* 2004;135:154-158.
- 187) Bjornsson E, Talwalkar J, Treeprasertsuk S, Kamath PS, Takahashi N, Sanderson S, et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. *HEPATOLOGY* 2010;51:2040-2048.
- 188) Czaja AJ. Drug-induced autoimmune-like hepatitis. *Dig Dis Sci* 2011;56:958-976.
- 189) Castiella A, Lucena MI, Zapata EM, Otazua P, Andrade RJ. Drug-induced autoimmune-like hepatitis: a diagnostic challenge. *Dig Dis Sci* 2011;56:2501-2503.
- 190) deLemos AS, Foureau DM, Jacobs C, Ahrens W, Russo MW, Bonkovsky HL. Drug-induced liver injury with autoimmune features. *Semin Liver Dis* 2014;34:194-204.
- 191) Licata A, Maida M, Cabibi D, Butera G, Macaluso FS, Alessi N, et al. Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: a retrospective cohort study. *Dig Liver Dis* 2014;46:1116-1120.
- 192) Gough A, Chapman S, Wagstaff K, Emery P, Elias E. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. *BMJ* 1996;312:169-172.
- 193) Herzog D, Hajoui O, Russo P, Alvarez F. Study of immune reactivity of minocycline-induced chronic active hepatitis. *Dig Dis Sci* 1997;42:1100-1103.
- 194) Bhat G, Jordan JJr, Sokalski S, Bajaj V, Marshall R, Berkelhammer C. Minocycline-induced hepatitis with autoimmune features and neutropenia. *J Clin Gastroenterol* 1998;27:74-75.
- 195) Teitelbaum JE, Perez-Atayde AR, Cohen M, Bousvaros A, Jonas MM. Minocycline-related autoimmune hepatitis: case series and literature review. *Arch Pediatr Adolesc Med* 1998;152:1132-1136.
- 196) Goldstein NS, Bayati N, Silverman AL, Gordon SC. Minocycline as a cause of drug-induced autoimmune hepatitis. Report of four cases and comparison with autoimmune hepatitis. *Am J Clin Pathol* 2000;114:591-598.
- 197) Abe M, Furukawa S, Takayama S, Michitaka K, Minami H, Yamamoto K, et al. Drug-induced hepatitis with autoimmune features during minocycline therapy. *Intern Med* 2003;42:48-52.
- 198) Ramakrishna J, Johnson AR, Banner BF. Long-term minocycline use for acne in healthy adolescents can cause severe autoimmune hepatitis. *J Clin Gastroenterol* 2009;43:787-790.
- 199) Hatoff DE, Cohen M, Schweigert BF, Talbert WM. Nitrofurantoin: another cause of drug-induced chronic active hepatitis? A report of a patient with HLA-B8 antigen. *Am J Med* 1979;67:117-121.
- 200) Sharp JR, Ishak KG, Zimmerman HJ. Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin. *Ann Intern Med* 1980;92:14-19.
- 201) Stricker BH, Blok AP, Claas FH, Van Parys GE, Desmet VJ. Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases. *HEPATOLOGY* 1988;8:599-606.
- 202) Paiva LA, Wright PJ, Koff RS. Long-term hepatic memory for hypersensitivity to nitrofurantoin. *Am J Gastroenterol* 1992;87:891-893.
- 203) Amit G, Cohen P, Ackerman Z. Nitrofurantoin-induced chronic active hepatitis. *Isr Med Assoc J* 2002;4:184-186.
- 204) Fontana RJ, Seeff LB, Andrade RJ, Bjornsson E, Day CP, Serrano J, et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. *HEPATOLOGY* 2010;52:730-742.
- 205) Appleyard S, Saraswati R, Gorard DA. Autoimmune hepatitis triggered by nitrofurantoin: a case series. *J Med Case Rep* 2010;4:311.
- 206) Germano V, Picchianti Diamanti A, Baccano G, Natale E, Onetti Muda A, Priori R, et al. Autoimmune hepatitis associated

- with infliximab in a patient with psoriatic arthritis. *Ann Rheum Dis* 2005;64:1519-1520.
- 207) Tobon GJ, Canas C, Jaller JJ, Restrepo JC, Anaya JM. Serious liver disease induced by infliximab. *Clin Rheumatol* 2007;26:578-581.
 - 208) Ozorio G, McGarity B, Bak H, Jordan AS, Lau H, Marshall C. Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis. *Med J Aust* 2007;187:524-526.
 - 209) Marques M, Magro F, Cardoso H, Carneiro F, Portugal R, Lopes J, et al. Infliximab-induced lupus-like syndrome associated with autoimmune hepatitis. *Inflamm Bowel Dis* 2008;14:723-725.
 - 210) Carlsen KM, Riis L, Madsen OR. Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept. *Clin Rheumatol* 2009;28:1001-1003.
 - 211) Fairhurst DA, Sheehan-Dare R. Autoimmune hepatitis associated with infliximab in a patient with palmoplantar pustular psoriasis. *Clin Exp Dermatol* 2009;34:421-422.
 - 212) Subramaniam K, Chitturi S, Brown M, Pavli P. Infliximab-induced autoimmune hepatitis in Crohn's disease treated with budesonide and mycophenolate. *Inflamm Bowel Dis* 2011;17:E149-E150.
 - 213) Goldfeld DA, Verna EC, Lefkowitz J, Swaminath A. Infliximab-induced autoimmune hepatitis with successful switch to adalimumab in a patient with Crohn's disease: the index case. *Dig Dis Sci* 2011;56:3386-3388.
 - 214) Bjornsson ES, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. *Gastroenterology* 2013;144:1419-1425.
 - 215) Efe C. Drug induced autoimmune hepatitis and TNF-alpha blocking agents: is there a real relationship? *Autoimmun Rev* 2013;12:337-339.
 - 216) Ghabril M, Bonkovsky HL, Kum C, Davern T, Hayashi PH, Kleiner DE, et al. Liver injury from tumor necrosis factor-alpha antagonists: analysis of thirty-four cases. *Clin Gastroenterol Hepatol* 2013;11:558-564.
 - 217) Dang LJ, Lubel JS, Gunatheesan S, Hosking P, Su J. Drug-induced lupus and autoimmune hepatitis secondary to infliximab for psoriasis. *Australas J Dermatol* 2014;55:75-79.
 - 218) Bjornsson ES, Gunnarsson BI, Grondal G, Jonasson JG, Einarsdottir R, Ludviksson BR, et al. Risk of drug-induced liver injury from tumor necrosis factor antagonists. *Clin Gastroenterol Hepatol* 2015;13:602-608.
 - 219) Rodrigues S, Lopes S, Magro F, Cardoso H, Horta e Vale AM, Marques M, et al. Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: a single center report of 8 cases. *World J Gastroenterol* 2015;21:7584-7588.
 - 220) French JB, Bonacini M, Ghabril M, Foureau D, Bonkovsky HL. Hepatotoxicity associated with the use of anti-TNF-alpha agents. *Drug Saf* 2016;39:199-208.
 - 221) Ricciuto A, Kamath BM, Walters TD, Frost K, Carman N, Church PC, et al. New onset autoimmune hepatitis during anti-tumor necrosis factor-alpha treatment in children. *J Pediatr* 2018;194:128-135.
 - 222) Young A, Quandt Z, Bluestone JA. The balancing act between cancer immunity and autoimmunity in response to immunotherapy. *Cancer Immunol Res* 2018;6:1445-1452.
 - 223) Myers G. Immune-related adverse events of immune checkpoint inhibitors: a brief review. *Curr Oncol* 2018;25:342-347.
 - 224) Czaja AJ. Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis. *Autoimmunity* 2019;52:144-160.
 - 225) Kleiner DE, Berman D. Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma. *Dig Dis Sci* 2012;57:2233-2240.
 - 226) Reddy HG, Schneider BJ, Tai AW. Immune checkpoint inhibitor-associated colitis and hepatitis. *Clin Transl Gastroenterol* 2018;9:180.
 - 227) Reynolds K, Thomas M, Dougan M. Diagnosis and management of hepatitis in patients on checkpoint blockade. *Oncologist* 2018;23:991-997.
 - 228) Zen Y, Yeh MM. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. *Mod Pathol* 2018;31:965-973.
 - 229) Nishida N, Kudo M. Liver damage related to immune checkpoint inhibitors. *Hepatol Int* 2019;13:248-252.
 - 230) Doherty GJ, Duckworth AM, Davies SE, Mells GF, Brais R, Harden SV, et al. Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury. *ESMO Open* 2017;2:e000268.
 - 231) Lewis JH, Zimmerman HJ. Drug-induced autoimmune liver disease. In: Krawitt EL, Wiesner RH, Nishioka K, eds. *Autoimmune Liver Diseases*. 2nd ed. Amsterdam: Elsevier Science; 1998:627-649.
 - 232) Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. *Clin Liver Dis* 2002;6:755-774.
 - 233) Watkins PB, Seeff LB. Drug-induced liver injury: summary of a single topic clinical research conference. *HEPATOLOGY* 2006;43:618-631.
 - 234) Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. *Gastroenterology* 2015;148:1340-1352.
 - 235) Ramachandran R, Kakar S. Histological patterns in drug-induced liver disease. *J Clin Pathol* 2009;62:481-492.
 - 236) de Boer YS, Kosinski AS, Urban TJ, Zhao Z, Long N, Chalasani N, et al. Features of autoimmune hepatitis in patients with drug-induced liver injury. *Clin Gastroenterol Hepatol* 2017;15:103-112.
 - 237) Suzuki A, Brunt EM, Kleiner DE, Miquel R, Smyrk TC, Andrade RJ, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. *HEPATOLOGY* 2011;54:931-939.
 - 238) Bjornsson E, Kalaitzakis E, Av Klinteberg V, Alem N, Olsson R. Long-term follow-up of patients with mild to moderate drug-induced liver injury. *Aliment Pharmacol Ther* 2007;26:79-85.
 - 239) Bjornsson E, Davidsdottir L. The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. *J Hepatol* 2009;50:511-517.
 - 240) Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. *HEPATOLOGY* 2005;42:481-489.
 - 241) Andrade RJ, Lucena MI, Fernandez MC, Pelaez G, Pachkoria K, Garcia-Ruiz E, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. *Gastroenterology* 2005;129:512-521.
 - 242) Robles-Diaz M, Lucena MI, Kaplowitz N, Stephens C, Medina-Caliz I, Gonzalez-Jimenez A, et al. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. *Gastroenterology* 2014;147:109-118.
 - 243) Montano-Loza AJ, Carpenter HA, Czaja AJ. Consequences of treatment withdrawal in type 1 autoimmune hepatitis. *Liver Int* 2007;27:507-515.
 - 244) van Gerven NM, Verwer BJ, Witte BI, van Hoek B, Coenraad MJ, van Erpecum KJ, et al. Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. *J Hepatol* 2013;58:141-147.
 - 245) Castiella A, Zapata E, Lucena MI, Andrade RJ. Drug-induced autoimmune liver disease: a diagnostic dilemma of an increasingly reported disease. *World J Hepatol* 2014;6:160-168.

- 246) Fontana RJ, Hayashi PH, Gu J, Reddy KR, Barnhart H, Watkins PB, et al. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. *Gastroenterology* 2014;147:96-108.
- 247) Ngo Y, Munteanu M, Messous D, Charlotte F, Imbert-Bismut F, Thabut D, et al. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. *Clin Chem* 2006;52:1887-1896.
- 248) Poinard T, Ngo Y, Perazzo H, Munteanu M, Lebray P, Moussalli J, et al. Prognostic value of liver fibrosis biomarkers: a meta-analysis. *Gastroenterol Hepatol (N Y)* 2011;7:445-454.
- 249) Poinard T, de Ledinghen V, Zarski JP, Stanciu C, Munteanu M, Vergniol J, et al. Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard. *J Hepatol* 2012;56:541-548.
- 250) Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. *HEPATOLOGY* 2003;38:518-526.
- 251) Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. *HEPATOLOGY* 2006;43:1317-1325.
- 252) Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. *Clin Gastroenterol Hepatol* 2009;7:1104-1112.
- 253) Parkes J, Roderick P, Harris S, Day C, Mutimer D, Collier J, et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. *Gut* 2010;59:1245-1251.
- 254) Parkes J, Guha IN, Roderick P, Harris S, Cross R, Manos MM, et al. Enhanced liver fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C. *J Viral Hepat* 2011;18:23-31.
- 255) Poinard T, Morra R, Ingiliz P, Imbert-Bismut F, Thabut D, Messous D, et al. Biomarkers of liver fibrosis. *Adv Clin Chem* 2008;46:131-160.
- 256) Czaja AJ. Review article: prevention and reversal of hepatic fibrosis in autoimmune hepatitis. *Aliment Pharmacol Ther* 2014;39:385-406.
- 257) Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. *HEPATOLOGY* 2008;47:455-460.
- 258) Mayo MJ, Parkes J, Adams-Huet B, Combes B, Mills AS, Markin RS, et al. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. *HEPATOLOGY* 2008;48:1549-1557.
- 259) Wu S, Yang Z, Zhou J, Zeng N, He Z, Zhan S, et al. Systematic review: diagnostic accuracy of non-invasive tests for staging liver fibrosis in autoimmune hepatitis. *Hepatol Int* 2019;13:91-101.
- 260) Hartl J, Denzer U, Ehlken H, Zenouzi R, Peiseler M, Sebode M, et al. Transient elastography in autoimmune hepatitis: timing determines the impact of inflammation and fibrosis. *J Hepatol* 2016;65:769-775.
- 261) Xu Q, Sheng L, Bao H, Chen X, Guo C, Li H, et al. Evaluation of transient elastography in assessing liver fibrosis in patients with autoimmune hepatitis. *J Gastroenterol Hepatol* 2017;32:639-644.
- 262) Guo L, Zheng L, Hu L, Zhou H, Yu L, Liang W. Transient elastography (FibroScan) performs better than non-invasive markers in assessing liver fibrosis and cirrhosis in autoimmune hepatitis patients. *Med Sci Monit* 2017;23:5106-5112.
- 263) Sagir A, Erhardt A, Schmitt M, Haussinger D. Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. *HEPATOLOGY* 2008;47:592-595.
- 264) Romanque P, Stickel F, Dufour JF. Disproportionally high results of transient elastography in patients with autoimmune hepatitis. *Liver Int* 2008;28:1177-1178.
- 265) Hartl J, Ehlken H, Sebode M, Peiseler M, Krech T, Zenouzi R, et al. Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis. *J Hepatol* 2018;68:754-763.
- 266) Huwart L, Sempoux C, Vicaut E, Salameh N, Annet L, Danse E, et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. *Gastroenterology* 2008;135:32-40.
- 267) Venkatesh SK, Yin M, Ehman RL. Magnetic resonance elastography of liver: technique, analysis, and clinical applications. *J Magn Reson Imaging* 2013;37:544-555.
- 268) Loomba R, Wolfson T, Ang B, Hooker J, Behling C, Peterson M, et al. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. *HEPATOLOGY* 2014;60:1920-1928.
- 269) Wang J, Malik N, Yin M, Smyrk TC, Czaja AJ, Ehman RL, et al. Magnetic resonance elastography is accurate in detecting advanced fibrosis in autoimmune hepatitis. *World J Gastroenterol* 2017;23:859-868.
- 270) Talwalkar JA, Yin M, Venkatesh S, Rossman PJ, Grimm RC, Manduca A, et al. Feasibility of in vivo MR elastographic splenic stiffness measurements in the assessment of portal hypertension. *Am J Roentgenol* 2009;193:122-127.
- 271) Shi Y, Guo Q, Xia F, Dzyubak B, Glaser KJ, Li Q, et al. MR elastography for the assessment of hepatic fibrosis in patients with chronic hepatitis B infection: does histologic necroinflammation influence the measurement of hepatic stiffness? *Radiology* 2014;273:88-98.
- 272) D'Onofrio M, Crosara S, De Robertis R, Canestrini S, Demozzi E, Gallotti A, et al. Acoustic radiation force impulse of the liver. *World J Gastroenterol* 2013;19:4841-4849.
- 273) Bruno C, Minniti S, Bucci A, Pozzi MR. ARFI: from basic principles to clinical applications in diffuse chronic disease—a review. *Insights Imaging* 2016;7:735-746.
- 274) Piscaglia F, Salvatore V, Di Donato R, D'Onofrio M, Gualandi S, Gallotti A, et al. Accuracy of VirtualTouch acoustic radiation force impulse (ARFI) imaging for the diagnosis of cirrhosis during liver ultrasonography. *Ultraschall Med* 2011;32:167-175.
- 275) Bota S, Herkner H, Sporea I, Salzl P, Sirlu R, Neghina AM, et al. Meta-analysis: ARFI elastography versus transient elastography for the evaluation of liver fibrosis. *Liver Int* 2013;33:1138-1147.
- 276) Ye XP, Ran HT, Cheng J, Zhu YF, Zhang DZ, Zhang P, et al. Liver and spleen stiffness measured by acoustic radiation force impulse elastography for noninvasive assessment of liver fibrosis and esophageal varices in patients with chronic hepatitis B. *J Ultrasound Med* 2012;31:1245-1253.
- 277) Morishita N, Hiramatsu N, Oze T, Harada N, Yamada R, Miyazaki M, et al. Liver stiffness measurement by acoustic radiation force impulse is useful in predicting the presence of esophageal varices or high-risk esophageal varices among patients with HCV-related cirrhosis. *J Gastroenterol* 2014;49:1175-1182.
- 278) Karlas TF, Pfrepper C, Rosendahl J, Benckert C, Wittekind C, Jonas S, et al. Acoustic radiation force impulse (ARFI) elastography in acute liver failure: necrosis mimics cirrhosis. *Z Gastroenterol* 2011;49:443-448.
- 279) Bacon BR, Treuhart WH, Goodman AM. Azathioprine-induced pancytopenia. Occurrence in two patients with connective-tissue diseases. *Arch Intern Med* 1981;141:223-226.
- 280) Ben Ari Z, Mehta A, Lennard L, Burroughs AK. Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis. *J Hepatol* 1995;23:351-354.

- 281) Szumlanski CL, Honchel R, Scott MC, Weinshilboum RM. Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. *Pharmacogenetics* 1992;2:148-159.
- 282) Otterness D, Szumlanski C, Lennard L, Klemetsdal B, Aarbakke J, Park-Hah JO, et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. *Clin Pharmacol Ther* 1997;62:60-73.
- 283) Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. *Ann Intern Med* 1997;126:608-614.
- 284) Sahasranaman S, Howard D, Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. *Eur J Clin Pharmacol* 2008;64:753-767.
- 285) Regueiro M, Mardini H. Determination of thiopurine methyltransferase genotype or phenotype optimizes initial dosing of azathioprine for the treatment of Crohn's disease. *J Clin Gastroenterol* 2002;35:240-244.
- 286) Lichtenstein GR. Use of laboratory testing to guide 6-mercaptopurine/azathioprine therapy. *Gastroenterology* 2004;127:1558-1564.
- 287) Richard VS, Al-Ismail D, Salamat A. Should we test TPMT enzyme levels before starting azathioprine? *Hematology* 2007;12:359-360.
- 288) Czaja AJ. Review article: the management of autoimmune hepatitis beyond consensus guidelines. *Aliment Pharmacol Ther* 2013;38:343-364.
- 289) Langley PG, Underhill J, Tredger JM, Norris S, McFarlane IG. Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis. *J Hepatol* 2002;37:441-447.
- 290) Heneghan MA, Allan ML, Bornstein JD, Muir AJ, Tendler DA. Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis. *J Hepatol* 2006;45:584-591.
- 291) Czaja AJ, Carpenter HA. Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis. *Dig Dis Sci* 2006;51:968-975.
- 292) Ferucci ED, Hurlburt KJ, Mayo MJ, Livingston S, Deubner H, Gove J, et al. Azathioprine metabolite measurements are not useful in following treatment of autoimmune hepatitis in Alaska native and other non-Caucasian people. *Can J Gastroenterol* 2011;25:21-27.
- 293) Centers for Disease Control and Prevention. Vaccines & immunizations. www.cdc.gov/vaccines. Published May 2016. Accessed December 2018.
- 294) Worns MA, Teufel A, Kanzler S, Shrestha A, Victor A, Otto G, et al. Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases. *Am J Gastroenterol* 2008;103:138-146.
- 295) Danziger-Isakov L, Kumar D; AST ID Community of Practice. Vaccination of solid organ transplant candidates and recipients: guidelines from the American society of transplantation infectious diseases community of practice. *Clin Transplant* 2019;33:e13563.
- 296) Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. *Gastroenterology* 2015;148:221-244.
- 297) Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. *Gastroenterology* 2015;148:215-219.
- 298) Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. *Gastroenterology* 2017;152:1297-1309.
- 299) Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. *HEPATOLOGY* 2018;67:1560-1599.
- 300) Pattullo V. Prevention of hepatitis B reactivation in the setting of immunosuppression. *Clin Mol Hepatol* 2016;22:219-237.
- 301) American Gastroenterological Association. American Gastroenterological Association medical position statement: osteoporosis in hepatic disorders. *Gastroenterology* 2003;125:937-940.
- 302) Bernstein CN, Katz S. Guidelines for osteoporosis and inflammatory bowel disease. A guide to diagnosis and management for the gastroenterologist. Wolters Kluwer Health. Bethesda, MD: American College of Gastroenterology; 2003.
- 303) Kornbluth A, Hayes M, Feldman S, Hunt M, Fried-Boxt E, Lichtiger S, et al. Do guidelines matter? Implementation of the ACG and AGA osteoporosis screening guidelines in inflammatory bowel disease (IBD) patients who meet the guidelines' criteria. *Am J Gastroenterol* 2006;101:1546-1550.
- 304) Long MD, Thiny MT, Sandler RS, Gangarosa LM. Bone health in a tertiary-care gastroenterology and hepatology population. *Dig Dis Sci* 2010;55:2263-2269.
- 305) Efe C, Kav T, Aydin C, Cengiz M, Imga NN, Purnak T, et al. Low serum vitamin D levels are associated with severe histological features and poor response to therapy in patients with autoimmune hepatitis. *Dig Dis Sci* 2014;59:3035-3042.
- 306) Ebadi M, Bhanji RA, Mazurak VC, Lytvyak E, Mason A, Czaja AJ, et al. Severe vitamin D deficiency is a prognostic biomarker in autoimmune hepatitis. *Aliment Pharmacol Ther* 2019;49:173-182.
- 307) Czaja AJ, Montano-Loza AJ. Evolving role of vitamin D in immune-mediated disease and its implications in autoimmune hepatitis. *Dig Dis Sci* 2019;64:324-344.
- 308) Pares A, Guanabens N. Treatment of bone disorders in liver disease. *J Hepatol* 2006;45:445-453.
- 309) Collier J. Bone disorders in chronic liver disease. *HEPATOLOGY* 2007;46:1271-1278.
- 310) Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation* 2009;120:1640-1645.
- 311) Rochlani Y, Pothineni NV, Kovelamudi S, Mehta JL. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. *Ther Adv Cardiovasc Dis* 2017;11:215-225.
- 312) Weiler-Normann C, Lohse AW. Treatment adherence—room for improvement, not only in autoimmune hepatitis. *J Hepatol* 2012;57:1168-1170.
- 313) Wusk B, Kullak-Ublick GA, Rammert C, von Eckardstein A, Fried M, Rentsch KM. Therapeutic drug monitoring of thiopurine drugs in patients with inflammatory bowel disease or autoimmune hepatitis. *Eur J Gastroenterol Hepatol* 2004;16:1407-1413.
- 314) Sockalingam S, Blank D, Abdelhamid N, Abbey SE, Hirschfield GM. Identifying opportunities to improve management of autoimmune hepatitis: evaluation of drug adherence and psychosocial factors. *J Hepatol* 2012;57:1299-1304.
- 315) Janik MK, Wunsch E, Raszeja-Wyszomirska J, Moskwa M, Kruk B, Krawczyk M, et al. Autoimmune hepatitis exerts a

- profound, negative effect on health-related quality of life: a prospective, single-centre study. *Liver Int* 2019;39:215-221.
- 316) Schramm C, Wahl I, Weiler-Normann C, Voigt K, Wiegand C, Glaubke C, et al. Health-related quality of life, depression, and anxiety in patients with autoimmune hepatitis. *J Hepatol* 2014;60:618-624.
 - 317) Mieli-Vergani G, Vergani D, Czaja AJ, Manns MP, Krawitt EL, Vierling JM, et al. Autoimmune hepatitis. *Nat Rev Dis Primers* 2018;4:18017.
 - 318) Takahashi A, Moriya K, Ohira H, Arinaga-Hino T, Zeniya M, Torimura T, et al. Health-related quality of life in patients with autoimmune hepatitis: a questionnaire survey. *PLoS One* 2018;13:e0204772.
 - 319) Gulati R, Radhakrishnan KR, Hupertz V, Wyllie R, Alkhoury N, Worley S, et al. Health-related quality of life in children with autoimmune liver disease. *J Pediatr Gastroenterol Nutr* 2013;57:444-450.
 - 320) Trevizoli IC, Pinedo CS, Teles VO, Seixas R, de Carvalho E. Autoimmune hepatitis in children and adolescents: effect on quality of life. *J Pediatr Gastroenterol Nutr* 2018;66:861-865.
 - 321) Wong LL, Fisher HF, Stocken DD, Rice S, Khanna A, Heneghan MA, et al. The impact of autoimmune hepatitis and its treatment on health utility. *HEPATOLOGY* 2018;68:1487-1497.
 - 322) Bozzini AB, Neder L, Silva CA, Porta G. Decreased health-related quality of life in children and adolescents with autoimmune hepatitis. *J Pediatr (Rio J)* 2019;95:87-93.
 - 323) Srivastava S, Boyer JL. Psychological stress is associated with relapse in type 1 autoimmune hepatitis. *Liver Int* 2010;30:1439-1447.
 - 324) Westbrook RH, Yeoman AD, Kriese S, Heneghan MA. Outcomes of pregnancy in women with autoimmune hepatitis. *J Autoimmun* 2012;38:J239-J244.
 - 325) Terrabuio DR, Abrantes-Lemos CP, Carrilho FJ, Cancado EL. Follow-up of pregnant women with autoimmune hepatitis: the disease behavior along with maternal and fetal outcomes. *J Clin Gastroenterol* 2009;43:350-356.
 - 326) Schramm C, Herkel J, Beuers U, Kanzler S, Galle PR, Lohse AW. Pregnancy in autoimmune hepatitis: outcome and risk factors. *Am J Gastroenterol* 2006;101:556-560.
 - 327) Buchel E, Van Steenberghe W, Nevens F, Fevery J. Improvement of autoimmune hepatitis during pregnancy followed by flare-up after delivery. *Am J Gastroenterol* 2002;97:3160-3165.
 - 328) Waldenstrom J. Leber, Blutproteine und Nahrungseiweiss. *Dtsch Gesellsch Verdau Stoffwechsellkr* 1950;15:113-121.
 - 329) Barnea ER, Kirk D, Ramu S, Rivnay B, Roussev R, Paidas MJ. Preimplantation factor (PIF) orchestrates systemic antiinflammatory response by immune cells: effect on peripheral blood mononuclear cells. *Am J Obstet Gynecol* 2012;207:313.
 - 330) Barnea ER, Lubman DM, Liu YH, Absalon-Medina V, Hayrabetdyan S, Todorova K, et al. Insight into preimplantation factor (PIF*) mechanism for embryo protection and development: target oxidative stress and protein misfolding (PDI and HSP) through essential RIKP [corrected] binding site. *PLoS One* 2014;9:e100263.
 - 331) Tran TT, Ahn J, Reau NS. ACG clinical guideline: liver disease and pregnancy. *Am J Gastroenterol* 2016;111:176-194; quiz 196.
 - 332) Centers for Disease Control and Prevention. National birth defects prevention study (NBDPS). <https://www.cdc.gov/ncbddd/birthdefects/nbdps.html>. Accessed 2017.
 - 333) Rosenkrantz JG, Githens JH, Cox SM, Kellum DL. Azathioprine (Imuran) and pregnancy. *Am J Obstet Gynecol* 1967;97:387-394.
 - 334) Akbari M, Shah S, Velayos FS, Mahadevan U, Cheifetz AS. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. *Inflamm Bowel Dis* 2013;19:15-22.
 - 335) de Boer NK, Jarbandhan SV, de Graaf P, Mulder CJ, van Elburg RM, van Bodegraven AA. Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites. *Am J Gastroenterol* 2006;101:1390-1392.
 - 336) Coscia LA, Armenti DP, King RW, Sifontis NM, Constantinescu S, Moritz MJ. Update on the teratogenicity of maternal mycophenolate mofetil. *J Pediatr Genet* 2015;4:42-55.
 - 337) Montano-Loza AJ, Czaja AJ. Current therapy for autoimmune hepatitis. *Nat Clin Pract Gastroenterol Hepatol* 2007;4:202-214.
 - 338) Montano-Loza AJ, Carpenter HA, Czaja AJ. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. *Am J Gastroenterol* 2007;102:1005-1012.
 - 339) Curtis JJ, Galla JH, Woodford SY, Saykaly RJ, Luke RG. Comparison of daily and alternate-day prednisone during chronic maintenance therapy: a controlled crossover study. *Am J Kidney Dis* 1981;1:166-171.
 - 340) Summerskill WH, Korman MG, Ammon HV, Baggenstoss AH. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. *Gut* 1975;16:876-883.
 - 341) Czaja AJ. Safety issues in the management of autoimmune hepatitis. *Expert Opin Drug Saf* 2008;7:319-333.
 - 342) Rumbo C, Emerick KM, Emre S, Shneider BL. Azathioprine metabolite measurements in the treatment of autoimmune hepatitis in pediatric patients: a preliminary report. *J Pediatr Gastroenterol Nutr* 2002;35:391-398.
 - 343) Nguyen TM, Daubard M, Le Gall C, Larger M, Lachaux A, Bouliou R. Monitoring of azathioprine metabolites in pediatric patients with autoimmune hepatitis. *Ther Drug Monit* 2010;32:433-437.
 - 344) Hindorf U, Jahed K, Bergquist A, Verbaan H, Prytz H, Wallerstedt S, et al. Characterisation and utility of thiopurine methyltransferase and thiopurine metabolite measurements in autoimmune hepatitis. *J Hepatol* 2010;52:106-111.
 - 345) Sheiko MA, Sundaram SS, Capocelli KE, Pan Z, McCoy AM, Mack CL. Outcomes in pediatric autoimmune hepatitis and significance of azathioprine metabolites. *J Pediatr Gastroenterol Nutr* 2017;65:80-85.
 - 346) Rumbo C, Shneider BL, Emre SH. Utility of azathioprine metabolite measurements in post-transplant recurrent autoimmune and immune-mediated hepatitis. *Pediatr Transplant* 2004;8:571-575.
 - 347) Miloh T, Annunziato R, Arnon R, Warshaw J, Parkar S, Suchy FJ, et al. Improved adherence and outcomes for pediatric liver transplant recipients by using text messaging. *Pediatrics* 2009;124:e844-e850.
 - 348) Kerker N, Annunziato RA, Foley L, Schmeidler J, Rumbo C, Emre S, et al. Prospective analysis of nonadherence in autoimmune hepatitis: a common problem. *J Pediatr Gastroenterol Nutr* 2006;43:629-634.
 - 349) Inman GJ, Wang J, Nagano A, Alexandrov LB, Purdie KJ, Taylor RG, et al. The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature. *Nat Commun* 2018;9:3667.
 - 350) Manns MP, Woynarowski M, Kreisel W, Lurie Y, Rust C, Zuckerman E, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. *Gastroenterology* 2010;139:1198-1206.
 - 351) Manns MP, Jaeckel E, Taubert R. Budesonide in autoimmune hepatitis: the right drug at the right time for the right patient. *Clin Gastroenterol Hepatol* 2018;16:186-189.
 - 352) Czaja AJ, Lindor KD. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. *Gastroenterology* 2000;119:1312-1316.

- 353) Geier A, Gartung C, Dietrich CG, Wasmuth HE, Reinartz P, Matern S. Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. *World J Gastroenterol* 2003;9:2681-2685.
- 354) Efe C, Ozaslan E, Kav T, Purnak T, Shorbagi A, Ozkayar O, et al. Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome. *Autoimmun Rev* 2012;11:330-334.
- 355) Hempfling W, Grunhage F, Dilger K, Reichel C, Beuers U, Sauerbruch T. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. *HEPATOLOGY* 2003;38:196-202.
- 356) Peiseler M, Liebscher T, Sebode M, Zenouzi R, Hartl J, Ehlken H, et al. Efficacy and limitations of budesonide as a second-line treatment for patients with autoimmune hepatitis. *Clin Gastroenterol Hepatol* 2018;16:260-267.
- 357) Woynarowski M, Nemeth A, Baruch Y, Koletzko S, Melter M, Rodeck B, et al. Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents. *J Pediatr* 2013;163:1347-1353.
- 358) Dyson JK, Wong LL, Bigirimurame T, Hirschfield GM, Kendrick S, Oo YH, et al. Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom. *Aliment Pharmacol Ther* 2018;48:951-960.
- 359) Niederau C, Herden D, van Thiel I, Kautz A, Bemba G, Wohn HP, et al. Prospective survey of health and socio-economic characteristics of 249 patients with autoimmune hepatitis. *Verdauungskrankheiten* 2013;31:55-65.
- 360) Zachou K, Gatselis N, Papadamou G, Rigopoulou EI, Dalekos GN. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients. *J Hepatol* 2011;55:636-646.
- 361) Zachou K, Gatselis NK, Arvaniti P, Gabeta S, Rigopoulou EI, Koukoulis GK, et al. A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis. *Aliment Pharmacol Ther* 2016;43:1035-1047.
- 362) Yu ZJ, Zhang LL, Huang TT, Zhu JS, He ZB. Comparison of mycophenolate mofetil with standard treatment for autoimmune hepatitis: a meta-analysis. *Eur J Gastroenterol Hepatol* 2019;31:873-877.
- 363) Van Thiel DH, Wright H, Carroll P, Abu-Elmagd K, Rodriguez-Rilo H, McMichael J, et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. *Am J Gastroenterol* 1995;90:771-776.
- 364) Alvarez F, Ciocca M, Canero-Velasco C, Ramonet M, de Davila MT, Cuarterolo M, et al. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. *J Hepatol* 1999;30:222-227.
- 365) Malekzadeh R, Nasser-Moghaddam S, Kaviani MJ, Taheri H, Kamalian N, Sotoudeh M. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. *Dig Dis Sci* 2001;46:1321-1327.
- 366) Marlaka JR, Papadogiannakis N, Fischler B, Casswall TH, Beijer E, Nemeth A. Tacrolimus without or with the addition of conventional immunosuppressive treatment in juvenile autoimmune hepatitis. *Acta Paediatr* 2012;101:993-999.
- 367) Nasser-Moghaddam S, Nikfam S, Karimiam S, Khashayar P, Malekzadeh R. Cyclosporine-A versus prednisolone for induction of remission in auto-immune hepatitis: interim analysis report of a randomized controlled trial. *Middle East J Dig Dis* 2013;5:193-200.
- 368) Nastasio S, Sciveres M, Matarazzo L, Malaventura C, Cirillo F, Riva S, et al. Long-term follow-up of children and young adults with autoimmune hepatitis treated with cyclosporine. *Dig Liver Dis* 2019;51:712-718.
- 369) Cuarterolo M, Ciocca M, Velasco CC, Ramonet M, Gonzalez T, Lopez S, et al. Follow-up of children with autoimmune hepatitis treated with cyclosporine. *J Pediatr Gastroenterol Nutr* 2006;43:635-639.
- 370) Yeoman AD, Westbrook RH, Zen Y, Bernal W, Al-Chalabi T, Wendon JA, et al. Prognosis of acute severe autoimmune hepatitis (AS-AIH): the role of corticosteroids in modifying outcome. *J Hepatol* 2014;61:876-882.
- 371) Karkhanis J, Verna EC, Chang MS, Stravitz RT, Schilsky M, Lee WM, et al. Steroid use in acute liver failure. *HEPATOLOGY* 2014;59:612-621.
- 372) Ichai P, Duclos-Vallee JC, Guettier C, Hamida SB, Antonini T, Delvart V, et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. *Liver Transpl* 2007;13:996-1003.
- 373) Czaja AJ. Corticosteroids or not in severe acute or fulminant autoimmune hepatitis: therapeutic brinkmanship and the point beyond salvation. *Liver Transpl* 2007;13:953-955.
- 374) Rahim MN, Liberal R, Miquel R, Heaton ND, Heneghan MA. Acute severe autoimmune hepatitis: corticosteroids or liver transplantation? *Liver Transpl* 2019;25:946-959.
- 375) Takikawa Y, Suzuki K. Clinical epidemiology of fulminant hepatitis in Japan. *Hepatol Res* 2008;38(Suppl. 1):S14-S18.
- 376) Yeoman AD, Westbrook RH, Zen Y, Maninchedda P, Portmann BC, Devlin J, et al. Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis. *HEPATOLOGY* 2011;53:926-934.
- 377) Sugawara K, Nakayama N, Mochida S. Acute liver failure in Japan: definition, classification, and prediction of the outcome. *J Gastroenterol* 2012;47:849-861.
- 378) Czaja AJ, Rakela J, Ludwig J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. *Gastroenterology* 1988;95:448-453.
- 379) Czaja AJ. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. *J Hepatol* 2009;51:161-167.
- 380) Chen J, Eslick GD, Weltman M. Systematic review with meta-analysis: clinical manifestations and management of autoimmune hepatitis in the elderly. *Aliment Pharmacol Ther* 2014;39:117-124.
- 381) Couto CA, Bittencourt PL, Porta G, Abrantes-Lemos CP, Carrilho FJ, Guardia BD, et al. Antismooth muscle and anti-actin antibodies are indirect markers of histological and biochemical activity of autoimmune hepatitis. *HEPATOLOGY* 2014;59:592-600.
- 382) Taubert R, Hardtke-Wolenski M, Noyan F, Lalanne C, Jonigk D, Schlue J, et al. Hyperferritinemia and hypergammaglobulinemia predict the treatment response to standard therapy in autoimmune hepatitis. *PLoS One* 2017;12:e0179074.
- 383) Efe C, Cengiz M, Kahramanoglu-Aksoy E, Yilmaz B, Ozseker B, Beyazt Y, et al. Angiotensin-converting enzyme for noninvasive assessment of liver fibrosis in autoimmune hepatitis. *Eur J Gastroenterol Hepatol* 2015;27:649-654.
- 384) European Association for the Study of the Liver. EASL Clinical Practice Guidelines: autoimmune hepatitis. *J Hepatol* 2015;63:971-1004.
- 385) Hartl J, Ehlken H, Weiler-Normann C, Sebode M, Kreuels B, Pannicke N, et al. Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis. *J Hepatol* 2015;62:642-646.
- 386) Czaja AJ, Davis GL, Ludwig J, Taswell HF. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. *HEPATOLOGY* 1984;4:622-627.

- 387) Czaja AJ, Menon KV, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. *HEPATOLOGY* 2002;35:890-897.
- 388) Czaja AJ, Carpenter HA. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. *Liver Int* 2003;23:116-123.
- 389) Guirguis J, Alonso Y, Lopez R, Carey W. Well-controlled autoimmune hepatitis treatment withdrawal may be safely accomplished without liver-biopsy guidance. *Gastroenterol Rep (Oxf)* 2018;6:284-290.
- 390) Czaja AJ. Late relapse of type 1 autoimmune hepatitis after corticosteroid withdrawal. *Dig Dis Sci* 2010;55:1761-1769.
- 391) Czaja AJ. Review article: permanent drug withdrawal is desirable and achievable for autoimmune hepatitis. *Aliment Pharmacol Ther* 2014;39:1043-1058.
- 392) Deneau M, Book LS, Guthery SL, Jensen MK. Outcome after discontinuation of immunosuppression in children with autoimmune hepatitis: a population-based study. *J Pediatr* 2014;164:714-719.
- 393) Czaja AJ, Beaver SJ, Shiels MT. Sustained remission after corticosteroid therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. *Gastroenterology* 1987;92:215-219.
- 394) Czaja AJ, Ammon HV, Summerskill WH. Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission. *Gastroenterology* 1980;78:518-523.
- 395) Hegarty JE, Nouri Aria KT, Portmann B, Eddleston AL, Williams R. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. *HEPATOLOGY* 1983;3:685-689.
- 396) Dhaliwal HK, Anderson R, Thornhill EL, Schneider S, McFarlane E, Gleeson D, et al. Clinical significance of azathioprine metabolites for the maintenance of remission in autoimmune hepatitis. *HEPATOLOGY* 2012;56:1401-1408.
- 397) Stellon AJ, Hegarty JE, Portmann B, Williams R. Randomised controlled trial of azathioprine withdrawal in autoimmune chronic active hepatitis. *Lancet* 1985;1:668-670.
- 398) Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. *N Engl J Med* 1995;333:958-963.
- 399) Harrison L, Gleeson D. Stopping immunosuppressive treatment in autoimmune hepatitis (AIH): is it justified (and in whom and when)? *Liver Int* 2019;39:610-620.
- 400) Czaja AJ. Low-dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis. *HEPATOLOGY* 1990;11:1044-1049.
- 401) Seela S, Sheela H, Boyer JL. Autoimmune hepatitis type 1: safety and efficacy of prolonged medical therapy. *Liver Int* 2005;25:734-739.
- 402) Parker R, Oo YH, Adams DH. Management of patients with difficult autoimmune hepatitis. *Ther Adv Gastroenterol* 2012;5:421-437.
- 403) Selvarajah V, Montano-Loza AJ, Czaja AJ. Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs. *Aliment Pharmacol Ther* 2012;36:691-707.
- 404) Devlin SM, Swain MG, Urbanski SJ, Burak KW. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. *Can J Gastroenterol* 2004;18:321-326.
- 405) Aw MM, Dhawan A, Samyn M, Bargiota A, Mieli-Vergani G. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. *J Hepatol* 2009;51:156-160.
- 406) Inductivo-Yu I, Adams A, Gish RG, Wakil A, Bzowej NH, Frederick RT, et al. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. *Clin Gastroenterol Hepatol* 2007;5:799-802.
- 407) Hlivko JT, Shiffman ML, Stravitz RT, Luketic VA, Sanyal AJ, Fuchs M, et al. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. *Clin Gastroenterol Hepatol* 2008;6:1036-1040.
- 408) Hennes EM, Oo YH, Schramm C, Denzer U, Buggisch P, Wiegand C, et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? *Am J Gastroenterol* 2008;103:3063-3070.
- 409) Baven-Pronk AM, Coenraad MJ, van Buuren HR, de Man RA, van Erpecum KJ, Lamers MM, et al. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes. *Aliment Pharmacol Ther* 2011;34:335-343.
- 410) Fallatah HI, Akbar HO. Mycophenolate mofetil as a rescue therapy for autoimmune hepatitis patients who are not responsive to standard therapy. *Expert Rev Gastroenterol Hepatol* 2011;5:517-522.
- 411) Hyams JS, Ballou M, Leichtner AM. Cyclosporine treatment of autoimmune chronic active hepatitis. *Gastroenterology* 1987;93:890-893.
- 412) Person JL, McHutchison JG, Fong TL, Redeker AG. A case of cyclosporine-sensitive, steroid-resistant, autoimmune chronic active hepatitis. *J Clin Gastroenterol* 1993;17:317-320.
- 413) Sherman KE, Narkewicz M, Pinto PC. Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis. *J Hepatol* 1994;21:1040-1047.
- 414) Jackson LD, Song E. Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis. *Gut* 1995;36:459-461.
- 415) Debray D, Maggiore G, Girardet JP, Mallet E, Bernard O. Efficacy of cyclosporin A in children with type 2 autoimmune hepatitis. *J Pediatr* 1999;135:111-114.
- 416) Zizzo AN, Valentino PL, Shah PS, Kamath BM. Second-line agents in pediatric patients with autoimmune hepatitis: a systematic review and meta-analysis. *J Pediatr Gastroenterol Nutr* 2017;65:6-15.
- 417) Aql BA, Machicao V, Rosser B, Satyanarayana R, Harnois DM, Dickson RC. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. *J Clin Gastroenterol* 2004;38:805-809.
- 418) Efe C, Hagstrom H, Ytting H, Bhanji RA, Muller NF, Wang Q, et al. Efficacy and safety of mycophenolate mofetil and tacrolimus as second-line therapy for patients with autoimmune hepatitis. *Clin Gastroenterol Hepatol* 2017;15:1950-1956.
- 419) Efe C, Taii HA, Ytting H, Aehling N, Bhanji RA, Hagstrom H, et al. Tacrolimus and mycophenolate mofetil as second-line therapies for pediatric patients with autoimmune hepatitis. *Dig Dis Sci* 2018;63:1348-1354.
- 420) Than NN, Wiegand C, Weiler-Normann C, Fussel K, Mann J, Hodson J, et al. Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on tacrolimus therapy. *Scand J Gastroenterol* 2016;51:329-336.
- 421) Pratt DS, Flavin DP, Kaplan MM. The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine. *Gastroenterology* 1996;110:271-274.
- 422) Hubener S, Oo YH, Than NN, Hubener P, Weiler-Normann C, Lohse AW, et al. Efficacy of 6-mercaptopurine as second-line treatment for patients with autoimmune hepatitis and azathioprine intolerance. *Clin Gastroenterol Hepatol* 2016;14:445-453.
- 423) Burak KW, Swain MG, Santodomingo-Garzon T, Lee SS, Urbanski SJ, Aspinall AI, et al. Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy. *Can J Gastroenterol* 2013;27:273-280.

- 424) Weiler-Normann C, Schramm C, Quaas A, Wiegand C, Glaubke C, Pannicke N, et al. Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. *J Hepatol* 2013;58:529-534.
- 425) Santiago P, Schwartz I, Tamariz L, Levy C. Systematic review with meta-analysis: mycophenolate mofetil as a second-line therapy for autoimmune hepatitis. *Aliment Pharmacol Ther* 2019;49:830-839.
- 426) De Lemos-Bonotto M, Valle-Tovo C, Costabeber AM, Mattos AA, Azeredo-da-Silva ALF. A systematic review and meta-analysis of second-line immunosuppressants for autoimmune hepatitis treatment. *Eur J Gastroenterol Hepatol* 2018;30:212-216.
- 427) Nicoll AJ, Roberts SK, Lim R, Mitchell J, Weltman M, George J, et al. Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis, who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels. *Aliment Pharmacol Ther* 2019;49:1314-1322.
- 428) Tannous MM, Cheng J, Muniyappa K, Farooq I, Bharara A, Kappus M, et al. Use of tacrolimus in the treatment of autoimmune hepatitis: a single centre experience. *Aliment Pharmacol Ther* 2011;34:405-407.
- 429) Hanounch M, Ritchie MM, Ascha M, Ascha MS, Chedid A, Sanguankeo A, et al. A review of the utility of tacrolimus in the management of adults with autoimmune hepatitis. *Scand J Gastroenterol* 2019;54:76-80.
- 430) Chatur N, Ramji A, Bain VG, Ma MM, Marotta PJ, Ghent CN, et al. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian Association for the Study of Liver (CASL) experience with mycophenolate mofetil and tacrolimus. *Liver Int* 2005;25:723-727.
- 431) Cravo M, Silva R, Serrano M. Autoimmune hepatitis induced by infliximab in a patient with Crohn's disease with no relapse after switching to adalimumab. *BioDrugs* 2010;24(Suppl. 1):25-27.
- 432) Harada K, Akai Y, Koyama S, Ikenaka Y, Saito Y. A case of autoimmune hepatitis exacerbated by the administration of etanercept in the patient with rheumatoid arthritis. *Clin Rheumatol* 2008;27:1063-1066.
- 433) Averbukh LD, Wu GY. Role of biologics in the development of autoimmune hepatitis: a review. *J Clin Transl Hepatol* 2018;6:402-409.
- 434) Nedelkopoulou N, Vadamalayan B, Vergani D, Mieli-Vergani G. Anti-TNF α treatment in children and adolescents with combined inflammatory bowel disease and autoimmune liver disease. *J Pediatr Gastroenterol Nutr* 2018;66:100-105.
- 435) D'Agostino D, Costaguta A, Alvarez F. Successful treatment of refractory autoimmune hepatitis with rituximab. *Pediatrics* 2013;132:e526-e530.
- 436) Elion GB. The pharmacology of azathioprine. *Ann N Y Acad Sci* 1993;685:400-407.
- 437) Weinsilboum R. Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. *Drug Metab Dispos* 2001;29:601-605.
- 438) Legue C, Legros L, Kammerer-Jacquet S, Jezequel C, Houssel-Debry P, Uguen T, et al. Safety and efficacy of 6-thioguanine as a second-line treatment for autoimmune hepatitis. *Clin Gastroenterol Hepatol* 2018;16:290-291.
- 439) van den Brand FF, van Nieuwkerk CMJ, Verwer BJ, de Boer YS, de Boer NKH, Mulder CJJ, et al. Biochemical efficacy of tioguanine in autoimmune hepatitis: a retrospective review of practice in the Netherlands. *Aliment Pharmacol Ther* 2018;48:761-767.
- 440) de Boer NK, van Nieuwkerk CM, Aparicio Pages MN, de Boer SY, Derijks LJ, Mulder CJ. Promising treatment of autoimmune hepatitis with 6-thioguanine after adverse events on azathioprine. *Eur J Gastroenterol Hepatol* 2005;17:457-461.
- 441) Dubinsky MC, Vasiliauskas EA, Singh H, Abreu MT, Papadakis KA, Tran T, et al. 6-Thioguanine can cause serious liver injury in inflammatory bowel disease patients. *Gastroenterology* 2003;125:298-303.
- 442) Seinen ML, van Asseldonk DP, Mulder CJ, de Boer NK. Dosing 6-thioguanine in inflammatory bowel disease: expert-based guidelines for daily practice. *J Gastrointest Liver Dis* 2010;19:291-294.
- 443) Trivedi PJ, Hirschfield GM. Review article: overlap syndromes and autoimmune liver disease. *Aliment Pharmacol Ther* 2012;36:517-533.
- 444) Joshi S, Cauch-Dudek K, Wanless IR, Lindor KD, Jorgensen R, Batts K, et al. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. *HEPATOLOGY* 2002;35:409-413.
- 445) McNair AN, Moloney M, Portmann BC, Williams R, McFarlane IG. Autoimmune hepatitis overlapping with primary sclerosing cholangitis in five cases. *Am J Gastroenterol* 1998;93:777-784.
- 446) Lohse AW, zum Buschenfelde KH, Franz B, Kanzler S, Gerken G, Dienes HP. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatic form of PBC in genetically susceptible individuals. *HEPATOLOGY* 1999;29:1078-1084.
- 447) Floreani A, Rizzotto ER, Ferrara F, Carderi I, Caroli D, Blasone L, et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. *Am J Gastroenterol* 2005;100:1516-1522.
- 448) Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Sheider B, et al. Diagnosis and management of primary sclerosing cholangitis. *HEPATOLOGY* 2010;51:660-678.
- 449) Al-Chalabi T, Portmann BC, Bernal W, McFarlane IG, Heneghan MA. Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival. *Aliment Pharmacol Ther* 2008;28:209-220.
- 450) Czaja AJ. The overlap syndromes of autoimmune hepatitis. *Dig Dis Sci* 2013;58:326-343.
- 451) Hoeroldt B, McFarlane E, Dube A, Basumani P, Karajeh M, Campbell MJ, et al. Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. *Gastroenterology* 2011;140:1980-1989.
- 452) Verma S, Torbenson M, Thuluvath PJ. The impact of ethnicity on the natural history of autoimmune hepatitis. *HEPATOLOGY* 2007;46:1828-1835.
- 453) Wong RJ, Gish R, Frederick T, Bzowej N, Frenette C. The impact of race/ethnicity on the clinical epidemiology of autoimmune hepatitis. *J Clin Gastroenterol* 2012;46:155-161.
- 454) Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. *HEPATOLOGY* 2007;46:1138-1145.
- 455) Czaja AJ. Clinical features, differential diagnosis and treatment of autoimmune hepatitis in the elderly. *Drugs Aging* 2008;25:219-239.
- 456) Czaja AJ. Autoimmune hepatitis in diverse ethnic populations and geographical regions. *Expert Rev Gastroenterol Hepatol* 2013;7:365-385.
- 457) Lim KN, Casanova RL, Boyer TD, Bruno CJ. Autoimmune hepatitis in African Americans: presenting features and response to therapy. *Am J Gastroenterol* 2001;96:3390-3394.
- 458) Wen JW, Kohn MA, Wong R, Somsouk M, Khalili M, Maher J, et al. Hospitalizations for autoimmune hepatitis disproportionately affect black and Latino Americans. *Am J Gastroenterol* 2018;113:243-253.
- 459) de Boer YS, Gerussi A, van den Brand FF, Wong GW, Halliday N, Liberal R, et al. Association between black race and

- presentation and liver-related outcomes of patients with autoimmune hepatitis. *Clin Gastroenterol Hepatol* 2019;17:1616-1624.
- 460) Wong RJ, Gish R, Frederick T, Bzowej N, Frenette C. Development of hepatocellular carcinoma in autoimmune hepatitis patients: a case series. *Dig Dis Sci* 2011;56:578-585.
- 461) Czaja AJ. Hepatocellular cancer and other malignancies in autoimmune hepatitis. *Dig Dis Sci* 2013;58:1459-1476.
- 462) Werner M, Almer S, Prytz H, Lindgren S, Wallerstedt S, Bjornsson E, et al. Hepatic and extrahepatic malignancies in autoimmune hepatitis. A long-term follow-up in 473 Swedish patients. *J Hepatol* 2009;50:388-393.
- 463) Ngu JH, Geary RB, Frampton CM, Stedman CA. Mortality and the risk of malignancy in autoimmune liver diseases: a population-based study in Canterbury, New Zealand. *HEPATOLOGY* 2012;55:522-529.
- 464) Wang KK, Czaja AJ, Beaver SJ, Go VL. Extrahepatic malignancy following long-term immunosuppressive therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. *HEPATOLOGY* 1989;10:39-43.
- 465) Leung J, Dowling L, Obadan I, Davis J, Bonis PA, Kaplan MM, et al. Risk of non-melanoma skin cancer in autoimmune hepatitis. *Dig Dis Sci* 2010;55:3218-3223.
- 466) Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. *Aliment Pharmacol Ther* 2009;30:37-47.
- 467) Gleeson D, Heneghan MA. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. *Gut* 2011;60:1611-1629.
- 468) Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. *HEPATOLOGY* 2018;68:723-750.
- 469) Adam R, Karam V, Delvart V, O'Grady J, Mirza D, Klempnauer J, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). *J Hepatol* 2012;57:675-688.
- 470) Carbone M, Neuberger JM. Autoimmune liver disease, autoimmunity and liver transplantation. *J Hepatol* 2014;60:210-223.
- 471) Mendes F, Couto CA, Levy C. Recurrent and de novo autoimmune liver diseases. *Clin Liver Dis* 2011;15:859-878.
- 472) Webb GJ, Rana A, Hodson J, Akhtar MZ, Ferguson JW, Neuberger JM, et al. Twenty-year comparative analysis of patients with autoimmune liver diseases on transplant waitlists. *Clin Gastroenterol Hepatol* 2018;16:278-287.
- 473) Jossen J, Annunziato R, Kim HS, Chu J, Arnon R. Liver transplantation for children with primary sclerosing cholangitis and autoimmune hepatitis: UNOS database analysis. *J Pediatr Gastroenterol Nutr* 2017;64:e83-e87.
- 474) Futagawa Y, Terasaki PI. An analysis of the OPTN/UNOS Liver Transplant Registry. *Clin Transpl* 2004;315-329.
- 475) Schramm C, Bubenheim M, Adam R, Karam V, Buckels J, O'Grady JG, et al. Primary liver transplantation for autoimmune hepatitis: a comparative analysis of the European Liver Transplant Registry. *Liver Transpl* 2010;16:461-469.
- 476) Baganate F, Beal EW, Tumin D, Azoulay D, Mumtaz K, Black SM, et al. Early mortality after liver transplantation: defining the course and the cause. *Surgery* 2018;164:694-704.
- 477) Hayashi M, Keeffe EB, Krams SM, Martinez OM, Ojogho ON, So SK, et al. Allograft rejection after liver transplantation for autoimmune liver diseases. *Liver Transpl Surg* 1998;4:208-214.
- 478) Milkiewicz P, Gunson B, Saksena S, Hathaway M, Hubscher SG, Elias E. Increased incidence of chronic rejection in adult patients transplanted for autoimmune hepatitis: assessment of risk factors. *Transplantation* 2000;70:477-480.
- 479) Thurairajah PH, Carbone M, Bridgestock H, Thomas P, Hebbar S, Gunson BK, et al. Late acute liver allograft rejection; a study of its natural history and graft survival in the current era. *Transplantation* 2013;95:955-959.
- 480) Vogel A, Heinrich E, Bahr MJ, Rifai K, Flemming P, Melter M, et al. Long-term outcome of liver transplantation for autoimmune hepatitis. *Clin Transpl* 2004;18:62-69.
- 481) Jain A, Kashyap R, Marsh W, Rohal S, Khanna A, Fung JJ. Reasons for long-term use of steroid in primary adult liver transplantation under tacrolimus. *Transplantation* 2001;71:1102-1106.
- 482) Pelletier SJ, Nadig SN, Lee DD, Ammori JB, Englesbe MJ, Sung RS, et al. A prospective, randomized trial of complete avoidance of steroids in liver transplantation with follow-up of over 7 years. *HPB (Oxford)* 2013;15:286-293.
- 483) Krishnamoorthy TL, Miezynska-Kurtycz J, Hodson J, Gunson BK, Neuberger J, Milkiewicz P, et al. Longterm corticosteroid use after liver transplantation for autoimmune hepatitis is safe and associated with a lower incidence of recurrent disease. *Liver Transpl* 2016;22:34-41.
- 484) Theocharidou E, Heneghan MA. Con: steroids should not be withdrawn in transplant recipients with autoimmune hepatitis. *Liver Transpl* 2018;24:1113-1118.
- 485) Everson GT, Trouillot T, Wachs M, Bak T, Steinberg T, Kam I, et al. Early steroid withdrawal in liver transplantation is safe and beneficial. *Liver Transpl Surg* 1999;5(Suppl. 1):S48-S57.
- 486) Trouillot TE, Shrestha R, Kam I, Wachs M, Everson GT. Successful withdrawal of prednisone after adult liver transplantation for autoimmune hepatitis. *Liver Transpl Surg* 1999;5:375-380.
- 487) Adams RW, Chapman RL, Smallwood GA. Steroid withdrawal in liver transplant recipients. *Prog Transplant* 2001;11:217-223.
- 488) Heffron TG, Smallwood GA, Oakley B, Pillen T, Welch D, Martinez E, et al. Autoimmune hepatitis following liver transplantation: relationship to recurrent disease and steroid weaning. *Transplant Proc* 2002;34:3311-3312.
- 489) Junge G, Neuhaus R, Schewior L, Klupp J, Guckelberger O, Langrehr JM, et al. Withdrawal of steroids: a randomized prospective study of prednisone and tacrolimus versus mycophenolate mofetil and tacrolimus in liver transplant recipients with autoimmune hepatitis. *Transplant Proc* 2005;37:1695-1696.
- 490) Llado L, Xiol X, Figueras J, Ramos E, Memba R, Serrano T, et al. Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: results from a prospective multicenter randomized study. *J Hepatol* 2006;44:710-716.
- 491) Campsen J, Zimmerman MA, Trotter JF, Wachs M, Bak T, Steinberg T, et al. Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal. *Liver Transpl* 2008;14:1281-1286.
- 492) Sgourakis G, Radtke A, Fouzas I, Mylona S, Goumas K, Gockel I, et al. Corticosteroid-free immunosuppression in liver transplantation: a meta-analysis and meta-regression of outcomes. *Transpl Int* 2009;22:892-905.
- 493) Sgourakis G, Dedemadi G. Corticosteroid-free immunosuppression in liver transplantation: an evidence-based review. *World J Gastroenterol* 2014;20:10703-10714.
- 494) Fairfield C, Penninga L, Powell J, Harrison EM, Wigmore SJ. Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients. *Cochrane Database Syst Rev* 2018;4:CD007606.
- 495) Satapathy SK, Jones OD, Vanatta JM, Kamal F, Kedia SK, Jiang Y, et al. Outcomes of liver transplant recipients with autoimmune liver disease using long-term dual immunosuppression regimen without corticosteroid. *Transplant Direct* 2017;3:e178.

- 496) Kalra A, Burton JR Jr, Forman LM. Pro: steroids can be withdrawn after transplant in recipients with autoimmune hepatitis. *Liver Transpl* 2018;24:1109-1112.
- 497) Prados E, Cuervas-Mons V, de la Mata M, Fraga E, Rimola A, Prieto M, et al. Outcome of autoimmune hepatitis after liver transplantation. *Transplantation* 1998;66:1645-1650.
- 498) Czaja AJ. Diagnosis, pathogenesis, and treatment of autoimmune hepatitis after liver transplantation. *Dig Dis Sci* 2012;57:2248-2266.
- 499) Montano-Loza AJ, Bhanji RA, Wasilenko S, Mason AL. Systematic review: recurrent autoimmune liver diseases after liver transplantation. *Aliment Pharmacol Ther* 2017;45:485-500.
- 500) Puustinen L, Boyd S, Arkkila P, Isoniemi H, Arola J, Farkkila M. Histologic surveillance after liver transplantation due to autoimmune hepatitis. *Clin Transplant* 2017;31:e12936.
- 501) Stirnimann G, Ebadi M, Czaja AJ, Montano-Loza AJ. Recurrent and de novo autoimmune hepatitis. *Liver Transpl* 2019;25:152-166.
- 502) Aravinthan AD, Doyle AC, Issachar A, Dib M, Peretz D, Cattral MS, et al. First-degree living-related donor liver transplantation in autoimmune liver diseases. *Am J Transplant* 2016;16:3512-3521.
- 503) Kerkar N, Hadzic N, Davies ET, Portmann B, Donaldson PT, Rela M, et al. De-novo autoimmune hepatitis after liver transplantation. *Lancet* 1998;351:409-413.
- 504) Gupta P, Hart J, Millis JM, Cronin D, Brady L. De novo hepatitis with autoimmune antibodies and atypical histology: a rare cause of late graft dysfunction after pediatric liver transplantation. *Transplantation* 2001;71:664-668.
- 505) Hernandez HM, Kovarik P, Whittington PF, Alonso EM. Autoimmune hepatitis as a late complication of liver transplantation. *J Pediatr Gastroenterol Nutr* 2001;32:131-136.
- 506) Miyagawa-Hayashino A, Haga H, Egawa H, Hayashino Y, Sakurai T, Minamiguchi S, et al. Outcome and risk factors of de novo autoimmune hepatitis in living-donor liver transplantation. *Transplantation* 2004;78:128-135.
- 507) Gibelli NE, Tannuri U, Mello ES, Cancado ER, Santos MM, Ayoub AA, et al. Successful treatment of de novo autoimmune hepatitis and cirrhosis after pediatric liver transplantation. *Pediatr Transplant* 2006;10:371-376.
- 508) Venick RS, McDiarmid SV, Farmer DG, Gornbein J, Martin MG, Vargas JH, et al. Rejection and steroid dependence: unique risk factors in the development of pediatric posttransplant de novo autoimmune hepatitis. *Am J Transplant* 2007;7:955-963.
- 509) Cho JM, Kim KM, Oh SH, Lee YJ, Rhee KW, Yu E. De novo autoimmune hepatitis in Korean children after liver transplantation: a single institution's experience. *Transplant Proc* 2011;43:2394-2396.
- 510) Heneghan MA, Portmann BC, Norris SM, Williams R, Muiesan P, Rela M, et al. Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults. *HEPATOLOGY* 2001;34:464-470.
- 511) Jones DE, James OF, Portmann B, Burt AD, Williams R, Hudson M. Development of autoimmune hepatitis following liver transplantation for primary biliary cirrhosis. *HEPATOLOGY* 1999;30:53-57.
- 512) Tan CK, Sian Ho JM. Concurrent de novo autoimmune hepatitis and recurrence of primary biliary cirrhosis post-liver transplantation. *Liver Transpl* 2001;7:461-465.
- 513) Tsuji H, Hiramatsu K, Minato H, Kaneko S, Nakanuma Y. Auxiliary partial orthotopic liver transplantation with de novo autoimmune hepatitis in the allograft and leftover primary biliary cirrhosis in the native liver. *Semin Liver Dis* 2005;25:371-377.
- 514) Rodriguez-Diaz Y, Reyes-Rodriguez R, Dorta-Francisco MC, Aguilera I, Perera-Moliner A, Moneva-Arce E, et al. De novo autoimmune hepatitis following liver transplantation for primary biliary cirrhosis. *Transplant Proc* 2006;38:1467-1470.
- 515) Yoshizawa K, Shirakawa H, Ichijo T, Umemura T, Tanaka E, Kiyosawa K, et al. De novo autoimmune hepatitis following living-donor liver transplantation for primary biliary cirrhosis. *Clin Transplant* 2008;22:385-390.
- 516) Zhang Y, Wang B, Wang T. De novo autoimmune hepatitis with centrilobular necrosis following liver transplantation for primary biliary cirrhosis: a case report. *Transplant Proc* 2010;42:3854-3857.
- 517) Aguilera I, Wichmann I, Sousa JM, Bernardos A, Franco E, Garcia-Lozano JR, et al. Antibodies against glutathione S-transferase T1 (GSTT1) in patients with de novo immune hepatitis following liver transplantation. *Clin Exp Immunol* 2001;126:535-539.
- 518) Berardi S, Lodato F, Gramenzi A, D'Errico A, Lenzi M, Bontadini A, et al. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? *Gut* 2007;56:237-242.
- 519) Guido M, Burra P. De novo autoimmune hepatitis after liver transplantation. *Semin Liver Dis* 2011;31:71-81.
- 520) Montano-Loza AJ, Vargas-Vorackova F, Ma M, Bain VG, Burak K, Kumar T, et al. Incidence and risk factors associated with de novo autoimmune hepatitis after liver transplantation. *Liver Int* 2012;32:1426-1433.
- 521) Kerkar N, Vergani D. De novo autoimmune hepatitis—is this different in adults compared to children? *J Autoimmun* 2018;95:26-33.
- 522) Fiel MI, Agarwal K, Stanca C, Elhajj N, Kontorinis N, Thung SN, et al. Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. *Liver Transpl* 2008;14:861-871.
- 523) Castillo-Rama M, Sebah M, Sasatomi E, Randhawa P, Isse K, Salgarkar AD, et al. "Plasma cell hepatitis" in liver allografts: identification and characterization of an IgG4-rich cohort. *Am J Transplant* 2013;13:2966-2977.
- 524) Demetris AJ, Bellamy C, Hubscher SG, O'Leary J, Randhawa PS, Feng S, et al. 2016 comprehensive update of the Banff Working Group on liver allograft pathology: introduction of antibody-mediated rejection. *Am J Transplant* 2016;16:2816-2835.
- 525) Demetris AJ, Sebah M. Plasma cell hepatitis in liver allografts: variant of rejection or autoimmune hepatitis? *Liver Transpl* 2008;14:750-755.
- 526) Fiel MI, Schiano TD. Plasma cell hepatitis (de-novo autoimmune hepatitis) developing post liver transplantation. *Curr Opin Organ Transplant* 2012;17:287-292.
- 527) Levitsky J, Fiel MI, Norvell JP, Wang E, Watt KD, Curry MP, et al. Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. *Gastroenterology* 2012;142:1132-1139.
- 528) Jones D, Manns MP, Terracciano L, Torbenson M, Vierling JM. Unmet needs and new models for future trials in autoimmune hepatitis. *Lancet Gastroenterol Hepatol* 2018;3:363-370.
- 529) Czaja AJ. Review article: chemokines as orchestrators of autoimmune hepatitis and potential therapeutic targets. *Aliment Pharmacol Ther* 2014;40:261-279.
- 530) Czaja AJ. Evolving paradigm for treatment of autoimmune hepatitis. *Expert Rev Clin Immunol* 2017;13:781-798.
- 531) Czaja AJ. Review article: next-generation transformative advances in the pathogenesis and management of autoimmune hepatitis. *Aliment Pharmacol Ther* 2017;46:920-937.
- 532) Czaja AJ. Nature and implications of oxidative and nitrosative stresses in autoimmune hepatitis. *Dig Dis Sci* 2016;61:2784-2803.

- 533) Montano-Loza AJ, Thandassery RB, Czaja AJ. Targeting hepatic fibrosis in autoimmune hepatitis. *Dig Dis Sci* 2016;61:3118-3139.
- 534) Czaja AJ. Adoptive cell transfer in autoimmune hepatitis. *Expert Rev Gastroenterol Hepatol* 2015;9:821-836.
- 535) Lapierre P, Beland K, Yang R, Alvarez F. Adoptive transfer of ex vivo expanded regulatory T cells in an autoimmune hepatitis murine model restores peripheral tolerance. *HEPATOLOGY* 2013;57:217-227.
- 536) Czaja AJ. Emerging therapeutic biomarkers of autoimmune hepatitis and their impact on current and future management. *Expert Rev Gastroenterol Hepatol* 2018;12:547-564.
- 537) Matsumoto K, Miyake Y, Matsushita H, Ohnishi A, Ikeda F, Shiraha H, et al. Anti-programmed cell death-1 antibody as a new serological marker for type 1 autoimmune hepatitis. *J Gastroenterol Hepatol* 2014;29:110-115.
- 538) Aarslev K, Dige A, Greisen SR, Kreutzfeldt M, Jessen N, Vilstrup H, et al. Soluble programmed death-1 levels are associated with disease activity and treatment response in patients with autoimmune hepatitis. *Scand J Gastroenterol* 2017;52:93-99.
- 539) Assis DN, Leng L, Du X, Zhang CK, Grieb G, Merk M, et al. The role of macrophage migration inhibitory factor in autoimmune liver disease. *HEPATOLOGY* 2014;59:580-591.
- 540) Assis DN, Takahashi H, Leng L, Zeniya M, Boyer JL, Bucala R. A macrophage migration inhibitory factor polymorphism is associated with autoimmune hepatitis severity in US and Japanese patients. *Dig Dis Sci* 2016;61:3506-3512.
- 541) Migita K, Komori A, Kozuru H, Jiuchi Y, Nakamura M, Yasunami M, et al. Circulating microRNA profiles in patients with type-1 autoimmune hepatitis. *PLoS One* 2015;10:e0136908.
- 542) Gronbaek H, Kreutzfeldt M, Kazankov K, Jessen N, Sandahl T, Hamilton-Dutoit S, et al. Single-centre experience of the macrophage activation marker soluble (s)CD163—associations with disease activity and treatment response in patients with autoimmune hepatitis. *Aliment Pharmacol Ther* 2016;44:1062-1070.
- 543) Wang JB, Pu SB, Sun Y, Li ZF, Niu M, Yan XZ, et al. Metabolomic profiling of autoimmune hepatitis: the diagnostic utility of nuclear magnetic resonance spectroscopy. *J Proteome Res* 2014;13:3792-3801.
- 544) Lian JS, Liu W, Hao SR, Chen DY, Wang YY, Yang JL, et al. A serum metabolomic analysis for diagnosis and biomarker discovery of primary biliary cirrhosis and autoimmune hepatitis. *Hepatobiliary Pancreat Dis Int* 2015;14:413-421.
- 545) Lytton SD, Osiecki M, MalgorzataWozniak CB, Wierzbicka A, Goliszek M, Socha P, et al. Tryptophan-kynurenine profile in pediatric autoimmune hepatitis. *Immunol Res* 2019;67:39-47.
- 546) Czaja AJ. Epigenetic changes and their implications in autoimmune hepatitis. *Eur J Clin Invest* 2018;48:e12899.
- 547) Czaja AJ. Factoring the intestinal microbiome into the pathogenesis of autoimmune hepatitis. *World J Gastroenterol* 2016;22:9257-9278.
- 548) Lin R, Zhou L, Zhang J, Wang B. Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis. *Int J Clin Exp Pathol* 2015;8:5153-5160.
- 549) Yuksel M, Wang Y, Tai N, Peng J, Guo J, Beland K, et al. A novel "humanized mouse" model for autoimmune hepatitis and the association of gut microbiota with liver inflammation. *HEPATOLOGY* 2015;62:1536-1550.
- 550) Markle JG, Frank DN, Mortin-Toth S, Robertson CE, Feazel LM, Rolle-Kampczyk U, et al. Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. *Science* 2013;339:1084-1088.
- 551) Yurkovetskiy L, Burrows M, Khan AA, Graham L, Volchkov P, Becker L, et al. Gender bias in autoimmunity is influenced by microbiota. *Immunity* 2013;39:400-412.
- 552) Markle JG, Frank DN, Adeli K, von Bergen M, Danska JS. Microbiome manipulation modifies sex-specific risk for autoimmunity. *Gut Microbes* 2014;5:485-493.
- 553) Czaja AJ. Under-evaluated or unassessed pathogenic pathways in autoimmune hepatitis and implications for future management. *Dig Dis Sci* 2018;63:1706-1725.
- 554) Czaja AJ, Manns MP, Homburger HA. Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. *Gastroenterology* 1992;103:1290-1295.
- 555) Mieli-Vergani G, Vergani D. Autoimmune hepatitis in children: what is different from adult AIH? *Semin Liver Dis* 2009;29:297-306.
- 556) Narkewicz MR, Horslen S, Belle SH, Rudnick DA, Ng VL, Rosenthal P, et al. Prevalence and significance of autoantibodies in children with acute liver failure. *J Pediatr Gastroenterol Nutr* 2017;64:210-217.
- 557) Czaja AJ, Nishioka M, Morshed SA, Hachiya T. Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis. *Gastroenterology* 1994;107:200-207.
- 558) Toh BH. Smooth muscle autoantibodies and autoantigens. *Clin Exp Immunol* 1979;38:621-628.
- 559) Manns MP, Griffin KJ, Sullivan KF, Johnson EF. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. *J Clin Invest* 1991;88:1370-1378.
- 560) Gelpi C, Sontheimer EJ, Rodriguez-Sanchez JL. Autoantibodies against a serine tRNA-protein complex implicated in cotranslational selenocysteine insertion. *Proc Natl Acad Sci USA* 1992;89:9739-9743.
- 561) Wies I, Brunner S, Henninger J, Herkel J, Kanzler S, Meyer zum Buschenfelde KH, et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. *Lancet* 2000;355:1510-1515.
- 562) Volkmann M, Martin L, Baurle A, Heid H, Strassburg CP, Trautwein C, et al. Soluble liver antigen: isolation of a 35-kd recombinant protein (SLA-p35) specifically recognizing sera from patients with autoimmune hepatitis. *HEPATOLOGY* 2001;33:591-596.
- 563) Volkmann M, Luithle D, Zentgraf H, Schnolzer M, Fiedler S, Heid H, et al. SLA/LP/tRNP((Ser)Sec) antigen in autoimmune hepatitis: identification of the native protein in human hepatic cell extract. *J Autoimmun* 2010;34:59-65.
- 564) Costa M, Rodriguez-Sanchez JL, Czaja AJ, Gelpi C. Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(Ser)Sec complex recognized by autoantibodies from patients with type-1 autoimmune hepatitis. *Clin Exp Immunol* 2000;121:364-374.
- 565) Terjung B, Herzog V, Worman HJ, Gestmann I, Bauer C, Sauerbruch T, et al. Atypical antineutrophil cytoplasmic antibodies with perinuclear fluorescence in chronic inflammatory bowel diseases and hepatobiliary disorders colocalize with nuclear lamina proteins. *HEPATOLOGY* 1998;28:332-340.
- 566) Terjung B, Bogsch F, Klein R, Sohne J, Reichel C, Wasmuth JC, et al. Diagnostic accuracy of atypical p-ANCA in autoimmune hepatitis using ROC- and multivariate regression analysis. *Eur J Med Res* 2004;9:439-448.
- 567) Schwarze C, Terjung B, Lilienweiss P, Beuers U, Herzog V, Sauerbruch T, et al. IgA class antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and autoimmune hepatitis. *Clin Exp Immunol* 2003;133:283-289.
- 568) Oikonomou KG, Zachou K, Dalekos GN. Alpha-actinin: a multidisciplinary protein with important role in B-cell driven autoimmunity. *Autoimmun Rev* 2011;10:389-396.

- 569) Lapierre P, Hajoui O, Homberg JC, Alvarez F. Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis. *Gastroenterology* 1999;116:643-649.
- 570) Muratori L, Sztul E, Muratori P, Gao Y, Ripalti A, Ponti C, et al. Distinct epitopes on formiminotransferase cyclodeaminase induce autoimmune liver cytosol antibody type 1. *HEPATOLOGY* 2001;34:494-501.
- 571) Lenzi M, Manotti P, Muratori L, Cataleta M, Ballardini G, Cassani F, et al. Liver cytosolic 1 antigen-antibody system in type 2 autoimmune hepatitis and hepatitis C virus infection. *Gut* 1995;36:749-754.
- 572) Manns MP, Griffin KJ, Quattrochi LC, Sacher M, Thaler H, Tukey RH, et al. Identification of cytochrome P450IA2 as a human autoantigen. *Arch Biochem Biophys* 1990;280:229-232.
- 573) Belloc C, Gauffre A, Andre C, Beaune PH. Epitope mapping of human CYP1A2 in dihydralazine-induced autoimmune hepatitis. *Pharmacogenetics* 1997;7:181-186.
- 574) Bourdi M, Gautier JC, Mircheva J, Larrey D, Guillouzo A, Andre C, et al. Anti-liver microsomes autoantibodies and dihydralazine-induced hepatitis: specificity of autoantibodies and inductive capacity of the drug. *Mol Pharmacol* 1992;42:280-285.
- 575) Clemente MG, Obermayer-Straub P, Meloni A, Strassburg CP, Arangino V, Tukey RH, et al. Cytochrome P450 1A2 is a hepatic autoantigen in autoimmune polyglandular syndrome type 1. *J Clin Endocrinol Metab* 1997;82:1353-1361.
- 576) Van de Water J, Cooper A, Surh CD, Coppel R, Danner D, Ansari A, et al. Detection of autoantibodies to recombinant mitochondrial proteins in patients with primary biliary cirrhosis. *N Engl J Med* 1989;320:1377-1380.
- 577) Kenny RP, Czaja AJ, Ludwig J, Dickson ER. Frequency and significance of antimitochondrial antibodies in severe chronic active hepatitis. *Dig Dis Sci* 1986;31:705-711.
- 578) Montano-Loza AJ, Carpenter HA, Czaja AJ. Frequency, behavior, and prognostic implications of antimitochondrial antibodies in type 1 autoimmune hepatitis. *J Clin Gastroenterol* 2008;42:1047-1053.
- 579) Maggiore G, Larizza D, Lorini R, De Giacomo C, Scotta MS, Severi F. Propylthiouracil hepatotoxicity mimicking autoimmune chronic active hepatitis in a girl. *J Pediatr Gastroenterol Nutr* 1989;8:547-548.
- 580) Fedotin MS, Lefer LG. Liver disease caused by propylthiouracil. *Arch Intern Med* 1975;135:319-321.
- 581) Jennings JJ, Mandaliya R, Nakhabandi A, Lewis JH. Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies. *Expert Opin Drug Metab Toxicol* 2019;15:231-244.
- 582) Black M, Mitchell JR, Zimmerman HJ, Ishak KG, Epler GR. Isoniazid-associated hepatitis in 114 patients. *Gastroenterology* 1975;69:289-302.
- 583) Aithal GP, Ramsay L, Daly AK, Sonchit N, Leathart JB, Alexander G, et al. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. *HEPATOLOGY* 2004;39:1430-1440.
- 584) Scully LJ, Clarke D, Barr RJ. Diclofenac induced hepatitis. 3 cases with features of autoimmune chronic active hepatitis. *Dig Dis Sci* 1993;38:744-751.
- 585) Maddrey WC, Boitnott JK. Severe hepatitis from methyldopa. *Gastroenterology* 1975;68:351-360.
- 586) Rodman JS, Deutsch DJ, Gutman SI. Methyldopa hepatitis. A report of six cases and review of the literature. *Am J Med* 1976;60:941-948.
- 587) Shalev O, Mosseri M, Ariel I, Stalnikowicz R. Methyldopa-induced immune hemolytic anemia and chronic active hepatitis. *Arch Intern Med* 1983;143:592-593.
- 588) Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL. Pembrolizumab (Keytruda). *Hum Vaccin Immunother* 2016;12:2777-2789.
- 589) Adar T, Mizrahi M, Pappo O, Scheiman-Elazary A, Shibolet O. Adalimumab-induced autoimmune hepatitis. *J Clin Gastroenterol* 2010;44:e20-e22.
- 590) Efe C, Purnak T, Ozaslan E, Wahlin S. Drug-induced autoimmune hepatitis caused by anti-tumor necrosis factor alpha agents. *HEPATOLOGY* 2010;52:2246-2247.
- 591) Grasland A, Sterpu R, Boussoukaya S, Mahe I. Autoimmune hepatitis induced by adalimumab with successful switch to abatacept. *Eur J Clin Pharmacol* 2012;68:895-898.
- 592) Graziadei IW, Obermoser GE, Sepp NT, Erhart KH, Vogel W. Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis. *Lupus* 2003;12:409-412.
- 593) Pelli N, Setti M, Ceppa P, Toncini C, Indiveri F. Autoimmune hepatitis revealed by atorvastatin. *Eur J Gastroenterol Hepatol* 2003;15:921-924.
- 594) Noel B. Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review. *J Eur Acad Dermatol Venereol* 2007;21:17-24.
- 595) Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. *Semin Liver Dis* 2009;29:412-422.
- 596) Neuberger J, Kenna JG. Halothane hepatitis: a model of immune mediated drug hepatotoxicity. *Clin Sci (Lond)* 1987;72:263-270.
- 597) Eliasson E, Gardner I, Hume-Smith H, de Waziers J, Beaune P, Kenna JG. Interindividual variability in P450-dependent generation of neoantigens in halothane hepatitis. *Chem Biol Interact* 1998;116:123-141.
- 598) Wolters LM, Van Buuren HR. Rosuvastatin-associated hepatitis with autoimmune features. *Eur J Gastroenterol Hepatol* 2005;17:589-590.
- 599) Cohen SM, O'Connor AM, Hart J, Merel NH, Te HS. Autoimmune hepatitis associated with the use of black cohosh: a case study. *Menopause* 2004;11:575-577.
- 600) Guzman G, Kallwitz ER, Wojewoda C, Chennuri R, Berkes J, Layden TJ, et al. Liver injury with features mimicking autoimmune hepatitis following the use of black cohosh. *Case Report Med* 2009;2009:918156.
- 601) Reynolds TB, Peters RL, Yamada S. Chronic active and lupoid hepatitis caused by a laxative, oxyphenisatin. *N Engl J Med* 1971;285:813-820.
- 602) Pessayre D, Degos F, Feldmann G, Degott C, Bernuau J, Benhamou JP. Chronic active hepatitis and giant multinucleated hepatocytes in adults treated with clometacin. *Digestion* 1981;22:66-72.
- 603) Pariente EA, Hamoud A, Goldfain D, Latrive JP, Gislou J, Cassan P, et al. Hepatitis caused by clometacin (Duperan). Retrospective study of 30 cases. A model of autoimmune drug-induced hepatitis? *Gastroenterol Clin Biol* 1989;13:769-774.
- 604) Kamiyama T, Nouchi T, Kojima S, Murata N, Ikeda T, Sato C. Autoimmune hepatitis triggered by administration of an herbal medicine. *Am J Gastroenterol* 1997;92:703-704.
- 605) Bourdi M, Larrey D, Nataf J, Bernuau J, Pessayre D, Iwasaki M, et al. Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P-450IA2. A specific marker of dihydralazine-induced hepatitis. *J Clin Invest* 1990;85:1967-1973.
- 606) Larrey D, Vial T, Pauwels A, Castot A, Biour M, David M, et al. Hepatitis after germander (*Teucrium chamaedrys*) administration: another instance of herbal medicine hepatotoxicity. *Ann Intern Med* 1992;117:129-132.
- 607) Homberg JC, Andre C, Abuaf N. A new anti-liver-kidney microsome antibody (anti-LKM2) in tienilic acid-induced hepatitis. *Clin Exp Immunol* 1984;55:561-570.

- 608) Fong TL, Klontz KC, Canas-Coto A, Casper SJ, Durazo FA, Davern TJ 2nd, et al. Hepatotoxicity due to hydroxycut: a case series. *Am J Gastroenterol* 2010;105:1561-1566.
- 609) Gilbert KM, Przybyla B, Pumford NR, Han T, Fuscoe J, Schnackenberg LK, et al. Delineating liver events in trichloroethylene-induced autoimmune hepatitis. *Chem Res Toxicol* 2009;22:626-632.
- 610) Poncin E, Silvain C, Touchard G, Barbier J, Beauchant M. Papaverine-induced chronic liver disease. *Gastroenterology* 1986;90:1051-1053.
- 611) Abraham C, Hart J, Locke SM, Baker AL. A case of indometacin-induced acute hepatitis developing into chronic autoimmune hepatitis. *Nat Clin Pract Gastroenterol Hepatol* 2008;5:172-176.
- 612) Aliberti S, Grignani G, Allione P, Fizzotti M, Galatola G, Pisacane A, et al. An acute hepatitis resembling autoimmune hepatitis occurring during imatinib therapy in a gastrointestinal stromal tumor patient. *Am J Clin Oncol* 2009;32:640-641.
- 613) Elkayam O, Yaron M, Caspi D. Minocycline-induced autoimmune syndromes: an overview. *Semin Arthritis Rheum* 1999;28:392-397.
- 614) Ratziu V, Samuel D, Sebah M, Farges O, Saliba F, Ichai P, et al. Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. *J Hepatol* 1999;30:131-141.
- 615) Reich DJ, Fiel I, Guarrera JV, Emre S, Guy SR, Schwartz ME, et al. Liver transplantation for autoimmune hepatitis. *HEPATOLOGY* 2000;32:693-700.
- 616) Duclos-Vallee JC, Sebah M, Rifai K, Johanet C, Ballot E, Guettier C, et al. A 10 year follow up study of patients transplanted for autoimmune hepatitis: histological recurrence precedes clinical and biochemical recurrence. *Gut* 2003;52:893-897.
- 617) Gonzalez-Koch A, Czaja AJ, Carpenter HA, Roberts SK, Charlton MR, Porayko MK, et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. *Liver Transpl* 2001;7:302-310.
- 618) Andries S, Casamayou L, Sempoux C, Burlet M, Reding R, Bernard Otte J, et al. Posttransplant immune hepatitis in pediatric liver transplant recipients: incidence and maintenance therapy with azathioprine. *Transplantation* 2001;72:267-272.
- 619) Duclos-Vallee JC. Recurrence of autoimmune hepatitis, primary biliary cirrhosis and primary sclerosing cholangitis after liver transplantation. *Acta Gastroenterol Belg* 2005;68:331-336.
- 620) Sempoux C, Horsmans Y, Lerut J, Rahier J, Geubel A. Acute lobular hepatitis as the first manifestation of recurrent autoimmune hepatitis after orthotopic liver transplantation. *Liver* 1997;17:311-315.
- 621) Ayata G, Gordon FD, Lewis WD, Pomfret E, Pomposelli JJ, Jenkins RL, et al. Liver transplantation for autoimmune hepatitis: a long-term pathologic study. *HEPATOLOGY* 2000;32:185-192.
- 622) Hubscher SG. Recurrent autoimmune hepatitis after liver transplantation: diagnostic criteria, risk factors, and outcome. *Liver Transpl* 2001;7:285-291.
- 623) Banff Working Group; Demetris AJ, Adeyi O, Bellamy CO, Clouston A, Charlotte F, et al. Liver biopsy interpretation for causes of late liver allograft dysfunction. *HEPATOLOGY* 2006;44:489-501.
- 624) Liberal R, Longhi MS, Grant CR, Mieli-Vergani G, Vergani D. Autoimmune hepatitis after liver transplantation. *Clin Gastroenterol Hepatol* 2012;10:346-353.
- 625) Hurtova M, Duclos-Vallee JC, Johanet C, Emile JF, Roque-Afonso AM, Feray C, et al. Successful tacrolimus therapy for a severe recurrence of type 1 autoimmune hepatitis in a liver graft recipient. *Liver Transpl* 2001;7:556-558.
- 626) Salcedo M, Vaquero J, Banares R, Rodriguez-Mahou M, Alvarez E, Vicario JL, et al. Response to steroids in de novo autoimmune hepatitis after liver transplantation. *HEPATOLOGY* 2002;35:349-356.
- 627) Pfitzmann R, Klupp J, Langrehr JM, Uhl M, Neuhaus R, Settmacher U, et al. Mycophenolatemofetil for immunosuppression after liver transplantation: a follow-up study of 191 patients. *Transplantation* 2003;76:130-136.
- 628) Kerkar N, Dugan C, Rumbo C, Morotti RA, Gondolesi G, Shneider BL, et al. Rapamycin successfully treats post-transplant autoimmune hepatitis. *Am J Transplant* 2005;5:1085-1089.
- 629) Gibelli NE, Tannuri U, Pinho-Apezato ML, Tannuri AC, Maksoud-Filho JG, Andrade WC, et al. Sirolimus in pediatric liver transplantation: a single-center experience. *Transplant Proc* 2009;41:901-903.
- 630) Milkiewicz P, Hubscher SG, Skiba G, Hathaway M, Elias E. Recurrence of autoimmune hepatitis after liver transplantation. *Transplantation* 1999;68:253-256.
- 631) Birnbaum AH, Benkov KJ, Pittman NS, McFarlane-Ferreira Y, Rosh JR, LeLeiko NS. Recurrence of autoimmune hepatitis in children after liver transplantation. *J Pediatr Gastroenterol Nutr* 1997;25:20-25.
- 632) Gelson W, Hoare M, Dawwas MF, Vowler S, Gibbs P, Alexander G. The pattern of late mortality in liver transplant recipients in the United Kingdom. *Transplantation* 2011;91:1240-1244.

Supporting Information

Additional Supporting Information may be found at onlinelibrary.wiley.com/doi/10.1002/hep.31065/supinfo.